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Abstract 
Melanoma is notoriously resistant to immuno- and even targeted 
chemotherapeutic strategies despite recent advances in drug development.  The 
overall mortality of melanoma correlates with its ability to metastasise.  Breslow 
thickness or the depth of invasion remains the most useful prognostic indicator, 
thereby linking the ability of the cells to invade with their propensity to 
metastasise.  Invasion occurs early during tumour development, but the factors 
driving this process remain poorly understood.  There is a growing appreciation 
that chemotaxis plays an important role in driving the migration and invasion of 
melanoma cells, but the key stimuli are not known.  
Through the generation and validation of an improved chamber for cancer cell 
chemotaxis, melanoma cells are shown to create chemotactic gradients that 
drive or disperse themselves outwards with remarkable efficiency.  This process 
is driven by strikingly positive chemotaxis and depends on the melanoma 
reaching a critical density to generate the gradient.  The principal attractant is 
the inflammatory signal lysophosphatidic acid (LPA). Unexpectedly, it is active 
across all stages of melanoma evolution and LPA is both necessary and sufficient 
for chemotaxis in 2D & 3D assays.  Growth Factors were previously considered to 
play essential roles in driving directed migration, but instead facilitate LPA 
chemotaxis.  Sampling across the margins of melanomas in vivo, gradients of LPA 
are reliably identified, which are capable of driving accurate chemotaxis. This 
not only confirms the physiological importance of the results, but also is the first 
time a chemoattractant gradient has been measured in vivo.   
The corollary of these findings is that, provided with an external homogenous 
source of LPA, a large enough melanoma will degrade the local LPA to generate 
an outward gradient.  Therefore it is the ability to degrade the gradient that 
acts as the signal to drive chemotaxis and invasion rather than the presence of 
LPA per se.  In the chambers, cells are observed dispersing in a wave and in 
addition to driving efficient melanoma invasion, this may be responsible for the 
patterning of melanocytes across the skin during embryogenesis.  Ultimately, 
identifying key aspects of and targeting the LPA-axis may prove a novel 
prognostic indicator and therapeutic target for invasion and metastasis.  
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Definitions/ Abbreviations 
BM Basement membrane 
BSA Bovine serum albumin 
cAMP Cyclic adenosine monophosphate 
CGM Complete growth media 
CI Chemotaxis index 
CM Conditioned media 
CO2 Carbon dioxide 
CRE Cre-recombinase 
CSF-1 Colony stimulating factor-1 
CTCs Circulating tumour cells 
0C Degree centigrade 
DIC Differential interference contrast 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
E Embryonic day 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EMT Epithelial-mesenchymal transition 
EMU Epidermal melanin unit 
ET-3 Endothelin-3 
FBS Foetal bovine serum 
FBSE Full body skin examination 
FFPE Formalin fixed paraffin embedded 
FN Fibronectin 
GFP Green fluorescent protein 
GF Growth Factor 
H&E Haematoxylin and eosin 
HGF Hepatocyte growth factor/ scatter factor 
HPLC High-performance liquid chromatography 
IHC Immunohistochemistry 
Kd Dissociation constant 
LC-MS Liquid chromatography – mass spectrometry 
LM Lentigo maligna 
LMM Lentigo maligna melanoma 
LPA Lysophosphatidic acid 
LPC  Lysophosphatidylcholine 
LPP Lipid phosphate phosphatase 
LPAR Lysophosphatidic acid receptor 
LUT Lookup table 
MAG Mono-acylglycerol 
MAPK Mitogen-activated protein kinase 
MC1R Melanocortin-1 receptor 
MITF Microphthalmia-associated transcription factor 
MEM Minimum Essential Medium 
MIS Melanoma in situ 
MM Metastatic Melanoma 
µL Microlitre 
mg Milligram 
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mL Millilitre 
mM Millimolar 
M Molar 
NA Numerical aperture 
nm Nanometre 
NM Nodular melanoma 
NMSC Non-melanoma skin cancer 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGF Platelet derived growth factor 
PFS Perfect focus system 
PA Phosphatidic acid 
PI3K Phosphatidylinositol (4,5)-bisphosphate 3-kinases 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate  
PTX Pertussis toxin 
PTEN  Phosphatase and tensin homolog 
PTX Pertussis toxin 
qPCR Quantitative polymerase chain reaction 
RCF Relative centrifugal force 
RGP Radial growth phase 
SC Subcutaneous 
SCF Stem cell factor 
SDF-1 Stromal cell derived factor-1 
SEM Standard error of the mean 
sPLA2 Secretory-type phospholipase A2 
SSM Superficial spreading melanoma 
TSSE Total skin self-examination 
Tyr Tyrosinase 
UV Ultraviolet 
UVA Ultraviolet wavelength A 
UVB Ultraviolet wavelength B 
UVR Ultraviolet radiation 
VEGF Vascular endothelial growth factor 
VGP Vertical growth phase
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Preface 
This thesis has been written from the perspective of both a dermato-oncologist 
and clinician-scientist and I have therefore chosen to divide the introductory 
chapter into two parts.  The first part is written primarily from a clinical 
perspective and aims to provide an overview of the key clinical and biological 
aspects of cutaneous melanoma.  This covers topics varying from its 
development to metastasis and provides background to the disease.  It also 
reviews the clinical management of melanoma aimed to reduce the risk of 
metastasis and highlights important translational developments and areas of 
unmet need.  The second part focuses on cell biology, reviewing the literature 
directly related to this thesis, starting from chemotaxis and progressing to an in-
depth review of the chemotaxis-driven invasion paradigm and the inflammatory 
signal lysophosphatidic acid (LPA).  There is, inevitably, some overlap between 
the two parts, although a gulf exists between the clinical management of 
melanoma and research into the biology underpinning the disease.  Therefore, 
the final chapter will attempt to address this issue by highlighting the key 
findings and translating these to clinical implications and areas for further 
focused research. 
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Part 1  
Cutaneous melanoma 
1.1.1 Introduction  
Early-stage cutaneous melanoma is curable, but advanced, metastatic melanoma 
is almost uniformly fatal (Zbytek et al., 2008).  Patients with such advanced 
disease have a median survival of only 6-9 months (Gogas et al., 2007).  
Melanoma is responsible for 75-80% skin cancer deaths despite being only 
responsible for 4% of skin cancers and is the 6th most common cancer type in the 
UK in 2010 (CRUK, 2013; Lee and Herlyn, 2007; Sladden et al., 2009).  Cutaneous 
melanoma therefore remains a disease with high unmet need.   
Not only is melanoma characterised by its aggressiveness, but the incidence 
rates in Europe, Australasia and North America have been rising since the mid 
1970s (Coory et al., 2006; de Vries and Coebergh, 2004; Swetter et al., 2005).  
This unmet need is therefore acutely exacerbated by the ongoing “melanoma 
epidemic” (Dennis, 1999; Schaffer et al., 2004).  The rising incidence is only 
tempered by the less dramatic rise in mortality, possibly due to the success of 
public awareness campaigns (Doherty and MacKie, 1988; Tucker, 2009).   
Detecting and excising melanoma early is key to improving survival but 
melanoma is characterised by clinical and biological heterogeneity (Herlyn, 
2009; Lachiewicz et al., 2008; Lee and Weinstock, 2009).  This creates complex 
challenges for professionals involved in the management of melanoma; 
strategically for both public health physicians and policy makers in the delivery 
of patient awareness messages and, clinically, for dermatologists and 
pathologists in the diagnosis of malignant disease, and for oncologists in the 
successful treatment of disseminated cancer.  Furthermore, melanoma is 
notoriously resistant to both chemo- and immunotherapeutic strategies (Vultur 
and Herlyn, 2009).  Until very recently, the best current treatment – dacarbazine 
- offered only a 4% durable remission (Eton et al., 1998). 
There are, however, major translational success stories emerging for this disease 
with the advent of personalised medicine, and tools to aid accurate diagnosis 
Chapter 1 
 19 
are now in routine use (Flaherty et al., 2012c; Guitera and Menzies, 2011).  That 
said, major hurdles lie ahead and further translational success depends on the 
successful interplay between physicians and surgeons managing the disease and 
scientists researching the biological mechanisms that underpin it (Wich et al., 
2009). 
One of the key questions this thesis addresses is: what drives melanoma cells to 
metastasise?  We do not know why two patients exhibiting the same degree of 
invasion in their primary lesion - Breslow thickness, the most powerful 
prognostic predictor of subsequent metastasis – can demonstrate such biological 
variability.  One may be cured with simple excisional surgery and yet another 
may present with, or go on to develop, widespread metastases (Balch et al., 
2009).  Although clinico-pathological parameters can to some extent identify 
those tumours at high risk of dissemination, the cellular mechanisms underlying 
this ability to metastasise early are poorly understood (Slingluff and Seigler, 
1992).  There is therefore a great need to understand this difference in 
biological behaviour and develop novel prognostic and therapeutic targets. 
1.1.2 Melanocyte development & homeostasis 
1.1.2.1 Melanoblasts & morphogenesis 
Melanocytes are derived from highly migratory precursors called melanoblasts 
and much of the knowledge about pigment cell embryogenesis has been derived 
from murine studies.  In theses murine models, melanoblasts appear from the 
neural crest around embryonic day 8.5 (E8.5; Fig. 1A).  They travel along the 
dorsolateral pathway between the dermatome and overlying ectoderm, before 
redirecting through the dermis (E10.5), and “invade” the epidermis through the 
developing basement membrane around E14.5 (Jordan and Jackson, 2000a; 
Mayer, 1973).  This pathway involves considerable axial mixing along with 
predominantly lateral migration (Wilkie et al., 2002).  The modes of motility and 
invasion required for this process have been associated with the paradigm of 
epithelial-mesenchymal transition (EMT; Micalizzi et al., 2010; Theveneau and 
Mayor, 2012).   
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Very few molecules have been implicated in directing melanoblast dispersal and 
migration along the dorsolateral pathway and currently the mechanism by which 
melanoblasts traverse this pathway is poorly understood (Kelsh et al., 2009; 
Larue et al., 2012).  The most well-studied is Stem Cell Factor (SCF), the Kit-
receptor ligand, which plays a critical role in permitting the survival of Kit 
expressing melanoblasts (Jordan and Jackson, 2000b; Wehrle-Haller, 2003).  SCF 
has also been shown to drive increased migration into hair follicles through 
enhancing migration speed (chemokinesis) rather than directed migration 
towards SCF (chemotaxis).  Other ligands (and their respective receptors) known 
to be involved in co-ordinating melanoblast migration include Endothelin-3 (ET-
3)/ Endothelin receptor B2 (EDNRB2) signalling, with disruption of this pathway 
in mouse models demonstrating spotting phenotypes (Baynash et al., 1994).  The 
chemokine-receptor axis SDF-1/ CXCR4 is implicated in the motility of cells 
within the hair follicle during cycles of hair growth (Belmadani et al., 2005; 
Belmadani et al., 2009).  Niche localisation is further guided by spatially and 
temporally directed micro environmental cues in the expression of cadherins 
(Nishimura et al., 1999). Contact inhibition of locomotion may play a role in the 
patterning of melanocytes in zebra fish (Inaba et al., 2012; Kondo and Miura, 
2010; Nakamasu et al., 2009; Theveneau et al., 2010).  Contact inhibition of 
locomotion was first described by Abercrombie who observed the inhibition of 
continuing forward locomotion when two cells meet while migrating toward one 
another (Abercrombie, 1970). 
Although these signals have been implicated in driving melanoblast migration, a 
clear model integrating the key pathways remains elusive and chemotaxis has 
yet to be shown to play a role in directing what is a tightly temporally and 
spatially controlled process.  The reactivation of dormant embryonic pathways is 
considered to be an essential mechanism by which cancer cells invade and 
metastasise (Gupta et al., 2005; Lee and Herlyn, 2007).  The extraordinary 
journey undertaken by melanoblasts during development/embryogenesis may, 
therefore, explain why melanoma has the ability to invade and metastasise so 
effectively.  
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1.1.2.2 Melanocyte homeostasis  
Melanocytes are the mature pigment producing cells of the skin (Uong and Zon, 
2010).  They reside in the basal layer of the epidermis (Fig. 1B) in a symbiotic 
relationship with keratinocytes in an epidermal melanin unit (EMU) (Fitzpatrick 
and Breathnach, 1963; Seiberg, 2001).  In 3 dimensions (3D) this highly ordered 
unit consists of approximately 36 keratinocytes associated with the dendritic 
processes of 1 (Meier et al., 2000) melanocyte.  In 2D, this results in a 
distribution of melanocytes along the basement membrane with keratinocytes in 
a ratio of 1:5.  The EMU is only disrupted to allow melanocyte proliferation, 
either to enable growth of skin in childhood or the development of a naevus or 
melanoma (Haass and Herlyn, 2005).  E-Cadherin is a key regulator of 
melanocyte homing and plays a pivotal role in maintaining melanocyte 
homeostasis and is expressed on the surface of both melanocytes and 
keratinocytes (Tang et al., 1994).  The melanocytes are further spatially 
regulated through CCN3 mediated basement membrane localisation via the 
discoidin domain receptor 1 (DDR1) that binds the basement membrane specific 
protein collagen 4 (Fukunaga-Kalabis et al., 2006). 
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Figure 1-1 Melanocyte development and homeostasis. 
A Melanoblasts are melanocyte pre-cursors, which migrate out laterally from the dorsally located 
neural crest between the dermatome and ectoderm to cover the entire trunk, before invading up 
into the epidermis. Adapted from Anne’s Rat Page. B A simplified schematic of the architecture of 
the skin, composed of two main layers, the dermis and more superficial epidermis. It shows the 
relationship of melanocytes with keratinocytes in the epidermis during homeostasis. One 
melanocyte contacts approximately 36 keratinocytes through its dendritic processes, forming an 
Epidermal Melanin Unit. Keratinocytes mature as they rise through the epidermis, becoming flatter 
and losing their nuclei. Melanocytes reside on the basement membrane, separating the epidermis 
from the vascular dermis below. Adapted from (Haass and Herlyn, 2005). 
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1.1.2.3 The role of melanocytes 
Melanocytes are photoprotective against the harmful effects of ultraviolet 
radiation-induced (UVR) damage (Brenner and Hearing, 2008).  Epidemiological 
data support the photoprotective role of melanin with the observation that 
there is an inverse correlation with the risk of skin cancer and skin pigmentation 
(Gilchrest et al., 1999).  Melanocytes synthesise melanin, which is transported 
within melanosomes via dendrites to adjacent keratinocytes.  The melanin 
aggregates to form perinuclear protective caps in both cell types, thereby 
directly shielding the DNA from UV-induced photodamage (Warren et al., 1991).  
This reduces the impact of photodamage from UVR. The UVR spectrum includes 
the two most important wavelengths for melanomagenesis, UVA (315-400 nm) 
(280-315 nm) and UVB.  On reaching the earth’s surface, UVB is preferentially 
absorbed by the epidermis, compared to 80% of UVA, which penetrates beyond 
the basement membrane to the upper papillary dermis (Svobodova and 
Vostalova, 2010).  UVR within the UVB wavelength range is particularly 
implicated in generating carcinogenic DNA damage, in the form of highly specific 
CCTT and CT nucleotide substitutions, which are described as classic UV 
fingerprint mutations (Brash et al., 1991).  This is important because a recent 
genome wide screen for somatic mutations in melanoma found that many of the 
33,000 mutations discovered had the hallmark of a UV fingerprint mutation 
(Pleasance et al., 2009).  UVA is also capable of producing DNA damage via 
photosensitised reactions that result in oxygen radical species (Peak and Peak, 
1991). 
1.1.3 Melanoma initiation 
1.1.3.1 Melanoma driver mutations  
Several key signalling pathways are deregulated in melanoma but of these it is 
the mitogen-activated protein kinase (MAPK) pathway (Fig. 2) mediating cellular 
responses to growth signals that appears pivotal in the early development of 
melanoma (Blokx et al., 2010; Haass and Herlyn, 2005). 
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Figure 1-2 The major signalling pathways in melanoma initiation 
The major signalling pathways in melanoma development are represented in this schematic, with 
the two key genetic networks involved in melanoma initiation, progression and maintenance. The 
CDKN2A locus, through alternate reading frames, encodes two separate tumour suppressors, p16 
and ARF, and deletion of this locus leads to evasion from apoptosis and senescence and 
uncontrolled tumour growth. NRAS/BRAF and PI3K/AKT3 pathways are mainly implicated in 
melanoma proliferation, survival, and progression. The oncoproteins are indicated in red and 
tumour suppressors in blue and the MAPK pathway is shaded in light brown. Adapted from (Ji et 
al., 2010). 
 
In 2002, the MAPK pathway was shown to be oncogenically mutated in 
melanomas, with the BRAFV600E (a single valine to glutamic acid substitution) 
mutation accounting for 80% of mutations in the BRAF protein (Davies et al., 
2002).  This key step involved in the development of a naevus is also found in 
50% of melanomas making it the most frequently activated oncogene (Flaherty 
et al., 2012a).  Despite the mutation, naevi very rarely progress to melanoma 
due to activation of classical oncogene-induced senescence with the induction of 
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both p16 (INK4a) and senescence-associated acidic beta-galactosidase activity 
(Dhomen et al., 2009; Michaloglou et al., 2005).  Interestingly, although 80% of 
acquired naevi are BRAF driven, 80% of congenital naevi are NRAS driven 
(Alikhan et al., 2012; Pollock et al., 2003). 
NRAS driven tumours are the other major group and constitute 15% of all 
tumours that arise in a mutually exclusive pattern with respect to BRAF 
mutations (Devitt et al., 2011).  Activation of NRAS driver mutations also signal 
through the MAPK pathway.   
Although UVR from sunlight is generally accepted as a major risk factor for 
melanomagenesis, mechanistic evidence has been lacking (Garibyan and Fisher, 
2010).  The recurrent base mutations that produce oncogenic NRAS and BRAF 
mutations are not C > T transitions indicative of UVB mutagenesis (Hodis et al., 
2012).  Tumour genome sequencing has now produced new contenders for driver 
mutations.  The identification of statistically significant “hot spot” mutations in 
RAC1 is particularly appealing, as it provides genomic evidence linking UVB 
mutagenesis mechanistically to this malignancy, with all samples tested 
exhibiting the C>T transition.  Hodis et al. discovered this mutation in 4% of 
melanomas and another group confirmed its presence as the third most common 
mutation in sun exposed melanomas (Krauthammer et al., 2012).  This mutation 
is particularly interesting from a metastasis perspective as it is the first 
mutation that has been shown to be involved in cellular migration (Insall and 
Machesky, 2009a). 
This year, 74% of human melanoma cell lines were shown to exhibit recurrent UV 
signature mutations in the telomerase reverse transcriptase (TERT) promoter 
region (Horn et al., 2013).  These mutations were found even more frequently 
than BRAF or NRAS mutations and CDKN2A.  Concomitant mutations were found 
at a higher rate than expected by chance together, suggesting that these are 
driver rather than passenger events. 
1.1.3.2 Tumour suppressor genes 
CDKN2A, and the less common CDK4/6, (Fig. 2) are considered high-risk 
melanoma tumour suppressor genes (Box et al., 2001; Palmer et al., 2000). 
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Mutations in these genes were identified in melanoma-prone kindreds conferring 
a risk of multiple melanomas across the kindred, multiple primary melanomas 
arising in individuals and melanomas arising at an earlier age (Lin et al., 2008).  
The CDKN2A gene encodes two tumour suppressor proteins, produced through 
alternative splicing: p16/INK4a and p14/ARF.  Downstream, these proteins signal 
via the Retinoblastoma (Rb) and p53 pathways and are proteins with critical 
roles in growth regulation and apoptosis respectively (Hsieh et al., 2012; Ji et 
al., 2010).  Although these pathways are very important, they will not be 
discussed further as they do not directly feature in this thesis. 
1.1.4 Melanoma progression model 
To generate a melanoma, melanocytes must undergo at least three key changes.  
Firstly, clonal expansion, secondly, immortalisation through overcoming 
melanocyte senescence, and thirdly, suppression of apoptosis (Bennett, 2003; 
Bennett, 2008).  There are then two key primary melanoma stages recognised 
biologically: radial growth phase (RGP), in which melanoma cells are capable of 
spreading along the basement membrane but remain keratinocyte dependent, 
and vertical growth phase (VGP), in which melanoma cells develop the ability to 
invade and survive in the dermis.  This latter stage alone is considered to be 
metastasis competent (Bennett, 2008). 
The melanoma progression model was described as a simple model of 
progression through 6 steps (1) common acquired melanocytic naevus; (2) 
melanocytic naevus with lentiginous melanocytic hyperplasia, i.e., aberrant 
differentiation; (3) melanocytic naevus with aberrant differentiation, and 
melanocytic nuclear atypia, i.e., melanocytic dysplasia; (4) the RGP of primary 
melanoma; (5) the VGP of primary melanoma; and (6) metastatic melanoma 
(Clark et al., 1984) This model belies the true complexity of melanoma in 
addition to the fact that less than half of sporadic melanomas are believed to 
arise through a naevus precursor (Clark et al., 1969; Haass and Herlyn, 2005).  
Figure 3 presents a simplified model of progression. 
In vitro, VGP and MM cells exhibit constitutive activation of Erk1/2 
(Satyamoorthy et al., 2003).  This switch to growth factor independence 
distinguishes non-tumorigenic RGP from tumorigenic VGP primary melanomas 
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and appears to be closely related to tumorigenicity and metastatic potential 
(Haass and Herlyn, 2005).  The mutual exclusivity of BRAF and NRAS mutations 
suggests that they are signalling through the same essential pathway (Davies et 
al., 2002).  Melanocyte localising mechanisms are also disrupted.  VGP 
melanomas (in vitro and in vivo) express markedly reduced levels of E- and P-
cadherin, and exhibit decreased affinity for normal keratinocytes in vitro, 
suggesting that loss of cadherins may play a role in melanoma metastasis 
(Sanders et al., 1999; Tang et al., 1994).  Knockdown of CCN3 or DDR1, which 
are essential for melanocyte localisation, result in dispersal of cells upwards into 
the epidermal layers of 3D skin reconstructs or downwards into the dermis 
(Fukunaga-Kalabis et al., 2006). 
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Figure 1-3 The biological stages of melanoma development. 
The stepwise progression of melanoma through various growth stages is presented from left to 
right. Less than 50% of melanomas progress through the naevus stage and some tumours exhibit 
minimal radial growth phase. Importantly, cells move away or disperse from the tumour, this is best 
exhibited by the pagetoid spread of melanoma cells up into the epidermis. This dispersal is shown 
by small brown arrows. Circulating tumour cells may progress in a non-linear fashion and return to 
niche of the primary site, in addition to extravasating at distant sites to form metastases. Adapted 
from (Gaggioli and Sahai, 2007). 
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1.1.5 Diagnosing melanoma 
1.1.5.1 Clinical phenotypes with increased risk of melanoma 
Cutaneous melanoma is primarily a disease of pale-skinned populations and 
evidence from meta-analyses clearly shows UVR to be an important risk factor 
(Gandini et al., 2005b; Lancaster, 1956).  The mechanism is complex, with 
intermittent sun exposure with a history of sunburn during childhood increasing 
risk in more northern latitudes and a role for chronic sun exposure in lower 
latitudes (Chang et al., 2009).  This observation is supported with the finding 
that polymorphisms in the MC1R gene confer an increased risk of melanoma. 
MC1R encodes the receptor coordinating the pigmentation phenotype and is 
therefore an important gene in melanocyte biology and polymorphisms result in 
the red hair and fair skin phenotype (Makova and Norton, 2005; Valverde et al., 
1995).  Genome-wide association studies have also implicated other 
pigmentation genes as key susceptibility loci, including ASIP, encoding the agouti 
signalling protein upstream of MC1R, and TYR, encoding the tyrosinase related 
protein down stream of MC1R (Bishop et al., 2009; Gudbjartsson et al., 2008).   
Whilst these phenotypes confer increased risk, by far in a way the most 
important risk factor is the presence of increased numbers of naevi and naevus 
atypia: the presence of 101-120 naevi compared with <15 (pooled relative risk 
(RR) = 6.89; 95% Confidence interval (CI): 4.63, 10.25) and for the number of 
atypical naevi (RR = 6.36 95%; CI: 3.80, 10.33; for 5 versus 0) (Gandini et al., 
2005a).  Although naevus number has a genetic basis, evidence has recently 
emerged that increase in naevus number is associated with UVR exposure (Falchi 
et al., 2009; Newton-Bishop et al., 2010).  A list of relative risks can be found in 
Table 1. 
Other groups at high risk that are beyond the scope of this thesis include 
patients with giant congenital naevi and individuals with a family history of 
three or more cases of melanoma, or of pancreatic cancer (Marsden et al., 
2010). 
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Risk Factor RR 95%CI 
Multiple naevi 6.89 4.63-10.25 
Atypical naevi 6.36 3.80-10.33 
Pre-malignant & skin cancer lesions 4.28 2.80-6.55 
Red Hair 3.64 2.56-5.37 
Freckles 2.10 1.80-2.45 
FH melanoma 1.74 1.41-2.14 
Table 1. Relative risk for the main melanoma risk factors 
A series of three systematic meta-analyses of observational studies for the relative risk of the main 
melanoma risk factors is summarised. Adapted from (Gandini et al., 2005a; Gandini et al., 2005b; 
Gandini et al., 2005c) 
 
1.1.5.2 Early clinical diagnosis 
By virtue of its heterogeneous nature, melanoma is characterised by a wide 
variety of clinical presentations, from small curable primary lesions, which can 
be cured by simple excision surgery, through to disease, which is widely 
disseminated at the time of initial diagnosis (Jerant et al., 2000).  Early 
melanoma diagnosis is the key factor in reducing mortality, by detecting 
melanomas before they have metastasised (Rigel et al., 2010)  
Most melanomas are detected based on their macroscopic appearance and with 
the “ABCD” or “7-point checklist” tools (Friedman et al., 1985; Healsmith et al., 
1994).  These risk assessment tools have proved a useful paradigm in enhancing 
early diagnosis.  Some melanomas however lack these criteria, particularly in 
the early stages. For example, 15% of all melanomas are nonpigmented/ 
amelanotic (Giuliano et al., 1982) and signs such as the “ugly duckling” sign have 
evolved to aid the diagnosis of these more atypical lesions (Scope et al., 2008).  
Despite these criteria, no one tool is perfect and clinical experience remains an 
important criterion for accurate diagnosis (Morton and Mackie, 1998). 
The dermatoscope is a handheld non-invasive in vivo imaging device with 10x 
magnification that is used by dermatologists to enhance diagnostic accuracy by 
visualising biological processes in the epidermis and upper dermis (Kittler et al., 
2002).  This results in fewer biopsies of benign lesions and more accurate 
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detection of early stages of melanoma (Argenziano et al., 2012).  Despite 
dermatoscopy and the advent of confocal microscopy in a research setting, there 
are no clinical markers for metastatic melanoma (Longo et al., 2013).  Following 
identification of a suspicious lesion, an initial excision with a 2mm margin is 
recommended to enable an accurate pathological assessment (McCarthy and 
Scolyer, 2004).   
1.1.5.3 Prognosis, histological features and risk of metastasis  
The histological examination of the primary melanoma is central to providing 
accurate prognostic information as it guides ongoing clinical management and 
informs patients and physicians alike about the likely outcomes (Scoyler et al., 
2012).  However, melanoma remains one of the most challenging and 
controversial fields in diagnostic histopathology, and it is one of the leading 
causes for litigation against pathologists (Troxel, 2004).  This is due largely to 
the wide morphological spectrum and often only subtle differentiating 
architectural, cytological and host response features, with potential for both 
under- as well as overdiagnosis of melanoma (Brenn, 2012; Metcalf, 1996). 
No one feature alone is diagnostic and therefore the differentiation between 
benign naevus cells and infiltrating melanoma cells can be extremely subtle 
(Mackie et al., 1989).  These features can also be complicated by trauma to the 
lesion, pregnancy, topical treatment or recent UV exposure (McCarthy and 
Scolyer, 2004).  The diagnosis usually rests on a correlation of histopathological 
and clinical factors and an expert review may be necessary if there is 
discordance between the clinician and pathologist (Scoyler et al., 2012; Van Dijk 
et al., 2008). 
Melanoma was initially categorised into three main groups based on a clinico-
pathological classification: superficial spreading melanoma (SSM), nodular 
melanoma and lentigo maligna melanoma.  The fourth, acral lentiginous 
melanoma, was added later and now forms part of the World Health 
Organisation’s classification (Arrington et al., 1977; Clark et al., 1969).  This 
approach has been criticised because it carries no independent prognostic 
significance (Romano et al., 2011; Weyers et al., 1999). 
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The melanoma AJCC staging and classification guidance was recently updated 
and provides valuable information regarding prognostic features that are also 
histologically identified from the primary lesion (Balch et al., 2009).  These 
parameters include: primary tumour thickness (Breslow thickness), primary 
tumour ulceration and primary tumour mitotic rate, which replaces the 
biological level of invasion.  These three factors are the dominant prognostic 
markers, with Breslow thickness the single most important marker.  For stage III 
disease the number and volume of metastases remain important and for stage IV 
disease LDH is the key marker with lung metastasis providing a slightly better 
prognosis than other visceral metastases.  The extent of the impact of these 
factors on 5-year survival can be seen on these graphs for localised and 
metastatic disease (Fig. 4).  It is clear from the graphs that the presence of 
metastasis is the major difference between patients surviving or not.  Based on 
these graphs, patients with stage IA melanoma (<1mm Breslow thickness, with 
no ulceration) have a greater than 95% 5-year survival and Stage IVC disease 
(metastasis to non-pulmonary viscera) have around a 10% 5-year survival rate. 
1.1.6 Treating cutaneous melanoma 
1.1.6.1 Primary melanoma: Treatment with curative intent 
Following identification of a suspicious lesion, an initial excision with a 2mm 
margin is recommended to enable an accurate pathological assessment and 
ensure the entire primary lesion is excised in its entirety (Marsden et al., 2010).  
Once the Breslow thickness has been calculated, a definitive wide local excision 
can be performed to excise any micro-metastases that have escaped the primary 
melanoma (Marsden et al., 2010; Sladden et al., 2009).  Recent UK guidance also 
takes into account the relatively benign biological nature of <1mm thick 
melanomas and these patients now only require a 1-year follow up period rather 
than the 5 years previously recommended.  Surgical excision currently remains 
the only curative treatment for cutaneous melanoma. 
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Figure 1-4 AJCC survival curves for primary and metastatic melanoma. 
A Survival curves from the American Joint Committee on Cancer Melanoma Staging Database 
comparing the stage groupings for stages I and II melanoma. B Survival curves of 7,635 patients 
with metastatic melanomas at distant sites (stage IV) subdivided by the site of metastatic disease. 
Adapted from (Balch et al., 2009). 
 
1.1.6.2 Metastatic melanoma: Treatments pre-2011 
Prior to 2011, only an occasional patient would experience long-term benefit 
from therapy (Atkins, 1997) with the treatment mainstay, dacarbazine (DTIC), 
giving a 6-year survival rate of <2% (Eton et al., 1998; Gogas et al., 2007).  Three 
decades of phase 2 trials showed virtually no difference in the response rates 
between DTIC and any other agent investigated (Korn et al., 2008).   
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1.1.6.3 Metastatic melanoma: Current treatments 
2011 was lauded as a landmark year for the treatment of melanoma with two 
new agents conferring a survival benefit: the immune-stimulatory anti-CTLA4 
antibody ipilimumab and the BRAF inhibitor vemurafenib (Hoos et al., 2010; 
Rebecca et al., 2012).   
Modelled around the success of trastuzamab (a monoclonal antibody used in the 
treatment of breast cancer) and with a biomarker, vemurafenib fulfils the 
paradigm of a personalised medicine (Slamon et al., 2001).  It was shown to 
demonstrate exquisite sensitivity against the V600E oncogene in pre-clinical 
studies enabling the rapid establishment of Phase 1 trials (Korn et al., 2008).  In 
a subsequent Phase 3 trial, patients with previously untreated melanoma 
carrying the V600E mutation were randomised to receive either vemurafenib or 
dacarbazine.  There were response rates of 48% for vemurafenib and 5% for 
dacarbazine, with median survival increased from 1.6 to 5.3 months in the 
vemurafenib arm (Chapman et al., 2011).  Remarkably, it has taken only 10 
years to translate the molecular biology to a licensed treatment to the clinic 
(Machesky and Sansom, 2012).  Despite the initial success of vemurafenib, 
resistance rapidly became problematic and, in addition, up to 25% of patients 
develop squamous cell carcinomas (SCCs).  Patients with increased sun exposure 
are at particular risk of developing SCCs. Even though vemurafenib inhibits MAPK 
signalling in BRAF mutant cells, it is postulated that this increase in SCCs arises 
through paradoxical activation of pre-existing RAS mutations in keratinocytes 
(Oberholzer et al., 2012; Sinha et al., 2012).   
1.1.7 Future directions 
1.1.7.1 Improving diagnostic accuracy and early detection 
Prevention and early detection are essential in the battle against the rising 
incidence of melanoma.  Dermatoscopy and the advent of modern in vivo 
imaging techniques such as confocal microscopy and multi-photon microscopy 
may offer new insights into the biology of melanoma through careful clinico-
pathological-molecular correlation (Dimitrow et al., 2009; Longo et al., 2013).   
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1.1.7.2 Classification 
Following the identification of key driver mutations and with the development of 
targeted therapies there is a move towards a genetic-morphologic classification: 
BRAF driven tumours are more common in SSM and show more pagetoid spread 
(upward migration into the epidermis), nest formation in the epidermis, 
epidermal thickening, greater pigmentation, a preponderance in younger 
population and a tendency to metastasise to the lymph nodes (although overall 
survival was not affected; Viros et al., 2008).  By contrast, NRAS tumours 
presented with a greater Breslow thickness, a higher mitotic rate and evidence 
of a shorter melanoma specific survival, but these tumours could not be 
identified by morphological features (Devitt et al., 2011; Viros et al., 2008).  
cKIT has recently been shown to be mutated in acral lentiginous melanomas 
(Carvajal et al., 2011).  These findings suggest that driver mutations can confer 
distinct pathological characteristics and further work is required to delineate 
and confirm these findings. 
1.1.7.3 Improving efficacy of targeted therapies  
The initial treatment successes have been tempered by the inherently 
heterogeneous and chemo-resistant nature of melanoma (Vultur and Herlyn, 
2009).  Importantly, it appears that the resistant tumours are still reliant on the 
MAPK pathway and therefore combining BRAF with MEK inhibition further 
downstream may go some way to abrogating this response (Smalley and Sondak, 
2010).  A Phase 1 and 2 clinical trial comparing this combination therapy with 
BRAF inhibition monotherapy found improvement in progression free survival and 
a Phase 3 trial is currently underway (Flaherty et al., 2012b).  There remains a 
pressing need for more effective agents, which, either alone or in combination 
with agents that may abrogate resistance and agents that may impact collateral 
pathways in a rational manner, may achieve a more significant impact on this 
disease (Gogas et al., 2007).  The heterogeneity of melanoma is being 
methodically deconstructed and now BRAF V600E mutations predict clinical 
efficacy of RAF inhibitors such as vemurafenib; activating KIT aberrations may 
predict response to tyrosine kinase inhibitors such as imatinib, nilotinib, or 
dasatinib, and some NRAS mutant tumours may exhibit sensitivity to MEK 
inhibition (Hodis et al., 2012).  
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New drugs studies should be carefully evaluated to show benefit in sub-groups of 
patients (Stewart et al., 2010).  Smarter clinical trial design will therefore be 
important and methods like enrichment strategies will prove more successful 
when the specific mutation is known and large gains can be expected in a subset 
of patients (Mandrekar and Sargent, 2011).  Based on current thinking and 
research, it is likely that in future patients will be given targeted therapies or 
combinations thereof based on the individual molecular profile of their tumours. 
1.1.7.4 Biomarkers for metastasis 
Currently, no single biomarker is prognostic for future metastatic relapse.  
Improving our understanding of the mechanisms of metastasis and identifying 
biomarkers associated with melanoma invasion and metastasis may also aid the 
development of novel therapeutic targets.  In recent years, studies have 
investigated gene expression signatures based on mRNA levels in melanomas 
(Bittner et al., 2000).  However, due to translational and post-translational 
alterations, these signatures cannot accurately reflect the protein levels in vivo.  
Therefore modern techniques such as proteomics screening tools may identify 
relevant and significant changes in protein expression (Huang et al., 2009).  
Given that metastasis is the most important cause of mortality, there remains an 
unmet need for a useful molecular marker of metastatic potential (Mackie, 
2000). 
Cancer cell metastasis 
1.1.8 Metastasis 
Cancer cell metastasis, the ability of tumour cells to spread from the primary to 
a distant site is the major cause of death in cancer patients, accounts for over 
90% of cancer related mortality (Sethi and Kang, 2011).  Most remarkable is the 
tortuous journey taken by a cancer cell to reach its site of metastasis.  This is a 
complex and multi-stage process for which the cancer cell has to overcome 
many barriers and unfavourable environments (Steeg and Theodorescu, 2008).  
Thus, only a few cells end up completing this journey (Fig. 3). These cells are 
likely to be derived from a sub-population within the primary tumour and one 
would therefore hypothesise that the heterogeneity, characteristic of 
melanoma, may enhance its chances of success (Fidler, 2003). 
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1.1.9 Models of metastasis 
One mechanistic theory is based on the anatomical/ mechanical model, whereby 
cells passively enter the blood stream or lymphatic system and grow in the first 
draining organ (Langley and Fidler, 2011).  Gastric cancers have a predilection 
for the liver, which has a rich blood supply via the portal vein.  Uveal melanoma 
by comparison also has a predilection for the liver, but it is unlikely that this 
organ bias arises simply through a direct filtering effect.  This organ-tropism 
suggests that there are sites that present desirable features for cancer cells.  
These are known as pre-metastatic niches.   
The first appreciation of the importance of such microenvironments was 
published in 1889, with the observation that breast cancer did not spread 
randomly.  Instead the fastidious cancer cell “seed” depends on the fertility of a 
particular organ “soil” (Paget, 1889).  Experimental evidence supporting the 
seed and soil hypothesis eventually emerged in the 1980s with the demonstration 
that melanoma allografts would metastasise to transplanted lungs and ovaries, 
but not kidneys, despite the passive spread and arrest of cells at different sites, 
confirmed with radiolabelling (Fidler and Nicolson, 1976).  There is evidence 
that this is a highly co-ordinated event mediated by chemotaxis.  Recently, Kim 
et al., revealed that metastasis is a multi-directional process with melanoma 
circulating tumour cells (CTCs) able to re-seed the site of the primary (Kim et 
al., 2009).  Two interesting observations from this study include the role of 
chemotaxis in actively directing cells to this site and the role of the motility 
protein fascin in facilitating the process. 
1.1.10 Invasion & cell motility 
Underlying the invasive behaviour is increased motility caused by genetic 
alterations, changes in cytoskeletal organisation and altered contacts with the 
extracellular matrix (Gaggioli and Sahai, 2007).  Cell motility can be 
deconstructed into a series of co-ordinated processes requiring cell protrusion, 
adhesion, contraction and de-adhesion.  Movement is generated through 
alterations in the actin cytoskeleton with cycles of actin polymerisation, cell 
adhesion and acto-myosin contraction (Olson and Sahai, 2009).  For efficient 
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motility, cells must co-ordinate these movements.  Small GTPases of the Rho 
family are central to regulating both protrusion and contraction. 
Key regulators of the motility have been shown to be up-regulated in a subset of 
motile cancer cells (Condeelis et al., 2005).  The recent finding that Rac1, a 
small GTPase of the Rho family, is a driver mutation in melanoma also implicates 
dysregulated motility as a mechanism of cancer progression (Hodis et al., 2012).  
P-Rex1, a Rac-specific Rho GTPase, has been shown to drive invasion and is 
elevated in the majority of human melanomas, implicating a role in melanoblast 
migration and cancer progression to metastasis in mice and humans (Lindsay et 
al., 2011). 
In an invasion model proposed by Liotta, cells must first attach to the 
extracellular matrix (ECM) and then degrade the matrix locally before 
commencing forward cellular migration.  Adhesion to ECM components present in 
the basement membrane and underlying stroma is an essential factor in the 
ability of cells to invade and ultimately metastasise (Klominek et al., 1997).  The 
second stage involves a programme of basement membrane transmigration, and 
first, cells must actively degrade this structure.  One key programme involves 
degradation through the membrane anchored matrix metalloprotease (MT1-MMP) 
(Hotary et al., 2006), which can be delivered by invadopodia, invasive actin-
dependent protrusions (Desmarais et al., 2009).  Cells then actively migrate 
through the surrounding stromal tissue, stimulated by interactions with 
cytokines, growth factors, motility factors and ECM components (Klominek et 
al., 1997).  
Melanoma is capable of spreading haematogenously and via the lymphatic 
channels.  There is also evidence supporting an angiotropic, extravascular 
migratory mechanism (Lugassy et al., 2007). 
1.1.11 Impact of the microenvironment on motility 
1.1.11.1 Role of the microenvironment 
“An often over-looked facet of tumour biology research is the involvement of the 
surrounding tumour microenvironment” (Lee and Herlyn, 2007).  There is 
Chapter 1 
 39 
increasing evidence to support a major role for stromal components in all stages 
of tumorigenesis including initiation, progression and metastasis.   
The influence of the microenvironment became clear with studies showing that 
changes in tissue structure were critical for the expression of the malignant 
phenotype and that ECM receptors are important modulators of this effect.  
Despite the malignant genotype, cellular and tissue architecture are considered 
to act as the most dominant tumour-suppressor of all (Weaver et al., 1997).  For 
example, the formation of a basement membrane has been shown to be 
accompanied by the cessation of growth and observations in melanomas in vivo 
concur with this hypothesis (Mackie et al., 1989).  Analysis of histological human 
melanoma samples show that breaks in and thinning of the normally continuous 
line of type IV collagen and laminin at the dermo-epidermal junction are seen in 
association with areas of melanocytic proliferation, either with the junctional 
activity of benign naevi or in melanomas in association with invasive tumour 
cells. 
1.1.11.2 2D v 3D motility 
One of the observations and challenges in studying cell motility has been the 
differing motility mechanisms seen in 2D and 3D models (Pinner and Sahai, 
2008).  It is therefore important to reflect on how the cells respond to the 3D 
environment they inhabit in vivo.  For example, RhoA activity during invasion, 
demonstrates significant differences in the subcellular spatial regulation of RhoA 
in 3 dimensions compared with standard 2-dimensional culture models (Timpson 
et al., 2011).  There is increasing evidence that 2D and 3D migration utilise the 
actin cytoskeletal machinery differently, although structures such as 
invadopodia can be visualised in 3D as well as 2D (Magalhaes et al., 2011; Tang 
et al., 2013). 
Mechanistic findings from standardised 2D assays can advance understanding of 
malignant transformation, but it is important to analyse the results in the 
context of the tumour microenvironment (Lee and Herlyn, 2007).  The majority 
of research is performed using 2D platforms yet solid tumours do not exist in 
monolayers and in 3D cells also have to detach from a tumour (Wells, 2000).  It 
may therefore not be a surprise that 90% of drugs exhibiting preclinical activity 
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fail given that a tumour is a mass of heterogeneous cells distributed within an 
ECM structure comprising a complex array of stromal components.  The invasion 
“gold standard” is pathologically identified invasion of tumours in in vivo.  This 
is currently largely unattainable for mechanistic studies in humans although 
animal models are providing important insights (Wells, 2000).  Interweaving the 
complexity of the 3D environment with the fundamental mechanisms displayed 
in 2D promises to result in more effective therapeutic approaches and enhance 
the overall success rate of drugs in the clinic (Lee and Herlyn, 2007).   
1.1.11.3 Single cell v collective migration 
Cells explanted for tissue culture often flatten and lose their differentiation 
markers, but when placed back into 3D culture conditions, will regain their in 
vivo morphology (Yamada and Cukierman, 2007).  This difference in cell culture 
morphology can translate to differences in cancer cell migration phenotypes in 
3D matrices: single cell and collective migration. 
Two main types of single cell motility have been described: amoeboid and 
mesenchymal (Olson and Sahai, 2009; Sanz-Moreno et al., 2011).  “Amoeboid” is 
similar to leucocyte migration with an amorphous phenotype.  This has been 
likened to the appearance of single cell migration in vivo with rapidly changing 
morphology.  It bears similarities with the blebbing morphology witnessed 
occasionally in the amoeba Dictyostelium and in cancer cells treated with 
proteases (Wolf et al., 2003).  Conversely, MDA-MB-231 carcinoma cells exhibit a 
constitutive protease dependent “mesenchymal” movement.  The phenotype is 
integrin dependent, involving cellular elongation with a tendency to polarise the 
binding end of the cell and it is the main mode of motility by which 
Dictyostelium migrate.  Cancer cells can transition between phenotypes without 
loss of speed (Smirnova and Segall, 2007).   
Alternatively, cancer cells can migrate collectively and this form of migration 
has been likened to the Epithelial-Mesenchymal Transition (EMT) and the reverse 
Mesenchymal-Epithelial Transition (MET; Micalizzi et al., 2010).  EMT is proposed 
to occur around the time of delamination during melanoblast migration, 
providing additional flexibility and is considered to be an important stage of 
metastasis (Theveneau and Mayor, 2012).  Melanoma demonstrates both forms of 
Chapter 1 
 41 
invasion histologically (Friedl and Gilmour, 2009).  Friedl demonstrated that 
melanoma cells migrating out of an explant collectively would switch to single 
cell “amoeboid” motility in a β-1 integrin dependent manner, suggesting 
efficient cellular and molecular plasticity in tumour cell migration strategies in 
response to microenvironmental cues (Hegerfeldt et al., 2002).   
1.1.11.4 Melanoma & the microenvironment 
Melanocytes or melanomas are surrounded by a range of cells from 
keratinocytes, fibroblasts, endothelial cells and immune cells (Lee and Herlyn, 
2007).  Under normal conditions, the proliferation of epidermal melanocytes is 
controlled by the surrounding keratinocytes (Herlyn and Shih, 1994).  Following 
invasion, the ability of melanoma cells to survive in the dermis appears to be 
dependent upon expression of cell–ECM adhesion molecules such as the integrins 
(Haass and Herlyn, 2005).  An important ligand is fibronectin, an ECM 
glycoprotein consisting of 220-250 KDa sub-units linked by disulphide bonds, 
which is widely distributed throughout plasma and tissue in dimeric and 
multimeric forms respectively (Aota et al., 1991). Its main function involves 
promoting cell attachment and spreading, and is stimulated primarily by a 
tetrapeptide sequence, Arg-Gly-Asp-Ser (RGDS) (Aota et al., 1991; Pierschbacher 
and Ruoslahti, 1984).  
The phenotype-switching paradigm involves changes in the local 
microenvironment driving transcriptional changes in melanoma cells (Hoek and 
Goding, 2010).  This argues that metastases arise because of microenvironment-
driven changes to a melanoma cell’s phenotype, leading to some cells acquiring 
a slow proliferating, stem cell-like phenotype with invasive potential.  Following 
migration, cells can switch back to a proliferative state.  There is data to 
support this via the action of TGF-beta, regulating the Microphthalmia-
associated transcription factor (MITF; Pinner et al., 2009).  Through intravital 
imaging, cells were visualised migrating in a low pigmented de-differentiated 
state.  Secondary site cells were differentiated in a high pigment state.  This 
challenges previous models of melanoma progression that evoke one-way 
changes in gene expression and provides a more rational context for explaining 
observed melanoma biology (Hoek et al., 2008). 
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1.1.12 Metastasis as a therapeutic target 
Drugs which target cancer cell invasion and metastasis have proven difficult to 
develop (Moustafa and Nicolson, 1997).  Unfortunately, conducting and designing 
clinical trials for the prevention of metastasis remains a controversial area.  One 
strategy to overcome this challenge may involve targeting metastatic 
colonisation in the adjuvant setting.  However the trials will be large, long, 
expensive and with a lack of hard intermediate endpoints.  Funding and carrying 
through with these trials will be challenging.  There are the ethical and practical 
questions of whether a patient with for example, thick melanoma and no signs of 
metastatic disease, should undergo potentially toxic treatment.  Conversely, is it 
ethical to treat patients to prevent metastasis, when many may have already 
developed metastases at presentation? How long should they be treated for? 
Arguably, the most ethically sound cohort to target, and with the greatest 
chance of trial success, are high-risk groups with stage III melanoma who have 
regional lymph node disease, but no detectable visceral metastases. It is not yet 
known if metastatic colonisation is an important therapeutic target and it will be 
challenging to validate this (Steeg and Theodorescu, 2008). There is also 
evidence to support the use of drugs targeting pre-invasive conditions to prevent 
subsequent invasion.  An example of this is the use of Cyclooxygenase-2 
inhibitors in preventing the progression of familial adenomatous polyposis from 
benign colonic polyps to invasive carcinoma (Taketo, 2012). 
The problem of validating success is complicated by our relative lack of 
understanding about the basic biology underlying the metastatic process.  One of 
the many challenges is to enhance this understanding to identify novel 
biomarkers (Wells, 2000).  One potential avenue could involve detecting CTCs as 
biomarkers for metastasis.  One trial using a filtration technique detected a 
statistically significant difference in CTCs present between primary invasive (18 
of 62, 29%) and metastatic melanoma patients (5 of 8, 62.5%), whereas controls 
were negative (De Giorgi et al., 2010).  An alternative strategy involves seeking 
molecular biomarkers from the primary tumour and/or its microenvironment.  
Another potential biomarker is fascin, an actin bundling protein, involved in 
melanoma motility.  Fascin, upregulated in advanced disease, has also been 
proposed as a potential therapeutic target (Mackesky and Li, 2010).  The 
potential key driver mutation discovered in Rac1 is also linked to cell motility 
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and potentially metastasis (Li et al., 2012).  These biomarkers could have three 
key uses: firstly, to predict response to specific therapies; secondly, to identify 
patients at high risk of metastasis; and finally, to measure response to therapy. 
Various strategies could be employed in developing targets and either the 
tumour or host cells could be targeted (Steeg and Theodorescu, 2008).  There is 
also clinical trial evidence supporting the use of dual agents, targeting growth 
and metastasis (Tortora et al., 2008).  Combining therapies that inhibit different 
signalling pathways has the potential to be more effective than inhibition of a 
single pathway.  For example, anti-VEGF treatment with anti-EGFR therapy has 
been shown to overcome EGFR resistance in pre-clinical trials and this combined 
treatment has shown benefit over standard chemotherapy.  The challenge for 
the analysis of treatments targeting metastasis is deconstructing what effects 
are induced either by host or tumour cells in this setting because both may 
express the target receptor, but targeting both cell types may of course prove 
beneficial.  These novel approaches will require further clinical trials to 
determine the benefit.  However, in order to progress to clinical trials, it is 
critical to understand and investigate the underlying biology driving invasion in 
order to seek novel targets.  Understanding the biology is critical for the 
successful development of new therapeutic compounds. In the 1990s, multiple 
large-scale clinical trials using matrix metalloproteinase (MMP) inhibitors did not 
show any benefit despite in vitro work to support their success.  These failed for 
a combination of factors ranging from unclear end-points to a lack of 
understanding about the ability of MMPs to exert a range of anti- as well as pro-
tumour effects (Fingleton, 2006). Fully appreciating the targets is therefore 
essential in ensuring the likely success of new compounds. 
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Part 2  
Chemotaxis 
1.1.13 Background 
Chemotaxis is the process by which cells perform directed migration towards 
gradients of soluble molecules (Insall, 2010a).  This is distinct from 
chemokinesis, the activated random migration of cells in response to an 
extracellular signal (T, 1995).  Chemotaxis is a very ancient evolutionary 
mechanism has been observed across species, from amoebas to eukaryotic cells 
(Van Haastert and Devreotes, 2004).  It is likely to have emerged from our 
single-celled ancestors and been preserved due to its essential role in survival, 
with key roles in fundamental physiological processes including cell division, 
embryogenesis and wound repair (King and Insall, 2009).  Importantly, it has key 
roles in pathophysiological processes and examples pertinent to this thesis 
include the homing of immune cells to pathogens and inflammatory mediators 
and the invasion of cancer cells (Smirnova et al., 2012; Zigmond and Hirsch, 
1973). 
1.1.14 Dictyostelium discoideum: the chemotaxis role model 
Chemotactic cell migration is orchestrated through a complex set of interacting 
processes.  These include detecting the chemoattractant, transducing the signal 
and resolving the information about the source’s direction whilst transmitting 
the information to the cell’s motility machinery to bias the direction of 
migration (King and Insall, 2009).  To deconstruct this process, researchers have 
studied the underlying principles of the process with the amoeba Dictyostelium 
discoideum.   
This unicellular organism has allowed the dissection and greater appreciation of 
the multiple and intertwined signalling pathways in an experimentally friendly 
model.  Significant understanding about chemotaxis has been derived from this 
organism due to its simpler genetics.  The relatively small genome was 
sequenced in 2005 showing that it had retained more of the diversity of the 
ancestral genome than plants, animals or fungi (Eichinger et al., 2005).  As a 
eukaryote, many of the cellular mechanisms mirror those of mammalian cells.  
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Axenic strains grown with defined media have been generated for laboratory 
investigation (Franke and Kessin, 1977; Sussman et al., 1967). 
Dictyostelium depends on chemotaxis for survival.  It performs chemotaxis to 
direct itself towards folate secreted by its bacterial food source.  During 
starvation it secretes cAMP in an autocrine fashion, which causes the cells to 
stream together to form a multicellular aggregate.  Both these processes 
resemble neutrophil chemotaxis and involve signal transduction through G-
protein coupled receptors (GPCRs). 
This form of motility is mediated through actin polymerisation and resembles 
mesenchymal migration.  Dictyostelium also migrate using an amoeboid 
morphology dependent on osmotic pressure (Yoshida and Soldati, 2006).  
Importantly, this means that as well as being an excellent model for GPCR 
transduced chemotaxis, it can model two of the key modes of motility exhibited 
by cancer cells (Sahai and Marshall, 2003). 
1.1.15 Translating the chemotactic signal to directional 
movement 
To generate directional movement the cell must bias its direction of migration 
towards the chemoattractant.  The paradigm involves sensing the gradient 
through cell surface receptors uniformly distributed along the cell surface (Van 
Haastert and Devreotes, 2004).  Dictyostelium and breast cancer cells will 
migrate efficiently towards the source until the concentration saturates the 
receptors (Bailly et al., 1998).  This (mesenchymal) motility is induced by the 
projection of a pseudopod.  There are two current hypotheses for steering cells: 
the “compass or signal-centred” and “pseudopod-centred” models.  The former 
is based on the concept of the cell first resolving the direction of the signal and 
then generating a pseudopod in that direction.  Experiments have confirmed 
that cells can respond spatially to localised high concentrations of 
chemoattractants (Gerisch and Keller, 1981).  The latter model supports the 
idea of pseudopod protrusion independent of a chemoattractant signal.  Instead 
the signal simply biases the lifetime of the pseudopod, thereby biasing the 
direction of migration (Andrew and Insall, 2007).  This model is predicted to 
produce a greater variety of motility responses, allowing greater adaptation to 
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and integration of the signals produced in the 3D environment inhabited by 
cancer cells (Insall, 2010a).  The co-existence of both models will allow cells to 
respond to a wide range of chemoattractant concentrations. 
Intracellular signalling driving chemotaxis remains poorly understood.  Following 
directional sensing based on receptor occupancy, one hypothesis supports the 
notion of a short-range pseudopod permissive signal (eg. phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) and a longer range antagonistic global inhibitory 
signal (eg. cGMP) (Kay et al., 2008).  In Dictyostelium, following GPCR 
occupancy, a PIP3, gradient is formed that is amplified in relation to the external 
gradient (Onsum and Rao, 2007).  This PIP3 gradient is generated either by the 
activation of the catalyst phosphatidylinositol (4,5)-bisphosphate 3-kinases 
(PI3K) or by the loss of Phosphatase and tensin homolog (PTEN) from the 
membrane in the same region.  However, recent knock out experiments of either 
PI3K or PTEN, individually or in combination, results in almost no reduction in 
their ability to perform chemotaxis, with accuracy continuing to approach that 
of wild-type cells (Hoeller and Kay, 2007) although their motility is impaired 
with slower chemotactic or random migration.  
The knowledge from Dictyostelium and neutrophil chemotaxis models therefore 
suggests that chemotaxis is transduced through at least two interconnected 
signalling networks.  This is an area of on going research and will not be 
discussed further.  The two main classes of cell surface receptors that transduce 
the extracellular signal, will be discussed later in this chapter.   
1.1.16 Measuring chemotaxis 
1.1.16.1 Background  
Despite its significance, chemotaxis is challenging to study due the highly 
dynamic and complex process of cell movement (Insall and Machesky, 2009b; 
Insall, 2010b).  This is further complicated by the great variety of biological and 
microenvironmental variables that can affect both cell movement and 
chemotaxis.   
Direct visualisation allows cells to be observed migrating using time-lapse 
microscopy (if needed) in real-time and bridge chambers are considered the gold 
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standard assay for investigating chemotaxis (Wells, 2000).  With the application 
of a consistent and measured gradient they are capable of accurately 
quantifying chemotaxis in a tightly controlled system.  The copious data 
generated are traditionally laborious to process, but offer detailed mechanistic 
insight into the behaviour of individual cells.  Logically, laboratories with an 
interest in the processes underlying chemotaxis therefore often favour these 
assays.   
One approach to managing the complexity of chemotaxis has been to use 
simplified indirect assays.  They are generally useful for screening 
chemoattractants and rapidly performing multiple simultaneous experiments.  
Zicha and Dunn propose that the evidence for any substance acting as a direct 
chemoattractant should also be carefully validated in a direct observation 
chamber (Zicha and Dunn, 1995). 
This section aims to review the key assays that are available to quantify or infer 
chemotaxis either directly or indirectly.  It considers their design relative to the 
study of cancer cell chemotaxis and focuses on 2D direct visualisation bridge 
chambers and their development as this formed the basis to the development of 
Insall chamber assay discussed in detail in chapter 3.  For brevity, the other 
types of important direct visualisation assays that exist including the under 
agarose (Ibarra et al., 2006), pipette (Gerisch and Keller, 1981) and microfluidic 
chamber assays (Li Jeon et al., 2002) are not discussed.  But the same principles 
of balancing ease, information and precision apply. 
1.1.16.2 2-Dimensional Assays:  
Bridge chambers provide a visualisation platform for observing the behaviour of 
cells between the two wells.  The cells are plated onto cover slips, which are 
then inverted leaving a small gap between the bridge and the cover slip.  Cells 
can then be observed using an inverted time-lapse microscope.  This means that 
individual chemotactic parameters can be recorded as well as separating the 
steps of the motility cycle, for example lamellipod protrusion and detachment of 
the rear aspect of the cell (Bailly et al., 1998; Maheshwari and Lauffenburger, 
1998). 
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The Zigmond chamber was the original direct visualisation platform and was 
designed for studying the process of neutrophil chemotaxis in detail.  The 
eponymous chamber allowed Sally Zigmond to obtain unparalleled insight into 
the basis of chemotaxis through the study of neutrophil migration in the 
presence of chemoattractant gradients.  For example, she was able to 
demonstrate that these cells could orient in a gradient with only a 1% change in 
concentration across their length and this becomes efficient with a 10% change 
(Zigmond, 1977).  Importantly, she also demonstrated that the ability to sense 
shallow gradients was optimal in the region of the dissociation constant Kd of the 
receptor (Zigmond, 1977).  This observation has been confirmed for tyrosine 
kinase signalling in addition to GPCR signalling (Sourjik and Berg, 2002).  This is 
logical because for a cell to chemotax, it must detect the change in 
concentration by a change in occupancy of its chemoattractant receptors.  The 
change in occupancy is greatest when the gradient is steepest and is well below 
the receptor saturation level.  Experimenting with progressively higher 
concentrations of chemoattractant solutions have demonstrated that chemotaxis 
accuracy tails off, supporting the adaptive process of receptor down regulation 
and saturation (Li Jeon et al., 2002).  It therefore follows that around the Kd of a 
specific receptor, a small change in the concentration of the chemoattractant 
results in the maximal change in the percentage of receptors occupied, giving 
optimal orientation (Zigmond et al., 2001). 
The Zigmond chamber was a great improvement on under agarose assays, due to 
its improved optical properties and near steady state linear gradient stable for 
30–90 minutes – perfectly adequate for assessing neutrophils, capable of rapidly 
migrating at speeds of up to 30 µm/min.  The chamber was designed with two 
medium-filled reservoirs, connected by a 1 mm wide, 20 µm deep, optically 
clear bridge (Fig. 4A).  
This 20 µm gap is large enough to allow the migration of cells, but small enough 
to ensure there is no flow and the only mechanism of mass transport over the 
bridge is diffusion (Zicha et al., 1991).  Therefore, adding a chemoattractant to 
one well will diffuse across the bridge, establishing a linear gradient.  This 
design also limits convection currents to the wells, which beneficially stirs the 
contents. 
Chapter 1 
 49 
 
Figure 1-4 Comparison of Mark 2 Insall chamber features. 
A Schematic showing the Insall Mark 2, Dunn and Zigmond chambers. The chemoattractant and 
buffer/control wells have been colour coded for direct comparison, along with the viewing bridges 
and cover slip supports. Note that the central cylindrical block on the Dunn chamber is the same 
height as the bridge and therefore offers no support to the cover slip. B demonstrates the versatility 
of the chamber with front or reverse side chemoattractant loading with no requirement for metal 
clips, unlike the Zigmond chamber. The latter technique involves loading after the cover slip has 
been secured and sealed in place with VALAP, producing a tight seal that reduces the risk of 
evaporation during experiments over one hour’s duration. C Cross section through the Insall 
chamber highlighting one key feature – the ability to use thin (#1.5, 0.16–0.18 mm) cover slips that 
permit high NA oil immersion microscopy. Bridges of differing widths provide different gradient 
steepnesses. D provides a close-up of the Insall chamber and demonstrates the directions of the 
two chemotactic gradients, which are unidirectional across each bridge. 
 
The design included non-sealed ends and a large bridge relative to the source 
and sink meaning that gradients are short-lived.  It is therefore not suited to the 
study of cancer cells, which move significantly more slowly than neutrophils and 
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therefore require longer periods of observation to allow movement to occur.  
Another major flaw with this chamber design when considering its use for 
investigating cancer cells is the variable gap between the bridge and cover slip.  
This arises as a result of the cover slip being held in place by temperature 
sensitive springs, which are capable of deforming the chamber, leading to 
unpredictable gradient variability both during and between experiments (Zicha 
et al., 1991). 
Published in 1991, and based on essentially the same bridge dimensions, the 
Dunn chamber was essentially an evolved version of the Zigmond chamber for 
the investigation of fibroblast chemotaxis (Fig 4A; Zicha et al., 1991).  These 
cells migrate significantly more slowly than neutrophils, at speeds of 0.42–1.25 
µm/min, (Ware et al., 1998).  The chamber design circumvented the problem of 
a variable gap between bridge and cover slip by seating a thick (#3, 0.25–0.35 
mm thickness) cover slip over a relatively inflexible glass chamber with annular 
wells of precise geometry.  Gradient characterisation experiments for this 
chamber found it was able to form a linear gradient within one hour of setting 
up the chamber.  One down side to this chamber design compared to similarly 
designed flow chambers is the delay in developing the linear profile (Li Jeon et 
al., 2002).  With proportionately less bridge compared to the volume of the 
wells and a stable gap between the cover slip and bridge, it generated a 
constant linear gradient for 12 hours and a significant gradient for 48 hours.  The 
reliable prediction and long-term stability of this chamber make it suitable for 
investigating the slower fibroblasts, which migrate at speeds similar to cancer 
cells that move around 1 µm/min (Friedl et al., 1997).  An important limitation 
of this particular assay concerns data analysis, which is complicated by the 
annular bridge design resulting in a variable chemoattractant gradient 
orientation (Monypenny et al., 2009).   
In 2010, we described the Insall chamber, as an improved tool for measuring 
cancer cell chemotaxis (Fig 4A; Muinonen-Martin et al., 2010).  This was a 
further refinement of the Zigmond and Dunn chambers and specifically designed 
for high quality imaging techniques for cancer cell chemotaxis, with attributes 
including ease of use and simplified gradient orientations.  The precise details 
and critique can be found in chapter 3: development, optimisation & validation 
of an efficient assay for cancer cell chemotaxis.  Modelling cancer cell migration 
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in an enhanced 2D chemotaxis assay should enable even greater appreciation of 
the diverse migratory behaviours exhibited in vivo (Soon, 2007). 
1.1.16.3 3-Dimensional Assays:  
The most commonly employed indirect assay is the high throughput Boyden 
chamber/ Transwell assay.  The design again uses 2-chambers, but the 
compartments are separated by a microporous filter onto which cells are seeded 
(Toetsch et al., 2009).  Chemoattractant gradients are established either side of 
a filter membrane in a 96-well plate and the cells are given a defined period of 
typically 3-4 hours to migrate.  Quantitative data is gained by counting cells that 
have migrated to the chemoattractant well.  A key difference is that this assay 
provides a limited 3D environment for cell migration.  It has been reported as a 
chemoinvasion assay with the simple addition of an acellular extracellular 
matrix, and this has been shown to correlate with invasion in vivo (Albini et al., 
1987).  It can be modified, for example, by exchanging the filter with a 
mammalian peritoneal basement membrane (Schachtner et al., 2013).  This has 
the benefit of providing a more realistic environment, and generating a physical 
barrier that requires active degradation. 
Quantification of cell migration can be improved by performing a checkerboard 
analysis, which attempts to separate the relative effects of chemokinesis and 
chemotaxis.  To produce these data, the chemoattractant is methodically added 
at differing concentrations both above and below the filter. A chemokinetic 
agent will enhance speed if the concentrations are equal both sides of the filter 
but a chemotactic agent will enhance the count only when there is a gradient 
(Zigmond and Hirsch, 1973). This can reliably quantify cell movement, but it is 
not able to unequivocally distinguish chemotaxis from chemokinesis (Rhodes, 
1982).  Boyden chambers are subject to a wide range of artefacts including an 
unknown concentration gradient over time and the effects of gradient 
dependent differential speeds with the net result that accurate analysis of 
chemotaxis is further hampered (Zigmond and Hirsch, 1973).   
With this closed design, cells cannot be directly imaged during the assay and 
therefore it does not provide detailed mechanistic understanding about 
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chemotaxis.  Detail including cell speed, cell polarity, pseudopod generation and 
turning rate are missed (Andrew and Insall, 2007). 
Tumour spheroid assays assess the invasion of embedded multicellular tumour 
spheroids into collagen.  Under the correct conditions melanoma cells will 
develop into smaller or even necrotic quiescent cells inside the spheroid and 
larger proliferating invasive cells outside, establishing a gradient of oxygen and 
nutrients and recapitulating the heterogeneity of tumour growth (Mueller-
Klieser, 2000).  Cells from the different biological stages will respond with an 
invasive phenotype indicative of their stage (Lee and Herlyn, 2007).  Typically 
this assay is used as a tumour model for drug resistance in discovery assays and 
is not easily adapted into an easily decipherable chemoinvasive assay (Naber et 
al., 2011). 
Driven by the need to develop assays more accurately reflecting the complexity 
and physiological nature of the in vivo environment, organotypic collagen assays 
are now commonly used to bridge the gap between in vitro and in vivo work 
(Berking and Herlyn, 2001).  They consist of collagen, extracted from rat tails, 
and polymerised in combination with human fibroblasts, with the latter 
contracting the gel into a rigid 3D coin like structure.  Cells can be seeded on 
top of the gel and invasion is believed to occur with the generation of a 
chemoattractant gradient, once the gel is lifted up to the air liquid interface.  
These gels have the capacity to recapitulate human melanoma initiation (Kiowski 
et al., 2011). Studies analysing the growth patterns of melanoma cells from 
different stages using these gels have also been shown to faithfully recapitulate 
progression across the biological stages (Meier et al., 2000).  The host fibroblasts 
have been shown to play an important role in enhancing invasion (Ridky et al., 
2010).  This is a malleable platform acting as a dermal equivalent assay with the 
option of assessing the invasion of cells from fresh tumour explants, thereby 
investigating a heterogeneous population of cells, rather than a clonal 
subpopulation (Commandeur et al., 2009). 
Finally, invasion can be quantified correcting for any growth defects that may 
occur with inhibitory drug treatments (Nystrom et al., 2005). 
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1.1.16.4 In Vivo Assays  
It is possible to study the effects of chemotaxis on cancer cell motility in vivo 
(Wyckoff et al., 2000b).  Implanting a needle containing a chemoattractant into 
a tumour in a murine model, cells can be collected that actively migrate into the 
lumen.  Wyckoff et al. used EGF as a chemoattractant to collect breast cancer 
cells from a primary tumour.  The cells can then be isolated and subjected to 
microarray analysis, and the results have contributed to the concept of a gene 
invasion signature (Wang et al., 2004).  Cells have also been shown to polarise 
towards blood vessels, a presumed rich source of chemoattractants (Pollard, 
2008; Wyckoff et al., 2004).  With advances in imaging technology, the field of 
cancer cell motility research is now focusing more on intravital imaging 
techniques with clear demonstrations of individual melanoma cells migrating/ 
chemotaxing during invasion (Pinner et al., 2009). 
This diversity of experimental models is reflected by the many pros and cons of 
each, with no one approach superior.  The choice of experimental system 
therefore depends on the question to be answered and ideally one would employ 
a combination of 2D, 3D and in vivo approaches to validate the physiological 
relevance of any mechanistic observations. 
Chemotaxis as a mechanism for cancer cell invasion  
1.1.17 The importance of cancer cell chemotaxis 
The last decade has seen the emergence of chemotaxis as an important player in 
the field of cancer migration, invasion and metastasis (Condeelis et al., 2005; 
Wang et al., 2002).  Many of the proteins that regulate motility are involved in 
chemotaxis and are also markers for metastasis and poor patient outcomes 
(Hodgson et al., 2003; Stathopoulos et al., 2008).  One chemotaxis pathway that 
has been interrogated in particular detail involves the invasion of breast cancer 
cells (Fig. 6). In this model, tumour cells establish paracrine signalling with 
macrophages by secreting CSF-1 and sensing EGF,  
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Figure 1-6 Paracrine and autocrine chemotactic driven tumour cell invasion. 
A schematic of breast cancer cell driven invasion driven by chemotactic gradients of EGF 
generated by macrophages. This are recruited through paracrine signalling by tumour cells with 
CSF-1. CSF-1 acts in an autocrine fashion to promote a more aggressive metastatic phenotype. 
Adapted from (Patsialou et al., 2009). 
 
whereas the macrophages secrete EGF and sense CSF-1. In addition, tumour cells 
also sense CSF-1 and this autocrine signalling contributes to the aggressive 
phenotype of human breast cancer cells (Patsialou et al., 2009).   
These results combined with the finding that cells polarise towards blood vessels 
has have been central to the development of the chemotaxis driven invasion 
paradigm in vivo and the concept that invasion is most efficient during active 
chemotaxis (Roussos et al., 2011a).  The metastatic signature generated from 
these studies is enlightening, but it is not clear whether tumour chemotaxis can 
be predicted from such gene expression patterns.  Currently, the physiological 
relevance of this work can only be inferred, as there are no available methods 
for quantifying actual levels of EGF in vivo.   
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The challenge now is to use this knowledge to increase our understanding of the 
role of chemotaxis in cancer cell metastasis.  This may enable the prioritisation 
of better drug targets, better drugs, appropriate patient selection and smarter 
early clinical study design. 
1.1.18 Correlation of chemotaxis with metastatic ability 
Liotta proposed that the various metastatic stages of tumour invasion require 
require three distinct steps.  1) Tumour cell attachment to the extracellular 
matrix 2) Local degradation and 3) tumour cell locomotion into the region of the 
matrix modified by proteolysis (Liotta, 1986).  Several studies have focused on 
the third step and investigated the relationship between the metastatic ability 
of cells in vivo and cell motility responses displayed in vitro (Raz and Ben-Ze'ev, 
1987).  These have been performed in general using pairs of related cell lines 
with differing degrees of metastatic potential.  These studies have supported 
the enhanced motility of highly metastatic cell lines.  Volk et al reported that 
poorly metastatic murine melanoma cells were slower with greater focal 
adhesion plaques, formed strong intercellular connections and in vivo formed 
compact tumours. Conversely, highly metastatic lines were poorly adherent, 
with loose intercellular connections, but faster (Mean speed 5.0+/-2.2 µm/hr) 
and, in vivo, easily detached and dispersed from the tumour (Volk et al., 1984).   
Murata et al investigated the chemotactic response to fibronectin using Boyden 
chambers and found both renal and melanoma high metastatic potential lines 
were approximately three times more chemotactic than low metastatic potential 
lines, although haptotactic migration (motility towards a bound substrate) 
remained unchanged (Murata et al., 1992).  With their in vivo chemoinvasion 
assay, Wyckoff et al collected cells of high metastatic potential with 
approximately 15-fold higher efficiency compared with low metastatic potential 
tumours (Wyckoff et al., 2000a).  This process was enhanced with the addition of 
either EGF or 10% Foetal Bovine Serum (FBS).  The current literature therefore 
supports significant differences in chemokinesis and chemotactic ability between 
cells of differing metastatic potential.  None of these studies were investigated 
with direct visualisation assays and therefore it is difficult to make robust 
conclusions about the relative roles of chemokinesis and chemotaxis. 
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1.1.19 Cancer cell chemotaxis: membrane receptor signal 
transduction 
1.1.19.1 Background 
There are myriad factors known to stimulate motility.  One large group of 
motility factors corresponds to the ECM proteins (Bogenrieder and Herlyn, 2003).  
These can either be solubilised by cleavage and stimulate chemotaxis or when 
bound they can stimulate haptotaxis.  These factors include fibronectin, laminin, 
collagens type 1 and 4 and thrombospondin, all of which have be shown to 
stimulate motility in melanoma cells through integrin receptors (Kleinman et al., 
1982; Klominek et al., 1997).  Despite these data, integrin mediated chemotaxis 
is not even mentioned in several reviews by leaders in the field of chemotaxis 
research.  Due to the paucity of data, this section will therefore focus on the 
two main classes of receptors that have been well studied and are known to 
mediate chemotactic signals activating cell motility pathways acting through the 
actin cytoskeleton:  signal transduction via receptor tyrosine kinases (RTKs) and 
G-protein coupled receptors (GPCRs). 
1.1.19.2 Receptor tyrosine kinase driven chemotaxis  
RTKs are membrane bound receptors with an extracellular ligand binding 
domain, a single transmembrane helix and a cytoplasmic region containing the 
protein tyrosine kinase (TK) domain plus additional carboxy terminal and 
juxtamembrane regulatory regions (Lemmon and Schlessinger, 2010).  The 
ligand, a growth factor (GF), binds and induces receptor dimerisation, thereby 
transducing signalling by stimulating tyrosine kinase activity through 
autophosphorylation at the cytoplasmic domain (Ullrich and Schlessinger, 1990).  
This phosphorylation increases its efficiency by 50-200 fold and this site acts as 
an assembly point for downstream signalling molecules.  Amongst many others, 
PI3K is the major protein associated with the activated receptor and this is 
stimulated through CSF-1 binding to macrophage RTKs (Kanagasundaram et al., 
1996).   
The most studied chemotactic signalling pathway in cancer cell chemotaxis, is 
via EGF and the EGF receptor (EGFR).  Importantly expression of epidermal 
growth factor receptor has been shown to correlate with invasive and metastatic 
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potential in animal models and human cancer (Pryczynicz et al., 2008).  EGF is a 
strong chemokinetic agent, but chemotactic signalling in fibroblasts is delayed 
for a 4 hour window following stimulation with EGF (Ware et al., 1998).  EGFR 
overexpression enhances the ability of MTLn3 mammary adenocarcinoma cells to 
intravasate and metastasise to the lung after mammary fat pad injection through 
the paracrine and autocrine loops with macrophages recently discussed 
(Patsialou et al., 2009; Xue et al., 2006).  This particular loop highlights the 
ability of cancer cells to hijack the body’s host response to enhance their chance 
of successful metastasis.  It thereby implicates the inflammatory response in 
metastasis, with macrophages shown to generate a chronic inflammatory 
response in malignancy (Wyckoff et al., 2007). 
Examples of the chemotactic responses induced by EGF are presented in this 
figure (Fig. 7A,B).  In a direct visualisation pipette assay, the chemotaxis index 
is high, with a mean 0.55, and this calculation is based on the average 
displacement of roughly one cell’s length.  The significance of this will be 
discussed further (Soon et al., 2005).  The Rose plot in Fig. 7B demonstrates the 
representative moderate bias in directionality induced by PDGF and IGF in a 
highly metastatic cell line, with a broad spread of end point positions relative to 
the chemoattractant (Zicha and Dunn, 1995). 
Other clinically relevant chemoattractants implicated in cancer cell chemotaxis 
activating RTKs include the motility receptor c-Met, which has been shown to 
drive bony metastasis (Ono et al., 2006), and signals through its ligand 
hepatocyte growth factor (HGF, scatter factor; Steeg and Theodorescu, 2008).  
The paracrine action of PDGF plays an important role on the tumour stroma and 
fibroblasts in particular on tumour progression, but it has also been implicated in 
autocrine PDGFR signalling promoting breast cancer metastasis (Jechlinger et 
al., 2006).  Not only are chemoattractants produced by host cells that attract 
malignant cells, but there is a substantial literature describing the role 
melanoma cells play in secreting chemotactic factors that attract host cells and 
thereby promote metastasis.  One recent example reported the maintenance of 
human mesenchymal stem cells in the melanoma tumour microenvironment. This 
arises through chemotaxis and invasion of these multipotent stem cells towards 
the tumour, and this migratory effect appears to be mediated in part through 
secretion of FGF2 by melanoma cells (Watts and Cui, 2012). 
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Figure 1-7 Representative comparisons of RTK and GPCR transduced chemotaxis. 
The chemoattractants are located on the right in all images. A Phase contrast imaging of MTLn3 
breast carcinoma cells showing polarisation and motility towards the micropipette (arrowhead) 
containing EGF over 1 hour. The chemotaxis index end-point and continual plots are also 
presented (Published by (Soon et al., 2005)). B Rose plot of highly metastatic rat T15 cells 
chemotaxing towards IGF and PDGF over 16 hours (Published by (Zicha et al., 1991)). C Murine 
neutrophil cells chemotaxing towards the chemotactic peptide fMLP, generating a chemotaxis 
index of approximately 0.95 (Published by (Kay et al., 2008)).  
 
1.1.19.3 G-protein coupled receptor driven chemotaxis 
GPCRs are composed of seven-transmembrane α-helices.  With more than 800 
members, GPCRs represent by far the largest family of cell-surface molecules 
involved in signal transduction, accounting for >2% of the total genes encoded by 
the human genome and they currently represent the target of over half of all 
current therapeutic agents (Dorsam and Gutkind, 2007).  Following binding with 
their ligand, GPCRs undergo conformational change and expose intracellular 
sites involved in the interaction with the G-protein hetero-trimer, which 
contains α, β and γ subunits.  This catalyses the dissociation of GDP for GTP 
thereby initiating several downstream signalling networks.  These include 
several second-messenger-generating systems including small GTPases of the Ras 
and Rho families, and signalling pathways. 
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GPCRs were directly implicated in transducing extracellular chemotaxis signals 
with the generation of a G-β null Dictyostelium mutant (Wu et al., 1995).  
Although this mutant displayed normal motility it failed to perform chemotaxis, 
which was also the phenotype of a G-α protein subunit mutant (Kumagai et al., 
1989).  A complex array of chemokines, as well as bio-active lipids such as 
lysophosphatidic acid (LPA) and sphingosine-1- phosphate (S1P) are implicated in 
aberrant cell proliferation in a wide range of cancer cells (Dorsam and Gutkind, 
2007).  Chemokines are one of the main classes of cues that initiate chemotaxis 
in tumour cells and they act via GPCRs.  One of their key roles in cancer 
metastasis has been shown to be the homing of cells to specific organs through 
chemotaxis but they have also been implicated in tumour growth and invasion 
(Payne and Cornelius, 2002).  There are many that have been shown to play a 
role in disease progression and these have been reviewed in detail (Payne and 
Cornelius, 2002; Roussos et al., 2011b).  From a melanoma perspective, CCR7 
signalling has been associated with directed growth towards lymphatic tissue via 
secretion of its ligand (CCL21) from lymphatic endothelial cells (Emmett et al., 
2011).  This has been confirmed in other studies and a soluble inhibitor of the 
ligand has been developed that showed promise in a study, confirming this as a 
potential therapeutic target and also confirming that lymphatic spread appears 
to be a chemokine dependent process (Lanati et al., 2010).  There is evidence to 
implicate the CXCL9/CXCR3 axis in transendothelial melanoma cell migration 
(Amatschek et al., 2011).   
One of the most widely studied examples of GPCR mediated chemotaxis is the 
stromal cell–derived factor 1 (SDF-1/ also known as CXCL12)/chemokine receptor 
4 (CXCR4) axis.  This has been linked to many cancers, but appears to play a 
critical role in mediating metastasis of a chemoresistant tumour subpopulation 
toward a lymphatic niche in specific target organs, regional lymph nodes and 
lungs (Kim et al., 2010).  SDF-1 is also an autocrine chemoattractant produced 
by melanoma cells to attract cytotoxic T lymphocytes, and the author argues 
that the expression of CXCR4 by the T-cells may be a beneficial prognostic 
marker (Zhang et al., 2006).  A typical example of GPCR chemotaxis (Fig. 7C) by 
neutrophils is presented, reflecting the long, straight and highly accurate tracks 
towards the chemoattractant (Kay et al., 2008).  These accurate tracks reflect 
the high chemotaxis indices generated by GPCR mediated chemotaxis compared 
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to the lower chemotaxis indices generated by RTK mediated chemotaxis 
described earlier.  
1.1.20 Modelling chemotaxis of cancer cells with melanoma  
1.1.20.1 The relevance of melanoma 
Melanoma is a particularly relevant cancer sub-type for researching the 
mechanisms and the role of chemotaxis in cancer cell metastasis for several 
reasons.  Firstly, studies have already shown that melanoma cell lines are 
chemotactic to soluble extracellular matrix components found particularly in 
basement membranes (Hodgson et al., 2003; Saito et al., 2009).  This work led 
some groups to begin to look at the interplay between haptotaxis, (directed 
migration on extracellular matrices), and chemotaxis.  As yet, no one has 
investigated the relative roles of these migration mechanisms in one 
experimental model (Aznavoorian et al., 1990; Hodgson et al., 2003; Klominek et 
al., 1997; Saito et al., 2009).  Secondly, based on the paradigm of cancer cell 
reactivation of embryonic pathways, and considering the journey taken by 
melanoblasts, melanoma cells should exhibit highly motile behaviour (Friedl and 
Gilmour, 2009).  This in turn makes melanoma an appealing experimental tool 
for the investigation of their chemotactic behaviour.  Finally, melanoma has 
clinico-pathologically distinct growth phases and a panel of primary and 
metastatic melanoma cells from all stages with representative mutations are 
available for study (See appendix 1; Satyamoorthy et al., 1997). 
1.1.20.2 Murine models of melanoma 
Fresh melanoma tissue for investigation can be derived from different 
mammalian models and humans.  The challenges of accessing primary melanoma 
tissue for research have been discussed (Wich et al., 2009).  Here I will present 
two key mouse models that are available for study locally and have a body of 
literature that supports their ability to recapitulate many of the features of 
human melanoma (Walker et al., 2011).   
One important caveat relates to the differences in architecture between mouse 
and human skin.  Human melanocytes are found primarily in the inter-follicular 
regions of the basal layer of the epidermis, and in the hair follicle.  In mice, the 
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melanocytes reside in the hair follicle, upper dermis and less typically in the 
inter-follicular basal epidermis.  Therefore the melanomas generated will arise 
from different environmental niches, which is problematic for many of the 
reasons already discussed and tends to generate melanomas resembling nodular 
melanoma rather than SSM.  Noonan et al generated a mouse overexpressing 
hepatocyte growth factor/scatter factor (HGF/SF), generating inter-follicular 
melanocytes like human skin and melanomas are generated recapitulating the 
growth characteristics of SSM following irradiation (Noonan et al., 2001).  
Assimilating these factors, combining cell lines, mouse and human melanoma 
models is considered the ideal paradigm to achieve physiological relevance 
(Herlyn and Fukunaga-Kalabis, 2010). 
There are murine models that are highly representative of the main genetic 
determinants of human melanoma and encompass the four most common driver 
and tumour suppressor mutations. These include activation of BRAFV600E or 
NRASQ61K, and deletion of PTEN or CDKN2A (the INK4a locus encodes both 
p16INK4a and p19 (ARF)).  McMahon et al discovered that activating BRAFV600E 
alone in a heterozygous or homozygous manner generated naevi, but PTEN 
deletion was necessary for melanomagenesis (Dankort et al., 2009).  Another 
BRAFV600E model, using a different source of alleles, generated melanomas 
without the requirement for PTEN deletion (Dhomen et al., 2009). 
Ackermann et al described the N-RasQ61K INK4a-/- transgenic mouse model 
(Ackermann et al., 2005).  This generated melanomas metastasising to viscera 
but not with the efficiency of the BRAFV600E PTEN-/- models suggesting that PTEN 
mutations are more likely to cause metastasis.   
1.1.20.3 Three key mechanisms of tumour dispersal  
In vivo, melanomas not only invade downwards, but they exhibit signs of 
dispersal, with spread above the tumour and lateral migration away from the 
tumour into a less (cancer cell) dense area (Wells, 2000).  This global outward 
migration suggests the cells are dispersing and I have presented evidence to 
support this as an active rather than mechanical process.  There are three key 
mechanisms by which a tumour could actively disperse: positive chemotaxis, 
negative chemotaxis and contact inhibition of locomotion. 
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Contact inhibition of locomotion, is exemplified by the migration of neural crest 
cells towards their final destination (Theveneau et al., 2010).  This can operate 
as a mechanism of pseudo-chemoattraction, whereby attractants such as Sdf1 
amplify and stabilise contact-dependent cell polarity, resulting in directional 
collective migration.  In the cancer setting, Friedl et al postulate, that contact 
inhibition of locomotion may maintain a high degree of polarity in cells invading 
collectively and this process would contribute to the directional persistence of 
motility even in the absence of a chemotactic gradient (Friedl et al., 1995). 
External factors such as chemorepellents (negative chemotaxis) and 
chemoattratants (positive chemotaxis) have been proposed to confer 
directionality on migratory cell populations (Kay et al., 2008).  I have discussed 
the role and evidence for positive chemotaxis in driving cancer cell and 
melanoma migration under the direction of a gradient.  Other than release of 
soluble factors via host cells, this could be mediated in a “sequestrine” manner 
by the appearance of new haptotactic or soluble chemotactic factors following 
invasive degradation (Wells et al., 1998).  However, little is known about how 
this, or other attractive signals, can be integrated by a migratory group 
(Theveneau et al., 2010).   
Negative chemotaxis is illustrated by the paradigm of Entamoeba histolytica cell 
movement (Zaki et al., 2006).  This organism is responsible for amoebic 
dysentery and its invasion through the mucosa of the gastrointestinal tract is 
postulated to be pathogenically driven by its motility response to the production 
of ethanol, which acts as a chemorepellent.  The closely related but non-
pathogenic Entamoeba dispar conversely fails to respond to ethanol.  
These three mechanisms of tumour dispersal therefore require close 
interrogation, especially because at present the relative influence of each is not 
known. 
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Lysophosphatidic acid (LPA) 
1.1.21 Background 
LPA (monoacyl-glycerol-3-phosphate) is a naturally occurring bioactive 
lysophospholipid eliciting growth-factor-like activities that signals through GPCRs 
(Van Corven et al., 1989; Moolenaar, 1994).  Its simple structure belies its 
critical roles in physiological and pathophysiological processes (Moolenaar and 
Hla, 2012).  Early studies demonstrated its bioactivity with the induction of 
smooth muscle contraction and platelet aggregation. 
1.1.22 Structure & biological activity 
1.1.22.1 Structure & sub-species 
LPA consists of a single fatty acid chain, a glycerol backbone and a free 
phosphate group and compared to other phospholipids is water-soluble.  It is 
present in numerous chemically distinct species with considerable variation in 
the length and degree of saturation of the fatty acid chain (Choi et al., 2010).  
The most abundant forms in plasma are 16:0, 18:1(the most commonly used 
laboratory reagent) and 18:2 (Sano et al., 2002).  It is esterified at the sn-1 or 
sn-2 position of the glycerol backbone (Fig.7). 
1.1.22.2 Biological activity 
Jalink et al, investigated the biological function of differing LPA structures on 
the ability of LPA to act as an agonist, activating phospholipase C-mediated Ca2+ 
mobilisation in human A431 carcinoma cells (Jalink et al., 1995).  Increasing 
biological activity was shown to correlate with longer acyl chain lengths (C16-
C20) and the short-chain species (<C14) are almost completely biologically 
inactive (Jalink et al., 1995; Van Corven et al., 1992).  For a given chain length, 
unsaturated LPA is more potent than the saturated species, but there is no 
further correlation with increasing double bonds and LPA’s potency.  Deletion of 
the glycerol backbone reduces potency by a factor of 1000 and the phosphate 
group is critical for function.   
In the current model for ligand-receptor interaction, the acyl chain and glycerol 
backbone anchors the LPA molecule to present the negatively charged phosphate 
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group to the positively charged residues in the extracellular domain of the LPA 
receptor.  Binding of the phosphate group triggers a conformational change that 
activates the receptor (Jalink et al., 1995). 
1.1.22.3 Role of albumin and carrier proteins 
In 1992, LPA was shown to bind to BSA (Van der Bend et al., 1992), and was 
biologically active in this form (Eichholtz et al., 1993) Further biological support 
for this was derived from studies with fibroblasts, whereby serum induced a 
stress-fibre response with albumin bound LPA and albumin also aids the delivery 
of LPA to cells within stroma (Meerschaert et al., 1998; Ridley and Hall, 1992).  
It is not known at the receptor ligand level whether the dissociation of LPA from 
albumin is necessary for its activation (Tigyi and Miledi, 1992).   
1.1.23 LPA homeostasis 
1.1.23.1 There are two main pathways to LPA production 
A natural exogenous source of LPA was first identified in 1993, with platelets 
shown to release LPA following activation with thrombin.  It was identified in 
mammalian serum bound to albumin at concentrations ranging from 1-5 µM, but 
is <100nM in plasma (Eichholtz et al., 1993).  Lysophosphatidylcholine (LPC) a 
precursor of LPA is by comparison found in abundance in the plasma.  LPA is 
fairly water-soluble with a critical micelle concentration ranging from 70µM-
1mM, high enough to permit its presence in serum.  Aoki et al investigated this 
finding and found that half the LPA in serum is produced via a platelet-
dependent pathway.  The two main pathways (Fig. 8) for LPA production were 
identified with thrombin induced platelet activation (Aoki et al., 2002).  In 
addition to platelets, fibroblasts, adipocytes and ovarian cancer cells have been 
shown to produce LPA. 
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Figure 1-8 Two pathways to LPA production and its structure. 
A hydrolysis of phosphatidic acid (PA) by soluble phospholipase A2 (sPLA2), which cleaves the 
fatty acyl chain at the sn-2 position of the glycerol backbone; B hydrolysis of 
lysophosphatidylcholine (LPC) by ATX, which liberates the hydrophilic headgroup (choline). LPC is 
produced by the action of PLA1 or PLA2 on membrane phosphatidylcholine. Adapted from (Mills 
and Moolenaar, 2003). 
 
LPA can be produced by at least two distinct enzymatic mechanisms: hydrolysis 
of phosphatidic acid (PA) by soluble phospholipase A2 (sPLA2), which cleaves the 
fatty acyl chain at the sn-2 position, or hydrolysis by phospholipase A1 (PLA1), 
which cleaves the fatty acyl chain at the sn-1 position of the glycerol backbone; 
or hydrolysis of lysophosphatidylcholine (LPC) by ATX/lyso PLD, which liberates 
the hydrophilic headgroup (choline). LPC is produced by the action of PLA1 or 
PLA2 on membrane phosphatidylcholine. Published by Mills & Moolenaar 2003 
In serum or plasma, LPA is predominantly produced in a two-step process.  LPC is 
present in abundance in plasma and is generated by secretory-type 
Phospholipase A2 (sPLA2) and sPLA1.  In the second step, LPC is hydrolysed by 
autotaxin (ATX) to produce LPA (Aoki et al., 2002).  sPLA1 and sPLA2 are enzymes 
catalysing the release of fatty acids from the sn-1 and sn-2 positions of fatty 
acids (respectively).  sPLA2 has been identified in the epidermis but both sPLA1 
and sPLA2 are released in abundance from activated platelets (and to a lesser 
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degree, by red blood cells) (Maury et al., 2000).  The ATX pathway generates the 
majority of LPA in blood.  This was established in experiments with ATX 
knockout mice, with ATX heterozygote mice having half of the normal ATX 
activity and plasma LPA levels.  From this paper, it was also clear that ATX 
activity and LPA production are essential factors in angiogenesis during 
development with ATX null mice dying at E9.5 with severe vascular defects (Van 
Meeteren et al., 2006). 
LPA is identical in structure to phosphatidic acid (PA), but posses only a single 
acyl chain, therefore the second pathway involves the straightforward cleavage 
of this second chain from PA by the action of sPLA2 (Aoki et al., 2008).   
1.1.23.2 Degradation 
Extracelluar LPA concentrations are tightly and rapidly controlled mainly by the 
balance of ATX and lipid phosphate phosphatase (LPP) activities producing a 
circulating half-life of only 3 minutes (Samadi et al., 2011).  Each LPP consists of 
six transmembrane domains and is an ecto-enzyme with its active site on the 
outer surface of the plasma membrane (Brindley, 2004; Moolenaar et al., 2004) 
There are three LPPs and four LPP-related proteins (LPRs, or plasticity- related 
genes, PRGs).  Dephosphorylation of extracellular LPA by the ecto-activities of 
the LPPs yields the minimally biologically active mono-acylglycerol (MAG) and 
rapidly terminates the signalling action of LPA (Smyth et al., 2003; Brindley and 
Pilquil, 2009).  Thus the balance between production and degradation spatially 
and temporally determines the concentration of extracellular LPA. 
1.1.24 LPA signal transduction 
Six LPA self-surface receptors (LPARs) have been identified belonging to the 
GPCR family (Choi et al., 2010).  GPCR signalling was initially implicated through 
the ability of pertussis toxin (PTX) to inhibit the mitogenic effects of LPA (Van 
Corven et al., 1989).  The LPARs were identified in 1992, in cells known to be 
LPA sensitive by photoaffinity labelleling (Van der Bend et al., 1992).  LPAR 1 
was first cloned in 1996 and following overexpression in a neuroblast cell line 
the cells rounded in a serum-dependent manner that was reproducible with the 
sole addition of LPA (Hecht et al., 1996).  LPAR 2 and LPAR 3 are also closely 
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related and two additional, distantly related receptors, LPAR 4 and LPAR 5, 
which belong to a purino-receptor family, are also activated by LPA (Ohuchi et 
al., 2008).  LPAR 6 was recently identified in hair follicles and has a key role 
regulating hair follicle development, with LPA generation in a novel pathway 
catalysed by PA-PLA1a (Inoue et al., 2011). Bandoh demonstrated that both 
LPARs 1 and 2 have broad ligand specificities, although LPAR 3 is less sensitive to 
18:1 LPA (Bandoh et al., 2000). 
Cellular signalling by the LPA receptors is relatively redundant, and extremely 
complicated with numerous downstream effectors known to be activated, 
including those driven by Ras, Rho and Rac1.  These effectors are known to be 
activated by at least three G-subunits and may explain the variety of biological 
responses (Mills and Moolenaar, 2003).  These include G12/13, Gi, and Gq, and 
possibly Gs (Moolenaar and Perrakis, 2011; Ohuchi et al., 2008).  The outcome of 
this signalling will depend on the LPAR expression signature (Fig. 9).  The 
receptors show distinct genetic and physiological properties.  LPA has been 
shown to induce transient elevation of cytosolic free Ca2+ and this response has 
been used as a quantitative read out for LPAR signalling (Ohta et al., 2003).  One 
of the key phenotypic changes induced by LPA are the acute and marked 
changes in the actin cytoskeleton.  In fibroblasts, LPA stimulated the production 
of stress fibres and focal adhesion formation within 2 minutes (Ridley and Hall, 
1992).  In PC12 cells it triggers rapid growth cone collapse, neurite retraction 
and transient rounding of the cell body (Tigyi and Miledi, 1992; Jalink et al., 
1994).   
During a search for its ability to induce chemotaxis in invertebrate cells, LPA was 
also shown to induce a weak response in Dictyostelium, independent of cAMP 
formation and secretion (Jalink et al., 1993) in µM concentrations by LPA and no 
other (lyso) lipids.  It was hypothesised that this function may have arisen in 
evolutionary terms as an alternative chemoattractant to cAMP, produced by 
bacteria at a different stage in the lifecycle, and signalling through an 
independent pathway (Jalink et al., 1993; Schenk et al., 2001).  
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Figure 1-9 Key pathways in LPAR 1-5 signal transduction 
The broad range of signalling pathways activated by the five known LPARs. Published by (Choi et 
al., 2010). 
 
1.1.25 Role of LPA signalling in vivo  
1.1.25.1 LPA signalling in health & disease 
LPA has diverse biological functions.  In the skin, LPA has important 
pathophysiological functions promoting wound (Mazereeuw-Hautier et al., 2005; 
Sauer et al., 2004) and corneal ulcer healing (Xu et al., 2007).  It also promotes 
the terminal differentiation of keratinocytes and thickening of the epidermis 
(Piazza et al., 1995).  It has a role in inflammatory and fibrosing conditions, 
resulting in radiation pneumonitis, lung and kidney fibrosis and scleroderma 
(Rancoule et al., 2011).  As already described, it has a key role in vascular 
development and the generation of atherosclerosis.  LPA is therefore essential 
for many biological processes but aberrant signalling results in pathological 
states within that organ system. 
1.1.25.2 Role of LPA signalling in cancer 
A melanoma “autocrine motility factor” was identified in A2058 melanoma cell 
conditioned medium and subsequently identified as ATX (Liotta et al., 1986; 
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Stracke et al., 1992).  This induced random and directed motility in Boyden 
chambers in a PTX-sensitive G protein manner through autocrine secretion (Nam 
et al., 2000).  ATX is reported to increase the aggressiveness and invasiveness of 
transformed cells, and ATX levels directly correlate with tumour stage and grade 
in several human malignancies including melanoma (Saunders et al., 2008).  LPA 
was also reported to be involved in cancer cell motility during the investigation 
of the role of serum in hepatoma and small cell lung cancer cell motility and 
invasion into mesothelial cell monolayers (Imamura et al., 1993). Serum was 
shown to be necessary for the invasive response and could be substituted by LPA 
in these two cell lines.   
Over the last decade there has been a growing appreciation that LPA plays an 
important role in cancer progression (Mills and Moolenaar, 2003).  Activation of 
LPARs induces a host of GPCR induced responses favourable to cancer 
progression.  LPA has been shown to be present at high concentrations in the 
plasma and ascites of ovarian cancer patients in advanced disease thus is 
regarded as a potential biomarker for epithelial ovarian cancer (Dorsam and 
Gutkind, 2007; Huang et al., 2008).  There is evidence to support that the 
primary effect of LPA in promoting cancer progression is primarily due to 
enhanced cell motility, rather than cell proliferation (Imamura et al., 1993; 
Stahle et al., 2003).   
Most carcinoma cells express more than one LPA receptor subtype, and the 
expression levels and responses to LPA vary among the different subtypes.  It has 
been reported that the migration of fibroblasts and multiple cancer cells is 
mediated by LPAR 1.  The migratory response of fibroblasts from LPAR 1 -/- mice 
was diminished and with a LPAR 1 and 3 antagonist (Ki16425), there was a “loss 
of migratory response” across multiple cancer cell lines in Boyden chamber 
assays (Hama et al., 2004).  Signalling through LPAR 1 was shown to activate 
both Rac1 and RhoA.  The importance of LPAR 1 mediated cell motility has also 
been reported in: colon cancer (Lee and Yun, 2010; Shida et al., 2003) and 
pancreatic cancer (Stahle et al., 2003; Lv et al., 2011; Yamada et al., 2004).  
There are also data to support a role in LPAR 1 mediated cell–cell dissociation 
and dispersal, an early step of cancer invasion and metastasis (Jourquin et al., 
2006; Shin et al., 2009).   
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Aims of this study 
Melanoma is a heterogeneous disease and, despite recent advances, remains 
resistant to chemo- and immunotherapeutic strategies, with multiple signalling 
pathways constitutively activated.  Current opinion suggests that more than one 
critical pathway will have to be targeted to induce an enhanced period of 
remission or cure.  This chapter is a review of the current scientific literature, 
highlighting the available knowledge of the key pathways driving metastasis.  
There is a growing but currently limited body of evidence to support the 
paradigm of chemotaxis driven invasion.  As metastasis is the major cause of 
mortality in cancer and the most important signalling pathways are not known, 
investigating chemotaxis is paramount.   
This thesis aims to clarify the role of chemotaxis in melanoma invasion through a 
detailed examination of the chemotactic responses of melanoma cells using a 
direct visualisation approach.  Due to the plasticity of motility responses 
exhibited by melanoma cells in different environments, a combination of 
melanoma models will be used to validate the findings.  The aims of the thesis 
are as follows: 
1. To develop a robust assay for cancer cell chemotaxis 
2. To comprehensively explore the relationship between the chemotactic 
behaviour of melanoma cells at different stages of progression 
3. To identify the key drivers of melanoma cell chemotaxis 
4. To identify novel melanoma prognostic and therapeutic markers 
  
 
 
 
Chapter 2:  
Materials & Methods 
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Materials 
All materials are listed by technique or assay.  Laboratory plastic ware is from 
Nucleon, Thermo Scientific and all reagents are prepared and stored at room 
temperature (unless indicated otherwise).  When disposing of all materials, 
Beatson Institute regulations were strictly adhered to.   
Cell biology 
All procedures were carried out at room temperature unless otherwise specified. 
2.1.1 Cell lines 
2.1.1.1 Melanoma 
All melanoma cell lines used are listed by biological stage of derivation and were 
transferred from the Wellcome Trust Genomics Cell Bank unless marked (*), in 
collaboration with Prof Dot Bennett (Biomedical Sciences Research Centre, St 
George's, University of London; See Appendix 1 for characterisation).   
Radial Growth Phase (RGP) melanoma 
WM35 (Herlyn, 1990) 
Vertical Growth Phase (VGP) melanoma 
WM98-1 (Herlyn et al., 1985b) 
WM278 (Satyamoorthy et al., 1997) 
Metastatic melanoma (MM)  
WM239A (Herlyn et al., 1985a) 
WM852 (Herlyn et al., 1990) 
WM1158 (Easty et al., 1995) 
MV3*(Friedl et al., 1997; Van Muijen et al., 1991), Prof. Laura Machesky (Beatson 
Institute for Cancer Research, Glasgow)  
 
2.1.1.2 Non-melanoma 
The following cells were kindly donated: 
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HaCaT: immortalised keratinocytes (Boukamp et al., 1988), Dr Gareth Inman 
(Beatson Institute for Cancer Research, Glasgow) 
Human primary fibroblasts, Passage 3, Dr Mike Edward (Glasgow University) 
hTert-immortalised foetal foreskin fibroblasts (Tiff; Munro et al., 2001), Prof 
Bradford Ozanne (Beatson Institute for Cancer Research, Glasgow) 
2.1.2 Cell Culture 
All Cells were maintained in complete growth media (CGM): WM cell lines, 
HaCaT cells and Tiff fibroblasts were nourished with Roswell Park Memorial 
Institute (RPMI, Invitrogen) 1640 medium, supplemented with 10% Foetal Bovine 
Serum (FBS; PAA Labs) and 2 mM L-Glutamine (Gibco, Invitrogen) and 1% 
penicillin and streptomycin (Gibco, Invitrogen) and stored at 4°C.  MV3 cells 
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) and the 
same supplements, minus the additional Glutamine.  All melanoma cell lines 
were incubated at 37°C in a 5% CO2 incubator until approximately 80% 
confluence was reached. 
2.1.3 Cell Passaging & Counting 
With the appropriate degree of confluence, the cells were passaged.  Cells were 
washed with Phosphate Buffered Saline (137mM NaCl, 2.68mM KCl, 7.98mM 
Na2HPO4, 1.47mM KH2PO4, pH7.2) and incubated at 37°C in a 5% CO2 incubator 
for five minutes with Trypsin-EDTA (Sigma-Aldrich).  After detachment, the 
Trypsin was deactivated by re-suspending the cells in CGM.   
For experiments, cells were counted automatically using a CASY counter 
(Roche).  400 µl of cell suspension was diluted with 19.6 mL Casyton prior to 
counting.  The cells were then seeded and the cell colony was maintained by 
diluting the remaining cells 1:5 with fresh CGM. 
2.1.4 Cell preservation and recovery 
To preserve cell stocks, cells were pelleted by centrifugation at 1000rpm for five 
minutes at the cell counting stage described above.  The pellet was re-
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suspended in the preservation mix (10% Dimethyl sulfoxide (DMSO), 40% FBS & 
50% CGM).  1 mL (2x106 cells) cryovial aliquots were placed in a chilled freezing 
container, Nalgene® Mr. Frosty and transferred to a -80oC freezer for storage. 
Cells were recovered by defrosting them in a 37oC water bath and immediately 
diluting them in 9 mL warmed CGM in a 10cm Petri-dish.  Following cell 
attachment and within 24 hours, the cells were washed with PBS and the media 
was replaced with fresh CGM.  Using this method the cells would reach the 
appropriate confluency for experiments within 48-72 hours.   
2.1.5 Transfection  
MV3 cells were transfected with the GFP-Lifeact fusion construct containing a 
neomycin resistance gene (kindly donated by Laura Machesky/ Roland Wedlich-
Soldner).  The cells were transfected by nucleofection with the Amaxa 
Nucleofection Kit (Lonza) V.  The manufacturers’ protocol was adhered to 
throughout.  In brief, 2x106 MV3 cells were centrifuged and the pellet was re-
suspended in 100 µL Nucleofector solution, warmed to room temperature.  2 µg 
GFP-Lifeact DNA was combined with the mixture.  Once transferred to a cuvette 
the cells were transfected using a Nucleofector device programme (P020).   
Approximately 80% of cells survived the transfection and allowed to recover for 
48 hours in CGM.  After this the GFP-Lifeact cells were selected by adding G418 
(Stock solution 50 mg/mL, Sigma) diluted to 1 µg/mL in the CGM (G418-CGM).  
The cells were maintained in G 418-CGM too maintain the stably transfected cell 
line. 
Cell Motility Assays 
2.1.6 Insall chamber chemotaxis assay 
2.1.6.1 Chambers and related materials 
The Insall chambers were originally designed by my supervisor Robert Insall.  
They were manufactured using microfabrication techniques by Epigem Ltd.  
(Redcar, UK).  The chamber is a two-layer structure made from an optically 
clear and non-polarising layer of polymethylacrylate (PMMA) coated with a 
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second thin 20 µm layer of SU8 photoresist.  To generate cover slip supports, UV 
light was used to cross-link the SU8 at the desired locations before generating 
the bridges by photo-etching the full 20 µm layer of SU8.  The wells were then 
produced by mechanically milling to a depth of 1mm around the edge of the 
bridges and supports, as described (Muinonen-Martin et al., 2010; Muinonen-
Martin et al., In Press).   
VALAP sealant (Vaseline, Lanolin and Paraffin) was prepared by combining the 
three components together in a weight ratio 1:1:1 and melting at 100°C on a 
heat block.  A fine artist’s paint brush was used to apply the VALAP.  A 
micropipette with P200 pipette tips were used to exchange media in the Mark 4 
chamber and ultrafine pipette tips, Microloader (Eppendorf) in the Mark 2 assay.  
22 x 22 mm #1.5 coverslips (VWR International).  1M HCl was pre-prepared in a 
50 mL stock for acid washing.  Absolute ethanol for sterilising and storing 
coverslips.  18G needle and coverslip forceps for handling the coverslips.  Blu 
Tack®  (Bostick Inc.) and chamber holder cassette. 
2.1.6.2 Chamber reagents	  
Human Fibronectin (BD Biosciences): prepared according to the manufacturer’s 
instructions by dissolving in distilled water to make a 1 mg/mL stock solution 
before storing aliquots at -20°C.  A working solution of 20 µg/mL was used 
throughout, generating an adsorbed concentration of 4.17 µg/cm2 in the range 
of 1-5 µg/cm2 as suggested by the manufacturer. 
0.5% (w/v) BSA solution in PBS: cell culture grade Bovine Serum Albumin (BSA; 
Sigma-Aldrich) was heat denatured at 85°C for 13 min and allowed to cool to 
room temperature.  It was passed through a 0.45 µm sterile filter (Minisart, 
Sigma-Aldrich) and stored for a maximum of 1 week at 4°C.  A BSA coating is 
applied to block non-specific binding using heat-denatured BSA after laying down 
the ECM.  The BSA is heat denatured to generate large β-sheet structures that 
enhance its ability to coat the non-ECM covered sites. It binds to the glass that is 
not occupied by fibronectin and prevents cell adhesion at these sites and is 
considered important for studies of cell motility (DIMilla, 1992; Grinnell and 
Feld, 1979; Wetzel et al., 1980). A 1% (w/v) BSA stock solution in PBS was 
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generated and diluted 1:20 in the chemoattractant solution to act as a carrier 
protein. 
Chemoattractant solutions: based on the appropriate Serum Free Medium (SFM), 
RPMI for WM cells and DMEM for MV3 cells.  Chemoattractant (e.g., 10% FBS) was 
added to the medium as required.  Addition of HEPES buffer to the media in the 
sealed chamber is essential to buffer the pH of the media throughout the 
experiment.  This sulfonic buffer is superior to bicarbonate buffers at 
maintaining the pH in the physiological range whilst the carbon dioxide 
concentration increases as a result of cellular respiration (Baicu and Taylor, 
2002). A 1M HEPES solution (PAA Labs) was added to both buffer (SFM-H) and 
chemoattractant solution (eg.  FBS-H) to a final working concentration of 5 mM.   
Lysophosphatidic acid (LPA) (Sigma, L7260): dissolved in a 1:1 ratio of distilled 
water: absolute ethanol to generate a 1mM stock solution and stored at -20oC.  
To use as a chemoattractant, BSA was diluted to a final concentration of 0.05% 
(w/v) to SFM-H (SFM-HB) and then 1 µL LPA was added to 1 mL to generate a 1 
µM LPA solution.   
EGF (Peprotech, AF-100-15): dissolved in PBS to a stock concentration of 100 
µg/mL and stored at -20oC.  In chemotaxis experiments two working 
concentrations were used after diluting in SFM-HB: Low (6.25 ng/mL) and High 
(25 ng/mL). 
PDGF, BB Homodimer (Merck, Calbiochem, 521225): dissolved in PBS to a stock 
concentration of 10µg/mL and stored at -20oC.  In chemotaxis experiments three 
working concentrations were used after diluting in SFM-HB: Low (25 ng/mL), Mid 
(25 ng/mL) and High (100 ng/mL). 
HGF/ Scatter Factor (Peprotech, 100-39): dissolved in PBS to a stock 
concentration of 10 µg/mL and stored at -20oC.  In chemotaxis experiments two 
working concentrations were used after diluting in SFM-HB: Low (6.25 ng/mL) 
and High (25 ng/mL). 
SDF-1α/ CXCL12 (Peprotech, 250-20A): dissolved in PBS to a stock concentration 
of 100 µg/mL and stored at -20oC.  In chemotaxis experiments two working 
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concentrations were used after diluting in SFM-HB: Low (100 ng/mL) and High 
(300 ng/mL). 
Ki16425 (Cayman, Cambridge Bio): stored in absolute ethanol at a stock 
concentration of 10mM as per the manufacturer’s instructions.  In Insall chamber 
assays, cells were pre-incubated for 5 minutes with a 10µM solution before 
combining with reagents in the chamber at the same concentration.   
2.1.6.3 Pre-assay cover slip preparation 
Acid washing coverslips.  It is not uncommon for coverslips to be contaminated 
with a fine layer of grease, and to remove this layer, routine acid washing is 
recommended (Fischer et al., 2008). Approximately 20 coverslips were etched 
with 1M HCl for 15 min in a 300 mL glass beaker and rinsed extensively for at 
least 15 min in a constant stream of water and stored in ethanol until use. 
Fibronectin coating.  Coverslips were air dried in a tissue culture hood and 
diluted from the 1 mg/mL fibronectin stock to a 20 µg/mL working solution with 
PBS.  Each coverslip was submerged with 1.5 mL of the fibronectin working 
solution in a six-well dish for 1 hour at room temperature or overnight at 4°C.   
BSA blocking.  The fibronectin solution was aspirated from the coverslips and 
washed three times with distilled water.  Coverslips were coated with 2 mL 0.5% 
BSA solution in each well for 1 hr. 
2.1.6.4 Insall chamber setup for standard cancer cell chemotaxis assay 
Chamber preparation.  The chambers were drilled in advance with a 1.3 mm 
drill bit using an overhead drill press.  During drilling, the chamber was secured 
in a small machine vice sitting inside a V-block at 45° and a hole was drilled into 
each ‘rabbit ear’ of the outer well to allow reverse filling.   
Cell seeding (T-minus 24 hrs).  The BSA solution was aspirated from the 
coverslips and washed thrice with PBS.  Cells were seeded at a density of 5.5x104 
cells/mL in CGM.  Each cover slip was coated with 2 mL of the seeding 
suspension.  After seeding cells, the six-well dish was shaken in the x and then y 
planes for five seconds each and placed in a CO2 incubator at 37oC on top of a 
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shock absorbent base to prevent vibration induced patterns of cell 
accumulation. 
Cell starvation (T-minus 14 hrs).  CGM was aspirated and washed thrice with 
PBS.  Add 2 mL SFM and continue to incubate at 37oC. 
Reagent preparation (T-minus 1 hr).  The microscope chamber holder cassette, 
and reagents in 1.5 mL centrifuge tubes, were pre-warmed to 37°C in a heating 
block.  Chambers were washed thoroughly under a stream of water to remove 
debris and then immersed in ethanol before blotting with a lint free cloth 
(Kimwipes, Kimtech) and left to air-dry.  VALAP mixture was warmed to 100°C 
for 10 min.   
Chamber assembly (T-minus 30 min).  The centre well of the Mark 2 or Mark 4 
Insall chamber was filled with control medium (SFM-H) - 12.5 µL or 45 µL 
respectively.  The exact medium depended on the precise experiment. A cell-
coated coverslip was picked up and held vertically to gently blot excess medium 
at the edge.  The coverslip was gently lowered onto the chamber ensuring it did 
not slip and was centrally placed. The VALAP mixture was gently applied along 
the edges with the fine paintbrush to seal the chamber.  Residue was wiped off 
the coverslip from the centre with a cotton bud or swab to prevent crystals 
forming.  
The chemoattractant solution e.g., FBS-H, was drawn up using a micropipette 
with a microloader tip for the Mark 2 and a 200 µL tip for the Mark 4 chamber 
and the outer wells were slowly filled from the reverse side.  The tip was either: 
(1) placed just inside the drilled hole allowing the outer well to fill by capillary 
action, or (2) inserted slightly further to form a seal between the hole and the 
pipette tip before gently pushing the solution through. Either way, care should 
be taken not to insert the tip too far and push on the inner surface of the 
coverslip, which will result in fluid flowing between the coverslip and the 
chamber thereby disturbing the integrity of the chamber and the quality of the 
linear gradients. 
As the outer well filled, the chamber was gently moved to allow air bubbles to 
rise towards the outlet hole as the solution passed each corner.  The Mark 2 
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outer chamber held approximately 80 µL and the Mark4 chamber 145 µL.  Once 
full, a further 40 µL was added to ensure any control medium that leaked from 
the centre well was washed out of the chamber. Excess solution was blotted 
from the outlet holes before sealing with electrical tape. The chamber was 
labelled and secured to the microscope cassette with Blu Tack® before 
incubating at 37oC until up to four chambers were assembled and secured in the 
cassette.   
2.1.6.5 Insall chamber setup for centre-well cancer cell chemotaxis assay 
Coverslips and chambers were prepared as described above. 
Cell Culture and seeding. Cells were grown until 50-80% confluent.  The medium 
was aspirated and the cells washed with PBSx3 and then incubated overnight in 
SFM.  The slightly rounded and less adherent cells were detached by triturating 
them with a 1,000 µL micropipette before harvesting them into a 15 mL 
centrifuge tube.  A portion of cells was counted and the rest were pelleted at 
1000 rpm for 5 min at room temperature. The cell pellet was re-suspended in 
SFM-H to a density of 5x105/mL. 
Chamber assembly. 40 µL of cells were added to the centre-well of a Mark 4 
Insall chamber.  After removing as much excess liquid as possible from the 
fibronectin/ BSA coated coverslip, it was secured onto the chamber. The 
medium was allowed to spread by capillary action to secure the coverslip and 
then gently (so as not to allow the coverslip to move) the chamber was flipped 
over and placed in the microscope cassette.  The chambers were placed in a 
37°C incubator for 10-15 min to allow the cells to settle and attach to the 
coverslip.  After incubation, the cells remained round, but loosely attached to 
the surface. The cassette was removed from the incubator and each chamber 
was carefully flipped over and sealed with VALAP.  As with the standard assay, 
the coverslips were cleaned and the outer wells filled with chemoattractant eg.  
FBS-H.  The outlets were sealed with electrical tape and each chamber was 
secured in the microscope cassette with Blu Tack®.	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2.1.6.6 Conditioned media preparation for chemotaxis assays 
Conditioned media were generated as follows.  A sub-confluent 10 cm petri dish 
of WM239A cells was washed with PBSx3.  Following the protocol for cell 
passaging, the cells were split in a 1:5 ratio into five new 10 cm petri dishes and 
combined with fresh CGM to a final volume of 10 mL.  The conditioned media 
were then harvested from one dish per time-point, staggered between 0-48 
hours (Marked T0, T6 etc).  All 10ml was aliquoted into 10x1ml eppendorf tubes.  
The samples were immediately frozen on dry ice before storing at -80oC.  The 
cells in each dish were then counted.  Tiff fibroblast and HaCaT keratinocyte 
conditioned media were also generated using the same method. 
Aliquots of conditioned media were thawed in a 37oC waterbath and centrifuged 
at max (≈16,000 rcf) for 10 mins using a lab top centrifuge (5415, eppendorf) to 
remove debris.  After decanting and filtering with a sterile 0.2 µm filter, the  
conditioned media were tested in the Insall chamber standard chemotaxis assay.  
I added T0 (mock) conditioned medium to the centre-well and a conditioned 
medium (from the various collection intervals eg. T6, T12 etc) was added to the 
outer well.  I then followed the protocol for the standard cancer cell chemotaxis 
assay. 
2.1.7 Quantification of chemotaxis and statistical analysis 
In order to quantify chemotaxis it was necessary to track the migration of cells 
in the presence of the chemoattractant gradient.   
2.1.7.1 Imaging processing  
The following software and plugins were used: 
1. ImageJ:	  http://rsb.info.nih.gov/ij/.	  2. LOCI:	  http://rsbweb.nih.gov/ij/plugins/index.html.	  3. Image	  stabilizer:	  (http://www.kangli.org/code/Image_Stabilizer.html).	  	  	  
  
Imagej was used to process all the work in this thesis, along with freely open-
access software unless otherwise stated.  First, the tiff image sequences were 
imported using the Bio-formats importer found within the LOCI plugin. Chamber 
movement during imaging occurred occasionally, resulting in the image gradually 
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drifting, most often in the y-plane.  Nearly all images could be corrected for this 
drift, by running the image sequence through the Image stabilizer plugin. Very 
occasionally, due to a large shift, it was necessary to split the image sequence 
into two or three smaller stacks to minimise the drift per stack.  These stacks 
could then be stabilised individually as described above before concatenating 
the image sequence again into one movie.   
Adjacent images were then stitched using a plugin generated by a former Insall 
lab PhD student, Michael Carnell, and the cells were individually tracked using 
MtrackJ.  The images were calibrated and stamped with time and distance.  The 
calibration was performed by measuring a set distance on a graticule and 
converting this distance to pixels.  
If the image of the bridge was not perfectly aligned to the screen, it was 
necessary to rotate the image to ensure that each bridge was perpendicular to 
the chemotactic gradient.  For consistency, all chemoattractant gradients were 
orientated from low (buffer) on the left to high (chemoattractant) on the right.   
2.1.7.2 Cell tracking 
For consistency, I attempted to track a minimum of 40 cells in every chamber 
assay and in most cases this was sufficient to ensure statistical significance.  
Regardless of the cell lines tested, all cells were tracked using the ImageJ plugin 
MTrackJ (http://www.imagescience.org/meijering/software/mtrackj/) and the 
track followed the path of the cell nucleus (Soon et al., 2005).  The following 
criteria were used for deciding which cells to track: 
• Cells that moved more than 1 cell length in 24 hours 
• Tracked continuously until the end of the experiment or until the cell 
migrated off the bridge or rounded up in preparation for mitosis 
• Tracked only cells that started on the bridge and excluded those that 
migrate onto the bridge during the experiment 
• Avoided tracking post-mitotic cells 
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2.1.7.3 Quantification of migration and chemotaxis parameters 
An abundance of tabulated chemotaxis data was generated in the tracking 
process that was readily exported from Mtrackj.  I developed an excel 
spreadsheet (written by Drs DM Veltman & AJ Muinonen-Martin) to facilitate the 
processing, analysis and quantification.  It has since been used as a tool by other 
lab members and other groups researching chemotaxis out with the Beatson 
(McCarty Lab, University of Oregon; Chapple Lab, University of Birmingham). 
This spreadsheet automatically produced spider plots, speed and chemotaxis 
index data over time.  A time window was selected (e.g., 6-12 hrs for melanoma 
cells) and values zeroed within this window to produce end-point data.  
Chemotaxis index (cosθ) plots are presented as mean +/- SEM (Soon et al., 
2005).  Cosθ is a function of the distance migrated in the direction of the 
gradient divided by the euclidian distance (the linear distance between the start 
and end position of the cell).  cosθ therefore equals +1 for migration directly up 
the gradient and equals -1 for migration directly away from the gradient.  The 
relative degree chemotaxis between experiments could then be compared 
between experiments.  These data were also processed in the Circstat toolbox 
for MATLAB by Dr Gabriela Kalna (Beatson Institute) (Berens, 2009).  This 
generated rose and polar plots with 95% confidence intervals and a Rayleigh 
test.   
It is important to know whether the end point positions of the cells are 
distributed uniformly suggestive of randomly motility or are not distributed 
uniformly, predicted with chemotactic migration (Berens, 2009).  Due to the 
circular nature of directional data, standard statistical tests cannot be used to 
analyse these data.  The Rayleigh test (Circstat toolbox) is the most powerful 
and well used circular statistical test for detecting a unimodal deviation from 
uniformity. 
Absolute chemotaxis was defined by meeting the following two criteria:  (a) the 
presence of a significant Rayleigh test, to determine whether there was 
statistical support for unimodal cell movement and (b) cell movement in the 
direction of the chemoattractant gradient (i.e., the actual direction of the 
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attractant gradient had to fall within the 95% confidence interval for the 
direction of the cell migration) (Muinonen-Martin et al., In Press).  
2.1.8 Random motility assay 
Six-well glass bottom dishes were coated with fibronectin serially diluted from 
the 1 mg/mL stock solution and then blocked with BSA as per the method 
described for Insall chamber cover slip preparation.  The following 
concentrations were used: 100, 30, 10, 3 and 1 µg/ml.  Cells were the counted 
and seeded at a density of 1x104 /mL in 2mL CGM.  This ensured the cells were 
evenly spread but were not contacting one-another.  At least three sites from 
each well were imaged by time-lapse microscopy with a 10x objective using the 
Nikon Perfect Focus System (described in detail in chapter 3) at a frame rate of 
one per 15 mins for 24 hours. 
2.1.9 Organotypic invasion assay 
This method was provided by Dr Mike Edward, Glasgow University, Dept of 
Dermatology. 
2.1.9.1 Collagen extraction 
The tendons from approximately 15 rat tails (Glasgow University) were 
extracted using toothed forceps and then bathed in 70% ethanol.  After blotting 
dry, the collagen was extracted for 48 hours in 2 L 0.5M acetic acid whilst 
stirring at 4oC.  The extract was centrifuged to remove debris and an equal 
volume of 10% NaCl (w/v) was added to the supernatant to re-precipitate the 
collagen before stirring for 30 mins.  The sample was centrifuged again, the 
supernatant discarded and the precipitate was re-dissolved over 48 hours in 
0.25M acetic acid, whilst stirring at 4oC.  The collagen solution was dialysed 
against 4-6 changes of 17.5mM acetic acid and then centrifuged at 20,000g for 
2hrs at 4oC.  The final solution was adjusted with 1:1000 acetic acid to ensure 
the gels contracted over 6-7 days.  The final collagen solution had an 
approximate concentration of 2mg/ mL and was stored at 4oC. 
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2.1.9.2 Collagen gel preparation 
The collagen gels were prepared by combining the collagen solution,10x 
Minimum Essential Medium (MEM, Invitrogen) and 0.22M NaOH in a ratio 8:1:1.  
The pH was finely adjusted to pH 7.2 with the 0.22M NaOH (this step is critical 
as fibroblasts are extremely sensitive to alkaline conditions).  All solutions were 
chilled to 4oC before combining to ensure the collagen did not polymerise 
prematurely.  1 volume of FBS containing 7.5x105 primary human skin 
fibroblasts (passage 5-7) was immediately combined with 10 mL of the gel 
mixture on ice.  After pipetting well, 2.5 mL of the gel and cell mixture was 
added to each 35 mm petri dish.  The gels were then placed in a humidified 
incubator with 5% CO2 to set for 15-30 minutes.  A further 1 mL MEM was added 
to each petri dish and the gels were carefully detached to enable gel 
contraction in the same incubator.  The media was changed every 3 days.  After 
6/7 days the gels measured approximately 1.5 cm in diameter and were 
transferred to a 24-well dish ready for tumour cell seeding.  The gels were 
typically made in batches of 12 requiring 24 ml collagen solution and one 
confluent T75 flask (Nunclon) of fibroblasts. 
2.1.9.3 Tumour cell seeding 
A simple organotypic invasion assay involved seeding only tumour cells onto the 
surface of each gel.  1-2x105 tumour cells were counted and allowed to seed on 
the surface of each gel.  Alternatively, a skin organotypic assay was generated 
by combining the melanoma cells with keratinocytes in a ratio 1:5 (Berking and 
Herlyn, 2001; Santiago-Walker et al., 2009). 48 hours after cell seeding, the 
organotypic invasion assay was ready to commence the experiment. 
2.1.9.4 Organotypic invasion assay 
The gel was carefully transferred with forceps to an elevated stainless steel grid 
(Sigma, Screens for CD-1, Size: 40 mesh, S0770-5EA) and placed in a 6cm petri 
dish and this was denoted Day 0.  CGM was added to cover the grid and was then 
carefully aspirated to leave a meniscus around the base of each gel, thereby 
generating an air-liquid interface.  Three gels were loaded onto each grid and 
the medium was changed three times weekly.  In experiments using Ki16425, the 
gels with adherent cells were pre-incubated for 5 minutes with 10 µM Ki16425 in 
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the CGM before raising the gels to the air-liquid interface.  10 µM Ki16425 was 
maintained in the CGM throughout the experiment with thrice weekly media 
changes as before.  A typical experiment lasted 7-12 days. 
2.1.9.5 Organotypic invasion assay fixation, embedding and sectioning 
At the end of the invasion assay, each gel was carefully divided into two with a 
scalpel and placed in 4% Paraformaldehyde at 4⁰C.  The embedding, sectioning, 
histology and IHC techniques were all carried out by staff at the Histology 
Service (Beatson Institute). The following protocol was provided by Colin Nixon.  
In brief, after overnight fixation, the samples were processed the following day 
on a Thermo Excelsior tissue processor using a day cycle program.  The samples 
were passed through a sequence of six graded alcohols (70%, 90%, 95%, 3 x 
100%), then through three changes of xylene before undergoing three changes of 
molten histology wax under pressure.  After this, the organotypics were 
transferred to a heated chamber where upon they were immersed and 
orientated correctly in molten histology wax and allowed to harden to form a 
wax block of the tissue. 4 µm sections were taken from this tissue block and 
placed upon polylysine coated glass slides to allow subsequent staining for tissue 
identification to take place.  These sections were baked onto the slides for at 
least 1 hour at 60⁰C before being stained with a Haematoxylin and Eosin stain. 
2.1.9.6 Histology and Immunohistochemistry (IHC) 
Haematoxylin and Eosin (H&E) staining performed on a Leica Autostainer 
Reagent	   Time	  
Xylene	   4	  min	  
Xylene	   2	  min	  
100%	  EtoH	   1	  min	  
100%	  EtoH	   1	  min	  
70%	  EtoH	   1	  min	  
Water	   1	  min	  
Gills	  Haematoxylin	   13	  min	  
Water	   1	  min	  
1%	  Acid	  Alcohol	   2	  secs	  
Water	   1	  min	  
Scotts	  Tap	  Water	  Substitute	   2	  min	  
Water	   30	  secs	  
Eosin	   3min	  15	  secs	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Water	   30	  secs	  
70%	  EtoH	   30	  secs	  
100%	  EtoH	   30	  secs	  
100%	  Etoh	   30	  secs	  
Xylene	   1	  min	  
Xylene	   1	  min	  
Xylene	   1	  min	  
Coverslip	  applied	  with	  DPX	   	  	  
 
S100 staining by IHC 
Sections were cut to the appropriate thickness and placed in an oven at 60ºC 
overnight.  The following protocol was performed on a Dako Autostainer and a 
Gut parcel was used as a positive control. 
 
Place sections in Xylene 5 mins 
Place sections in Ethanol 1 min 
Place sections in Ethanol 1 min 
Place sections in 70% Ethanol 1 min 
Wash sections in Tris Buffered Tween (TbT) (Thermo, TA-
999-TT) 
5 mins 
Block endogenous peroxidase (Dako, S2023) 5 mins 
Wash sections in TbT 1 washes 
S100 Rabbit polyclonal Ig (Dako, Z0311) Diluted 1/100 
with Primary Ig Dilutent (Dako, S2022) 
35 mins 
Wash sections in TbT 2 washes 
Rabbit EnVision (Dako, K4003) 30 mins 
Wash sections in TbT 2 washes 
3,3’-Diaminobenzidine tetrahydrochloride (Dako, K4011) 10 mins 
Wash sections in deionised water 1 mins 
Haematoxylin Z (Cell Path, RBA-4201-00A) 7 mins 
Wash sections in deionised water 1 min 
1% Acid Alcohol 2 dips 
Wash sections in deionised water 30 seconds 
Scotts Tap Water Substitute 1 min 
Wash sections in deionised water 1 min 
Dehydrate, clear and mount sections with DPX    
 
2.1.9.7 Quantification of invasion 
Invasion was quantified by generating an invasion index from images captured 
with 10x or 20x objectives.  This was calculated as the ratio of cells in the 
organotypic gel that invaded beyond approximately 30 µm as a ratio of all the 
cells on top and within the gel.  This corrected for any changes in cell number 
due to the drug treatment.  At least three different, but representative, 
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locations on each gel are analysed.  Mean +/- SEM is tested for statistical 
difference using the unpaired student t test.  Over 2000 cells were counted for 
each condition. 
Imaging 
2.1.10 Live cell imaging  
2.1.10.1 Time-lapse Microscopy  
I used a Nikon TE2000-E inverted time-lapse microscope equipped with a 
motorised stage (Prior) and Perfect Focus System (PFS) to prevent focal drift due 
to thermal fluctuations.  The entire microscope was enclosed in a plexiglass box, 
humidified and maintained at 37°C with 5% CO2.  The Insall chamber experiments 
did not require the addition of supplementary CO2.  The microscope system was 
driven by Metamorph software (Molecular Devices) and the x, y positions were 
manually selected and pre-loaded.   
2.1.10.2 Imaging cells using phase, DIC or fluorescence microscopy 
For Insall chamber assays, the inverted chambers were secured in the holding 
cassette.  Objectives used to capture images included Nikon achroplan x10 and 
x60.  For most cell tracking, a 10x objective was used as it enabled the entire 
width of the bridge to be imaged as well as a few cell widths either side into the 
wells.   
Fluorescent images were acquired using a 60x, 1.45NA achroplan objective, and 
a digital camera controlled by metamorph software.  Differential interference 
contrast (DIC) images were acquired using a Zeiss Axiovert 200 M inverted time-
lapse microscope equipped with a 370C incubation chamber and motorised stage. 
During fluorescence microscopy it is essential to image using as small an 
illuminated field as possible to reduce the fluorescent illumination on the cells 
of interest and neighbouring cells.  This reduces the phototoxic effect of 
reactive oxygen species produced by excited fluorophores (Nishigaki et al., 
2006).  To optimise the duration of imaging and the quality of the images the 
condenser was therefore focussed and the shutter aperture minimised.  For 
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consistency, imaging always moved clockwise, starting from the bottom left 
corner of each chamber.  Great care was taken to always image each corner to 
ensure verification of the chamber orientation and hence the gradient direction 
during processing.  
For cell tracking, frame rates and imaging duration depended on the cell speed, 
but generally frame rates between 15 min to 1 hr were adequate for cancer cell 
chemotaxis for a duration of 24-36 hrs.  
2.1.11 Nikon Perfect Focus System (PFS)  
PFS (or a similar system) has proved an essential system, providing real time 
focus correction for focus drift arising during time-lapse experiments as a result 
of thermal and mechanical effects.  This drift occurred despite allowing the 
chambers to acclimatise for 30-60 minutes and securing them in the holding 
cassette with Blu-Tack.  The system eradicated the need to perpetually reset 
the focus, thereby enabling prolonged time-lapse experiments, without the need 
to image in multiple planes simultaneously (Peters, 2008).  
2.1.12 Insall chamber validation 
2.1.12.1 Confocal microscopy 
The concentration gradient profile was characterised using 100 µM fluorescein 
isothiocyanate in 100 mM Tris.Cl pH 8.0 in the outer chemoattractant well and 
100 mM Tris.Cl pH 8.0 in the inner control well.  Images were captured using a 
Leica confocal microscope with excitation by a 488 nm laser and an emission 
filter within the 502-542 nm spectra.  The laser intensity was determined prior 
to capturing each image using a peri-saturating power for the chemoattractant 
well by referring to a Lookup Table (LUT) with a high contrasting upper limit 
(Glow (Over & Under), LUT, Leica).  This was determined by reducing the laser 
intensity until just below the upper saturating limit.  16 bit greyscale images 
were acquired at intervals during 24 hours and pixel intensity across the bridge 
was quantified using the imagej plot profile function.  In brief, a representative 
section across the bridge was sampled and a line plotted perpendicular to the 
bridge.  Using the plot profile command, tabulated pixel intensity data relative 
to location along the line was acquired and extracted for processing. 
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In vivo studies: fresh melanoma tissue collection 
2.1.13 Fresh murine melanoma tissue collection 
2.1.13.1 Murine melanoma tissue 
I used the inducible Tyr::CreERT2 BRAFV600E/+ PTENlox/- melanoma model, in which 
the melanomas were all generated in mixed background mice from 6-12 weeks 
of age (Dankort et al., 2009).  This model was generated through the breeding 
programme of Prof Sansom and Prof Ozanne at the Beatson Institute by Dr 
Lindsay and Dr Faller.  All work was performed with the appropriate personal 
and project licences under the UK Home Office guidelines. 
The alleles used were as follows: Tyr::CreERT2 (Bosenberg et al., 2006) 
BRAFV600E/+ (Mercer et al., 2005) PTENlox/- (Lesche et al., 2002).  After activating 
Cre-recombinase, this model generated a melanocyte-specific expression of one 
copy of BRAFV600E/+ and melanocyte-specific deletion of one copy of PTEN. 
To induce recombination in the Tyr::CreERT2 mice, animals were treated with 2 
mg tamoxifen topically to shaved back skin daily for 5 days.  There was no 
discernable phenotype until naevi or primary melanomas started developing 6-8 
weeks after induction predominantly on the treated area.  Typical grooming 
behaviour spread the tamoxifen to other parts of the skin and/ or was ingested 
leading to activation in other cutaneous regions.   
All mice used were part of my collaborators’ cohort study.  Before they were 
sacrificed, all mice had reached the primary or secondary end-points of their 
designated study. 
2.1.13.2 Tumour sample collection  
Suitable mice were identified with at least one and up to four tumours, ideally 
located on the back.  4x4 mm was the smallest tumour size to enable at least 2 
areas to be sampled.  The mice were all sacrificed using the Schedule one home 
office protocol.  Once the mice were sacrificed, the skin containing the tumours 
was rapidly dissected off the back and pinned slightly taut to paper overlying a 
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corkboard.  Where possible, the samples were photographed before and after 
sampling. 
To sample the tumours, sterile Punch Biopsy tools (Stiefel) were used to punch 
circular samples from the tumour and surrounding skin.  The size of punch biopsy 
depended on the tumour size and varied from 3-6 mm in diameter. 
Samples were taken at various locations across the tumour and were coded as 
follows:  within the tumour (A), across the margin (B), 5 mm from the margin 
(C), 10 mm from the margin (D), 15mm from the margin (E), >20mm from the 
margin (Distant) and subcutaneous tissue (SC). 
Samples were immediately snap frozen in liquid nitrogen in eppendorf 2 ml safe-
lock micro tubes (Sigma).  The samples were then transferred to a -80oC freezer 
for storage. 
2.1.13.3 Control samples 
Control samples of normal appearing skin in the same melanoma model 
activated with tamoxifen were used to calculate the basal level of LPA.  Each 
section of mouse skin underwent a series of nine punch biopsies (A, B and C in 3 
replicate series). 
2.1.14 Fresh human melanoma tissue collection 
2.1.14.1 Ethical approval for a melanoma tissue collection programme 
A great deal of consideration was given to the challenges of collecting fresh 
melanoma tissue and in particular the primary lesions.  Support and advice from 
Prof Dot Bennett and Dr Julia Soo, (St. George’s, London) was instrumental in 
providing the framework for the application, given their recent successful 
primary melanoma tissue collection programme.   
Ethical approval for the collection of melanoma tissue was originally granted 
through the West of Scotland Research Ethics Service in February 2010.  NHS 
Greater Glasgow & Clyde (GGC) granted management approval in June 2010 
(Appendix 2).  The study was in accordance with “Good Clinical Practice” and 
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the World Medical Association’s Declaration of Helsinki (1964) and its’ revisions 
(Tokyo 1978, Venice 1983, Hong Kong 1989, South Africa 1996 and Edinburgh 
2000).  (Appendix 3) A minimum primary melanoma size of 10 mm was agreed 
with the GGC lead skin pathologist, Dr Karen Blessing.  Key extracts from the 
protocol highlighting the tissue approved for collection is as follows: 
“5.1 Collection of Tumour samples  
5.1.1 Collection of fresh tumour samples 
Samples of both suspected primary and secondary melanoma will be 
collected at the point of excision and carried immediately to the 
Department of Pathology at the corresponding hospital site.  Tissue 
deemed excess to diagnostic requirements will be identified and prepared 
by, or under the supervision of, a member of the pathology department.  
This will then be transported to the Beatson Institute for Cancer Research 
or another laboratory. 
5.1.2 Collection of archival tumour samples 
All patients included in the fresh tumour sample collection programme 
will be asked to consent to retrieval of paraffin embedded, formalin fixed 
tissue from the pathology archive where there is sufficient in excess of 
diagnostic requirement (as decided by the responsible pathologist).  In 
addition, excess tissue held in the archive from other patients meeting the 
appropriate eligibility criteria will be retrieved by appropriately trained 
healthcare workers in the department of pathology. 
No additional visits will be required for any subjects taking part in this 
study.” 
Tissue collection commenced in November 2012.  By this time, the 2006 Human 
Tissue Act legislation in Scotland had been altered, following the 2011 update.  
This led to the formation of NHS Research Scotland and I therefore reapplied to 
the local representative, the GGC NHS Bio-repository, to seek project approval 
Chapter 2 
 92 
to allow the project to proceed using the framework from the initial approved 
application.   
The terms were renegotiated with the new GGC lead consultant skin pathologist, 
Dr Colin Moyes.  The major change re-negotiated was an increase in the size of 
the primary melanoma from 10 to 25 mm to ensure there was no risk of harming 
the accuracy of the diagnosis or prognosis.  In addition, it was agreed a 
consultant pathologist would attend the procedure to decide whether tissue 
excess to diagnostic requirements could be provided. 
2.1.14.2 Tumour identification 
A pilot of between three and five samples was agreed with the GGC Bio-
repository.  Samples were identified through plastic surgery and dermatology 
skin cancer clinics, in addition to support from the multi-disciplinary teams leads 
across the region and the staff at the Bio-bank who actively searched through 
pre-operative lists.  The study was advertised through presentations and 
dissemination of a 1-page summary (Appendix 4) to all plastic surgeons and 
dermatologists involved in melanoma care across the West of Scotland. 
2.1.14.3 Tumour sample collection  
Following identification, potential samples were screened both by Dr Moyes and 
myself.  Informed consent was obtained using the appropriate bio-bank form.  
The lesion was photographed with and without a dermatoscopic lens following 
informed consent.  Immediately following excision of the lesion, Dr. Moyes 
determined if samples were permitted to be taken across the lesion with a 3 or 4 
mm punch biopsy tool.  These samples were labelled with the letter coding as 
per the mouse samples. 
The samples were immediately snap frozen in liquid nitrogen and as per the 
mouse samples, stored at -80oC 
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2.1.15 Conditioned media & fresh melanoma LPA 
quantification  
2.1.15.1 Tumour weighing 
To generate a concentration of LPA within the tissue, the frozen tumour core 
was first weighed to the nearest mg. 
2.1.15.2 Liquid chromatography-mass spectrometry (LC-MS) 
The LPA was extracted and quantified at my collaborator’s laboratory (Prof 
Wakelam, Lipidomics Mass Spectrometry Laboratory, Babraham Institute, 
Cambridge).  The frozen conditioned media samples and tumour cores were 
posted next-day delivery in a copious bath of dry-ice.  The following protocol 
was provided by my collaborators. 
Mice and human melanoma/ skin samples (1-20mg) were pulverised after 
thoroughly cooling with liquid nitrogen.  The pulverised powder was suspended 
in 750 µL water then used for LPA extraction.  For cell culture media samples, 
750 µL of cell culture media was used for LPA extraction.  Media or tissue 
samples were spiked with 50 ng of 17:0-LPA as an internal standard before 
extraction.  LPA was extracted with 1 mL n-butanol three times at room 
temperature. 
The combined LPA extract was dried under vacuum with SpeedVac (Thermo) and 
re-dissolved in 60 µL chloroform/methanol/water 2:5:1.  14 µL was injected for 
liquid-chromatography with tandem mass spectrometry (LC-MS/MS) analysis.  For 
LC-MS/MS analysis, we used a Thermo Orbitrap Elite system (Thermo Fisher) 
hyphenated with a five-channel online degasser, four-pump, column oven, and 
autosampler with cooler Shimadzu Prominence HPLC system (Shimadzu) for lipids 
analysis.  High resolution / accurate mass and tandem MS were used for 
molecular species identification and quantification.  The identity of the lipid 
subspecies was further confirmed by reference to appropriate lipids standards.  
All the solvents used for lipid extraction and LC-MS/MS analysis were LC-MS 
grade from Fisher Scientific.   
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2.1.15.3 Quantification & statistical analysis 
The final amount of LPA (ng) is presented as a concentration per 750 mL of 
conditioned media analysed or per mg tissue.  The data is represented 
graphically plotting mean +/- SEM for the concentration of LPA v conditioning 
time (for conditioned media samples); and distance from tumour margin (for 
tumour samples).  Samples were normalised to position “A” for comparison 
between tissue samples. 
 
  
 
 
 
Chapter 3:  
Development, Optimisation & Validation of an 
Efficient Assay for Cancer Cell Chemotaxis 
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Introduction 
The current challenge is to build on the knowledge developed through studying 
chemotaxis in model organisms like Dictyostelium to enhance our understanding 
of the role of chemotaxis in human cancer.  The introductory chapter contained 
a review of the growing body of evidence that chemotaxis plays an important 
role in the invasion and metastasis of caner cells.  Drugs which target cancer cell 
invasion and metastasis have proven difficult to develop, so an improved 
understanding of the detailed mechanism of chemotaxis may enable the 
prioritisation of better drug targets, better drugs, appropriate patient selection 
and smarter early clinical study design (Kedrin et al., 2007).   
Research into the field of cancer chemotaxis is still in its infancy.  The 
introductory chapter reviewed the investigative tools that have had to be 
developed for investigating chemotaxis.  In the introduction, I outlined two of 
these key tools in detail, the Zigmond and Dunn chambers.  These tools were 
initially designed for investigating rapidly moving cells like neutrophils and 
Dictyostelium and so require refinement in order to study cancer cell 
chemotaxis.  To recap, these direct visualisation bridge chambers use a two-well 
design whereby cells are seeded between one well containing a control or buffer 
substance and the other the chemoattractant.  In standard assays, the cells lying 
within the gradient are free to migrate between them.   
Direct visualisation chambers are considered the gold standard assay for 
investigating the behaviour of cells whilst performing chemotaxis due to the 
defined conditions and the wealth of data generated (Wells, 2000).  However, 
this assay is challenging, due to the delicate assembly and short-lived gradient, 
compounded by non-perpendicular gradients complicating analysis. These factors 
render the observation of slowly-moving cells unfeasible or almost impossible 
(Zengel et al., 2011).  We therefore established a user-friendly, robust assay for 
cancer cell chemotaxis in order to comprehensively explore the chemotactic 
behaviour of melanoma cells. 
In developing the assay, it was important to consider the various advantages, 
disadvantages and caveats of existing direct and indirect visualisation assays and 
these were dissected in some detail in the introductory chapter.  There were 
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several attributes of the Dunn chamber that were considered important for the 
new and improved chamber, and most important, was reproducing a similar gap 
of 20 µm between bridge and cover slip to reproduce a stable linear gradient 
over 24 hours allowing slowly-moving cells to be tracked.  Previous chamber 
designs including the Dunn and Zigmond chambers were intentionally designed 
for use with thick (#3, 0.25-0.35 mm thickness) cover slips.  This “dictates that 
high-power, non-immersion objectives with a fixed compensation for the 
standard (#1.5) coverslips (0.16—0.18 mm) should not be used for critical work” 
(Zicha et al., 1991).  Therefore the use of high numerical aperture (NA) oil 
immersion objectives for the critical work of investigating the mechanisms of 
chemotaxis with fluorescently tagged proteins in known gradients has been very 
technically challenging.  In addition, changing the gradient in Dunn chambers is 
inefficient due to the method of sealing the chambers. 
In 2010, we described the Insall chamber as an improved tool for measuring 
cancer cell chemotaxis (Muinonen-Martin et al., 2010).  It was designed, by my 
supervisor, as a refined derivative of the Dunn chemotaxis chamber.  Particular 
advantages include easy handling, simple perpendicular gradient orientations, 
and two different gradient steepnesses in the same assay, and above all the 
ability to use standard thin (#1.5) cover slips, allowing the use of high NA oil 
immersion lenses. Using this improved (Mark 2) chamber and a further evolved 
(Mark 4) model.  
This chapter charts the development, optimisation and validation of the Insall 
chamber.  Although the chamber has been optimised for use with melanoma 
cells throughout this body of work, it is equally at home as a tool for cancer cell 
chemotaxis in general or with other slow moving cells such as fibroblasts.  I 
outline the “standard assay”, which is comparable with typical Zigmond or Dunn 
assays, with cells spread throughout the linear chemoattractant gradient (Zicha 
et al., 1997; Zigmond, 1977).  This assay allows cells to move freely in any 
direction within the gradient, with the caveat that cells may locally modify the 
gradient through autocrine or paracrine effects, or as yet unidentified 
mechanisms (Wyckoff et al., 2004; Zicha and Dunn, 1995).  We have described 
protocols for this assay in a published detailed methods paper (Muinonen-Martin 
et al., 2013). 
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Chamber Development & optimisation 
3.1.1 Chamber design  
As discussed, previous chamber designs were designed for use with #3 cover slips 
and therefore did not include support structures.  Without any extra structural 
support, the #1.5 coverslips we desired to use bow, causing occlusion of the 
chamber.  This interferes with the gradient formation across the bridge with 
resultant intra- and inter-chamber gradient inconsistencies.  Careful 
consideration was therefore given to the positioning of supporting material 
within the bridges to minimise the distance that the cover slip spans (Fig. 1-
5A,D).  By ensuring that the supports were the same height as the surrounding 
chamber, the thin coverslip was provided with enough support to ensure that the 
bridge height did not fluctuate more than 1µm anywhere across the bridge (Fig. 
1).  Additional supports were also included for the cover slip at the upper and 
lower ends of the chamber.  This had the benefit of further supporting the 
coverslip and reducing the wasteful diffusion of chemoattractant from the 
source.   
3.1.2 Extracellular matrix (ECM) coating  
ECM coating is important to enhance the adhesion to hydrophobic surfaces such 
as glass (DIMilla, 1992).  Throughout the experiments, fibronectin has been used 
as the ECM for melanoma cell chemotaxis.  The introduction highlighted how 
ubiquitously expressed this protein is in stromal tissue.  This coating is beneficial 
to allow better attachment of cells to enhance motility, although cells have 
been shown to chemotax with only minimal adherence (Aznavoorian et al., 
1990).  It is important to determine the ideal concentration of fibronectin to 
maximise the migration speed to increase the number of cells that can be 
quantified in a given Insall chamber assay.  This is due to the biphasic migration 
speed response with varying attachment strength, with maximal migration at an 
intermediate level of cell-substratum adhesiveness (DiMilla et al., 1993).  The 
optimal concentration should be determined after performing a serial dilution of 
the ECM and testing which concentration enables the fastest random motility of 
cells in a 6-well dish.  This experiment was performed with varying 
concentrations of fibronectin between 25 µg/ml and 2.5 µg/ml and 5 µg/ml was 
Chapter 3 
 99 
visually identified as the optimal concentration for MV3 melanoma cells.  For 
consistency, this concentration was used throughout all the experiments. 
 
 
Figure 3-1 Bridge heights in Insall and Dunn chambers during use.  
Bridge heights are measured in µm at four locations across the Insall chamber narrow and wide 
bridges and the Dunn chamber using a #1.5, 0.16–0.18 mm cover slip. Chambers were filled with 
fluorescein and images were taken in a z-stack using 1 mm intervals to calculate the distance 
between the bridge and cover slip. The bridge height was consistent at all sites in the Insall 
chamber with less than 1 mm variation demonstrating that thin cover slips can be used without 
affecting the geometry of the chamber and hence the diffusion profile. 
 
3.1.3 Handling and securing the coverslip 
As the cells are adherent to the cover slip, any movement can be potentially 
harmful to cells by either exerting shear stresses on them or crushing them 
against the supports.  The coverslip is secured in place to both ensure that there 
is no movement relative to the chamber and no evaporation of chamber contents 
during imaging for around 24 hours in a 37oC environment. This is particularly 
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essential to avoid in the centre-well assay described later because in addition to 
cellular damage it will move cells relative to the origins of the bridge.  A second 
important factor is the need to prevent evaporation of chamber contents, which 
is noticeable within 30-60 minutes even at room temperature.  This problem 
became apparent whilst trialling Zigmond chamber clips to secure the coverslip 
in the early stages of development (Zigmond et al., 2001).  The clips also 
exerted tension on the chamber with a resultant bowing deformation leading to 
a variable interface between the cover slip and chamber. After experimentation 
with nail polish and beeswax, a published VALAP formula was used with great 
success to seal the coverslip to the chamber avoiding the complications of 
shearing cells, evaporation of contents or chamber deformation (Sluder et al., 
2007). 
3.1.4 Reverse filling of the outer chemoattractant well 
With a similar principle and methodology, the chamber handling is similar to the 
Dunn chamber, but with a few advantages.  The “rabbit ears” at the top of the 
external well (Fig. 1-5A,B & 3A) facilitate the filling and refilling of the external 
well.  These can if desired be drilled to allow the contents of the 
chemoattractant/outer well to be changed in situ by reverse filling (Fig.  1-5B).  
To investigate slow moving cancer cells over longer time frames it is imperative 
to seal the chamber effectively and this necessitates the drilling of all chambers 
to enable reverse filling. 
The other advantage of this technique and one, which is still in the theoretical 
stages of development, is the possibility of pumping fresh chemoattractant 
solution through the drilled holes using a micropump (Toetsch et al., 2009).  This 
is a useful technique to explore the response to a new chemoattractant/ 
inhibitor or to ensure that any local effects generated by the cells is negated by 
the constant flow of fresh media.  
3.1.5 Gradients with simple orientations  
The microfabrication techniques used enabled the design of a square bridge or 
viewing platform. The Dunn chamber, in particular, was manufactured by 
grinding glass and hence they produced a circular bridge.  This complicates the 
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calculation of chemotaxis index, which to be accurate must always be corrected 
for the angle of the gradient at that point.  The square geometry across all the 
bridges provides a simple and consistent chemoattractant gradient orientation 
perpendicular to the bridge.  This makes the analysis of chemotaxis parameters 
considerably easier than for Dunn chambers (Zicha et al., 1997; Fig.  1-5D). 
The only essential consideration to bear in mind when preparing to analyse the 
data is the orientation of the inner and outer wells that are diametrically 
opposite depending on which side of the chamber is being viewed.  To ensure 
this error is avoided, I always systematically imaged the four corners of the 
chamber.  The corners possess a curved inner edge in all versions of the 
chamber, which enables the easy orientation of the images relative to the 
gradient direction. 
3.1.6 Gradients with different steepnesses 
Dunn chambers were milled from glass and only one 1 mm bridge width could be 
incorporated into the design.  Due to the fabrication technique of the Insall 
chambers, it was straightforward to create different bridge widths in the two 
sides of the device (Fig. 1-5C, D).  As the concentrations of attractant in the 
inner and outer wells are constant, this translates into two different steepnesses 
of gradients.  With an automated XY stage it is thus possible to track cells 
chemotaxing in both gradients simultaneously.  In the Mark 2 version of the 
chamber shown here bridge widths of 0.5 mm and 1.0 mm were constructed. 
3.1.7 Ongoing chamber evolution 
The Mark 2 chamber provided an improved platform from which to start 
investigating cancer cell chemotaxis.  It became clear with use that the design 
required further improvement to simplify the filling of the outer well, further 
increase the stability of the gradient over time and improve the data yield from 
each experiment.  The Mark 3 design attempted to address these issues but 
failed and will not be discussed further.   
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Figure 3-2 Mark 4 Insall Chamber features.  
A Schematic of a Mark 4 Insall chamber from above highlighting the key features. Drilled holes in 
the ‘rabbit ears’ necessary for >1 hour experiments to allow reverse side filling in order to seal the 
chamber and prevent evaporation. The inner buffer well and outer chemoattractant wells along with 
the 8 viewing bridges are also emphasised. Magenta highlights the location and intensity of the 
chemoattractant. B A cross-section along the blue dashed line in A highlights the chamber shape, 
the 0.6mm bridges throughout and the resultant linear chemoattractant gradient (again in magenta) 
produced towards the outer wells. 
The Mark 4 design proved a great success and has been used for all the work 
presented in this thesis unless otherwise stated.  The outer well was designed 
with a U rather than an A shape (Fig. 2A).  This meant it was no longer necessary 
to fill the well with a microloader pipette and instead a standard pipette tip 
attached to a P200 pipette could be used to fill the entire outer well in one 
load.  Importantly, this reduced the number of experiments lost due to bacterial 
contamination and reduced the presence of trapped air bubbles due to the A-
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frame design.  Air bubbles expand once inside the incubator, affecting the 
pressure inside the chamber and potentially the rate of diffusion of the 
chemoattractant (Jowhar et al., 2010).  The bridges were all manufactured to 
0.6mm in diameter (Fig. 2B) to allow enough distance for cells to migrate over 
with a steep enough gradient to enable efficient chemotaxis.  Both the inner and 
outer wells were increased in size to enhance the stability of the gradient by 
increasing the source and the sink (Torisawa et al., 2010).  To increase the data 
yield, the number of bridges was doubled to eight in total.  Due to the random 
nature of cell seeding, it is not uncommon to see some bridges with low density 
and almost no cells and others with too high a density and nearly all cells 
contacting one another.   
The latest incarnation, the Mark 5 chamber, is identical to the Mark 4 chamber 
but has two chambers per slide allowing a control or duplicate experiment to be 
performed in exactly the same conditions.  In the future it will also be possible 
to automate the replacement of buffer in the outer chamber, with 
improvements in the possible range of experiments. 
Validation 
3.1.8 Gradient stability and linearity 
Gradient formation was directly observed using fluorescein as a diffusible 
marker, which demonstrated that the profiles of both gradients remain stable 
for 24 hours (Fig. 3A,B).  These validation experiments were carried out with the 
assistance of Douwe Veltman.  In the Mark 2 chamber, the narrow (0.5 mm 
width; Fig. 3A) bridge produced a linear gradient and the wide (1.0 mm; Fig. 3B) 
bridge a less steep gradient, but both remain relatively stable throughout the 24 
hour period, although with time, the steepness of both gradients gently reduce.  
Interestingly, the wider (1 mm width) bridge produced a stable linear gradient 
again with gentle reduction in steepness, but only over the two-thirds of the 
bridge nearest the buffer following initial stabilisation.  I therefore concluded 
that the central area of the wide bridge should be imaged for consistency.  The 
gradient generated in the Mark 4 chamber was validated using the same method 
and as predicted, the resulting gradient is more linear and stable over the 24 
hour window than either gradient generated in the Mark 2 chamber (Fig. 3C). 
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Figure 3-3 Stability of linear gradients.  
Gradients were established for between 1 and 24 hours across the (A) narrow and (B) wide 
bridges in the Mark 2 Insall chamber and the (C) standard 0.6mm bridge in the Mark 4 Insall 
chamber. The outer chemoattractant chamber was loaded with 100 mM fluorescein in 100 mM 
Tris-Cl pH 8.0 and the inner control chamber with 100 mM Tris-Cl pH 8.0. Confocal images were 
acquired at various intervals and quantification of the gradient was performed by measuring pixel 
intensity from the fluorescence signal as it diffused across the respective bridges. The pixel 
intensities across the bridges in (A-C) are represented by the respective colour panel inserts. 
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Capturing cell images & image processing 
Time-lapse microscopy was performed to capture the chemotactic responses of 
the relatively slow moving cancer cells.  A motorised x, y stage allows multiple 
positions to be imaged during the course of an experiment.  All microscopes used 
were controlled using metamorph software.  A major benefit of the Insall 
chamber over previous chamber designs is the ability to use differential 
interference contrast (DIC) microscopy and high NA oil immersion microscopy to 
provide the highest quality fluorescence images.  I was therefore able to capture 
high resolution images using phase, DIC and fluorescence microscopy. 
3.1.9 Phase & DIC microscopy 
With phase microscopy, I have been able to successfully demonstrate the 
chemotaxis of MV3 melanoma cells towards a 10% Foetal Bovine Serum (FBS) 
gradient. This can be successfully and reliably performed using a range of 
objectives from 10x to 60x magnification (Fig. 4A).  The use of nonpolarising 
substrates in the chamber fabrication means that DIC microscopy may also be 
used, which is not possible with many plastic devices (Fig. 4B).  Due to limited 
PFS compatible objectives, it has not been possible to use PFS with DIC 
microscopy.  DIC imaging, therefore involved selecting images from a vertical 
series (z-stack).  When reviewing the images, the in focus z-planes were then 
selected for onward processing. Movies were generated by concatenating the 
focussed images, which was a laborious process and is one of the key reasons I 
did not pursue this technique, despite the detailed images it can produce. 
3.1.10 Fluorescence microscopy 
Due to the thin cover slips high NA oil immersion microscopy is also possible and 
I demonstrated the chemotaxis of Lifeact-GFP transfected MV3 metastatic 
melanoma cells over 24 hours using fluorescence microscopy with a 60x 1.45NA 
oil immersion objective (Fig. 4C).  Two daughter cells can be seen emerging 
from mitosis, polarising and then chemotaxing towards the FBS gradient.  Their 
paths are highlighted by the red and yellow tracking lines. 
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Figure 3-4 Insall chamber imaging modalities.  
A shows chemotaxis of MV3 melanoma cells towards a 10% FBS gradient on the right of each 
image and imaged using inverted phase contrast microscopy with a 10x phase objective with time-
lapse imaging. Cell tracking lines have been created using the ImageJ MTrackJ plugin. B DIC 
imaging of melanoma chemotaxis. MV3 melanoma cells migrating towards a 10% FBS 
chemoattractant at the top of the image(s) over the course of 24 hours were imaged in differential 
image contrast using a 40x 1.3NA objective. C Live cell fluorescence microscopy using high-NA 
objective. Insall chamber chemotaxis assay with identical set-up and analysis to experiment in Fig. 
2, but the MV3 cells are stably transfected with GFP-Lifeact. Time-lapse images are taken using a 
60x, 1.4NA oil immersion objective. 
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3.1.11 Capturing and processing multiple images 
The PFS system not only ensured a focussed image at one site throughout a 24 
hour time-lapse movie, but importantly, it allowed images at multiple x, y 
positions to be captured reliably.  Two 10x overlapping images on the Mark 4 
chamber covered one entire bridge.  Stitching these two images (Fig. 5A) was 
helpful to provide an overview of the responses of all the cells across the entire 
bridge and to track some cells that passed between one field of view and 
another (McCluggage, 2006).  
With eight bridges per chamber, all 16 positions could be imaged (Fig. 5A).  The 
yield and consistency between experiments was significantly enhanced by 
designing a cassette that was capable of holding 4 chamber slides per 
microscope (Fig. 5B).  Using the Mark 4 chamber, it was therefore possible to 
image all 32 (8x4 Insall chambers) bridges in one time-lapse experiment.  This 
was a major improvement from early experiments with the Mark 2 chamber 
where images of only 4 bridges could be captured during any one experiment.   
Chapter 3 
 108 
 
Figure 3-5 Insall chamber imaging set-up. 
A The rectangular area over the viewing bridges in A is exploded. The coloured dashed squares 
represent the field of view for a 10x objective showing that the entire width of the bridge can be 
viewed. Two overlapping images can be stitched together to provide footage of the entire bridge 
between the coverslip supports. B Up to four chambers can be positioned inverted on a purpose 
built aluminium cassette. The chambers are secured in place with Blu Tack®. 
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Metastatic melanoma cells perform accurate chemotaxis 
towards 10% FBS  
Having developed, optimised and validated the Insall chamber, I first asked the 
question, are metastatic melanoma cells chemotactic to serum? To answer this, I 
employed the standard assay and analysed the cell tracks of 43 MV3 metastatic 
melanoma cells in the presence of a 10% FBS gradient (SFM inner well: 10% FBS 
outer well – denoted as SFM: FBS) and 46 cells without a 10% FBS gradient (SFM 
inner well: SFM outer well – denoted as SFM: SFM) migrating on the narrow 
bridge of a Mark 2 Insall chamber (Movie S1 and Movie S2). 
The quantification and analysis of the data demonstrating chemotaxis in the 
presence of 10% FBS and random migration with no chemotactic gradient can be 
seen in (Fig. 6).  Rose plots (A & B) demonstrate that cells migrated randomly in 
the absence of FBS but predominantly up the gradient in the chemoattractant 
experiment.  Polar plots use end-point data to plot points on a unit circle and 
the red line indicates the direction and magnitude of the resultant mean vector.  
The polar plots for the control experiment (C) reveal a short mean resultant 
vector for the control experiment with the cells so randomly spread that it was 
not possible to calculate a 95% confidence interval.  Conversely, the cells in a 
chemoattractant gradient demonstrate a much longer mean resultant vector 
with a narrow 95% confidence interval falling directly over the direction of the 
chemoattractant (D).  The evidence for directed migration is further supported 
by a highly significant Rayleigh test (p = 2.30×10−9) demonstrating a unimodal 
deviation from uniformity (or non-random migration).  The paths of individual 
cells in the spider plots highlight a strong bias for migration towards FBS. 
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Figure 3-6 Quantification and statistical analysis.  
(A, C, E) represent the results for the migration of all 46 MV3 cells tracked in a control experiment 
(SFM:SFM) and (B, D, F) represent the results for the migration of all 43 MV3 cells in the presence 
of a chemoattractant (SFM:FBS) both across the narrow bridge of a Mark 2 Insall chamber over 12 
hours. In the chemoattractant experiment the chemoattractant is to the right. Rose plots (A, B) and 
polar plots (C, D) use end-point data to demonstrate the final position of cells relative to their 
starting position. Below these, Mean resultant vector, 95% CI and Rayleigh tests provide evidence 
for directed migration. (E, F) The paths of individual cells during the experiment are presented in 
the spider plots. 
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Insall chamber assay refinement 
3.1.12 Starvation 
Serum starving cells is frequently performed to enhance cell responses.  This 
provides a period of cellular stress that drives a multitude of cellular responses.  
The effects are known to be variable and cell-type specific but it has been 
shown to be important for example in promoting cancer cell invasion by 
recycling receptors and upregulating EGFR signalling and forcing cells into a 
“survival state” (Ye et al., 2012).  It is also regarded as in important step to 
provide reproducible experimental conditions by eliminating the variation that is 
found in different batches of FBS (Pirkmajer and Chibalin, 2011).  
Recognising that the effects of starvation are experiment and cell type-specific, 
the length of starvation should be experimentally determined to optimise 
chemotaxis.  The results of a serum starvation experiment using the WM239A 
metastatic melanoma cell line are summarised (Fig. 7A).  The speed and 
chemotactic responses were compared over time for cells undergoing starvation 
for 0 hr, 6 hrs and 14 hrs.  Both speed and chemotactic index (CI) are greatest 
after a period of 14 hrs starvation.  This period of starvation was therefore used 
consistently throughout this thesis. 
3.1.13 Cell density 
Early experiments with <10 cells per bridge produced results with minimal if any 
movement or chemotaxis.  Optimising the cell density to produce an even spread 
of cells, near but without contacting one another, reliably produced good 
chemotaxis.  This meant seeding 5.5x104 cells/ml in 2 ml growth media and this 
density was used consistently throughout the thesis.  
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Figure 3-7 Insall chamber assay refinement. 
A Spider plots for three parallel Insall chamber standard assay 10% FBS chemotaxis experiments 
with WM239A metastatic melanoma cells. Starvation times were varied: 0 hr starvation (brown), 6 
hr magenta, 14 hr blue. B Speed and C chemotaxis index plots respectively for the three starvation 
experiments plotted against time. D two separate experiments for WM239A cells performing serum 
chemotaxis with speed and chemotaxis index plotted on the same graphs with the best time 
window chosen for analysis. 
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3.1.14 Best time window for analysis 
In order to obtain consistent data, it is necessary to select a time window for 
analysis because the chemotactic parameters evolve.  In the initial stages of any 
assay, the cells are sensing the gradient, polarising and accelerating (Veltman 
and Van Haastert, 2008).  Following a period during which CI and cell speed 
plateaux, there follows a gradual fall in these parameters almost certainly due 
to the limited supply of nutrients and oxygen in the chamber. 
To choose the best time window for analysis I reviewed the speed and CI data 
over time from separate assays performed on different days.  The representative 
graphs all clearly show a period of acceleration and increasing CI that starts to 
level out after approximately six hours (Fig. 7B,C).  This period is maintained for 
another six hours before chemotaxis consistently starts to decline.  This 6-12 hr 
window was therefore selected to generate end-point data for analysis and is 
used consistently throughout all experiments unless otherwise stated. 
Discussion 
This chapter has charted the development, optimisation and validation of the 
Insall chamber.  I have argued why this is a significant improvement over 
existing direct visualisation bridge chambers.  The latest versions have further 
enhanced the assay by stabilising the gradient for longer and increasing the data 
yield.  The chamber continues to evolve and the latest version contains two 
chambers on one slide.  This allows the imaging of up to eight assays on one 
microscope to facilitate the multiplexing of experiments and associated controls 
in identical environments.   
The major challenge with the Insall chamber assay, despite its relative ease of 
use, arises as a complication of its strength.  From generating very large movie 
files to processing the images, requires suitable storage hardware and presents a 
logistical and time-consuming challenge respectively.  To ease this process, it 
will be important to develop automated cell processing and stitching packages 
combined with automated cell tracking software.  Nevertheless the development 
of the chemotaxis processing spreadsheet used throughout this work has enabled 
the rapid processing of cell tracking data.   
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Most remarkable is the striking accuracy with which MV3 metastatic melanoma 
cells perform chemotaxis towards 10% FBS.  Chemotaxis of melanoma cells to 
serum has been reported in Boyden chamber assays (Lanati et al., 2010), but 
never before in direct visualisation chambers.  Reviewing the literature for 
cancer cell chemotaxis I observe the most accurate chemotaxis over the longest 
time frame (Bailly et al., 1998; T, 1995; Jensen et al., 2011; Sturge et al., 2003; 
Wang et al., 2004).  The chemotactic accuracy is more akin to the behaviour of 
haemopoeitic lineage cells (Kay et al., 2008; Zicha et al., 1998) and this poses 
the question of whether they share similar signalling pathways? 
Saadi et al investigated chemotaxis of MDA-MB-231 cells in their parallel-
gradient microfluidic chamber in response to linear and polynomial EGF gradient 
profiles (Saadi et al., 2006).  Their data suggested linear gradients were not 
effective at inducing chemotaxis whereas polynomial gradients did induce a 
chemotactic response.  This is contrary to my data that show robust chemotaxis 
in linear gradient profiles.  The effect of differing gradient profiles on cancer 
cell chemotaxis is therefore an area that merits further research.  Their result 
may be explained by the relatively short three hour assay period, which is also 
often used for transwell assays, but only allows time for the cells to move a few 
cell lengths.  This may produce a false negative result due to time taken to 
initiate movement (Maheshwari et al., 1999) as confirmed during my 
optimisation studies.  This further justifies the use of a relatively long (8–24 
hour) assay period, especially for slowly moving cells.  Other assays have 
required steep gradients to induce chemotaxis, but again have been limited by a 
short experimental duration (Soon et al., 2005).  The ability to chemotax in less 
steep, linear profiles may therefore require a greater time window and raises 
the question of whether cells are actively modifying the linear gradient? 
3.1.15 Conclusion 
In conclusion, we have created a significantly improved chemotaxis chamber and 
processing package for studying cancer cell chemotaxis.  The Insall chamber 
satisfies our design criteria and, most importantly, it allows us to track and 
investigate cancer cell chemotaxis for at least 24 hours. 
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We have demonstrated that utilising the Insall chamber in the standard assay 
format, provides a new opportunity for this robust and powerful system to probe 
the chemotactic behaviour of slow-moving cancer cells in detail.  My data reveal 
that metastatic melanoma cells are capable of performing chemotaxis with a 
degree of accuracy not previously appreciated.  The factor(s) and mechanism(s) 
driving this therefore require careful investigation. I will therefore describe my 
investigation of this in the following chapters. 
  
 
 
 
Chapter 4:  
The Inflammatory Signal LPA Drives Melanoma 
Chemotaxis and Invasion  
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Introduction 
Having demonstrated MV3 metastatic melanoma cells performing strong 
chemotaxis towards serum, I wished to validate this result by testing another 
metastatic melanoma cell line.  The standard cell line used by many researchers 
over the years as a melanoma model has been the B16 family of mouse 
melanoma cell lines (Bobek et al., 2010; Fang et al., 2008; Hirayama et al., 
1984).  The B16-f10 line has been highly selected for its ability to metastasise to 
lung in an intra-cardiac/ IV injection model and was characterised by Fidler et al 
during the 1970s as a model for metastasis research (Fidler and Nicolson, 1976) 
but concern has been raised about its use as a melanoma model due to its failure 
to reflect many of the molecular attributes of the human disease (Herlyn and 
Fukunaga-Kalabis, 2010). 
The WM239A cell line, by contrast, is derived from a human metastatic 
melanoma.  It is held by the Wellcome Trust genomics cell bank at St George’s in 
London and freely available through collaboration with the curator, Prof Dot 
Bennett.  The advantage of using this cell line is that it is part of a larger 
collection of human melanoma cells derived from different biological stages of 
development.  These cells have been tested and shown to maintain many of the 
biological and molecular characteristics of human melanomas relevant to each 
stage (Herlyn et al., 1985; Herlyn, 1990).  This collection therefore provides a 
powerful tool for understanding the responses exhibited by melanoma cells 
across the various stages of melanoma development.   
A multitude of chemoattractants have been targeted for study, and there are 
reviews that attempt to order these as a list of serum factors that have 
chemotactic properties (Roussos et al., 2011).  From a translational perspective, 
this catalogue is a starting point but it is not clear what the key chemotaxis 
pathways are.  Melanoma is an aggressive cancer that metastasises early during 
tumour evolution, contributing greatly to its high mortality (Broekaert et al., 
2010; Zbytek et al., 2008).  So an understanding of the factors driving this 
process is essential, especially the chemotactic factors involved in the essential 
invasive step, which are poorly delineated (Payne and Cornelius, 2002).  Reviews 
have gathered together those chemoattractants that are known to be involved in 
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the process (Roussos et al., 2011).  However, it is unknown which of these factors 
are key to driving cancer cell invasion.  
Identifying the key driver(s) of melanoma cell chemotaxis could be an important 
step in developing novel therapeutic and/ or prognostic targets.  There are 
reports attempting to characterise the motility of melanoma cells towards 
various chemoattractants using Boyden chambers and pipette assays but it is 
unknown which is the most potent, or physiologically relevant (Dong et al., 
2002; Quinones and Garcia-Castro, 2004).  The robust chemotactic response of 
the MV3 cell line to serum provides a clear starting point from where to begin 
this explorative process.  This chapter begins by validating this finding by fully 
characterising the chemotactic response of the WM239A metastatic melanoma 
cell line towards 10% FBS. 
4.1.1 WM239A metastatic melanoma cells perform chemotaxis 
with a high degree of accuracy towards 10% FBS  
In the absence of a chemoattractant, WM239A cells migrate randomly as shown 
in Fig 1A.  In the presence of 10% FBS, the cell tracks clearly orientate in the 
direction of the gradient over the same 21 hour experimental period.  The 
presence of serum also elicits a strong chemokinetic effect, increasing the cell 
speed by approximately 1 µm/hr (p=0.0004; Fig. 1B).  Although the cells in SFM 
are moving slower, a similar proportion of cells are migrating as those in 10% 
FBS.  The absence of chemotaxis cannot therefore be occurring due to a lack of 
cellular motility. 
To fully characterise the chemotactic response of the cells, a multifaceted 
approach was utilised. Cell tracking data is presented as both spider and rose 
plots for a visual representation of chemotaxis.  Quantifiable data is presented 
with the Rayleigh test and chemotaxis index (CI) plot (Mean +/- SEM).  The 
former provides a degree of certainty with which the cells are migrating in a 
unimodal fashion and the CI plot describes the mean degree of chemotaxis and 
permits a simple graphical comparison between experiments.   
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Figure 4-1 Characterisation of the chemotactic response of the WM239A metastatic 
melanoma cell line towards 10% FBS.  
A Still images of standard Insall chamber standard assays were acquired after 21 hours with a SFM control on the left and a 
10% FBS gradient experiment on the right. Cell tracks are generated using the mtrackj plugin. B Box and whisker plots 
comparing speed of cells using data from tracking >100 cells in 3 independent experiments for both conditions. The means 
are statistically compared with a 2-tailed t-test. C Spider plots for these SFM (upper panel) and 10% FBS (lower panel) 
experiments in A. Using 6-12 hour window data generated from all 3 experiments, I quantified the speed (B) and 
chemotactic responses using a combination of rose plots (with red dashed lines representing the 95% confidence interval) 
and a confirmatory Rayleigh test. D Chemotaxis index plots (Mean +/- SEM) were generated using the same window data 
for SFM (upper panel) and 10% FBS (lower panel). The individual experiments are marked in black and the combined data 
for each condition is marked in blue. 
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The spider plots each represent the cell tracks from one Insall chamber 
experiment, with data collected from >1 viewing bridge (Fig. 1C).  In the SFM 
experiment, the tracks centre around the origin (0, 0) and this is supported by a 
rose plot with migration in all directions during the peak window for chemotaxis 
and it was not possible to calculate a 95% confidence interval.  Numerical data 
generated from 3 experimental repeats confirms the absence of chemotaxis.  
These include an insignificant Rayleigh test (Fig. 1C; p=0.735) and a combined CI 
≈ 0.0 (Fig. 1D).  Conversely, the data for the 10% FBS experiment(s) supports a 
very strong chemotactic response.  The spider plot is overwhelmingly biased 
towards the direction of the chemoattractant gradient (Fig. 1C).  This is also 
reflected in the rose plot with the majority of cells in the 10% FBS group tightly 
distributed (red dashed lines in the rose plot represent the 95% confidence 
interval) in the direction of the gradient.  The Rayleigh test is highly significant 
(p=1.44x10-15) and again the experimental repeats in the CI plot show a high 
degree of uniformity, producing an overall CI≈0.4, with a narrow SEM (Fig. 1D). 
These data again demonstrate the robustness of the Insall chamber standard 
assay in producing high quality consistent data.  Importantly, I show another 
metastatic melanoma cell line is capable of performing accurate chemotaxis 
towards 10% FBS (also referred to as serum in subsequent text). 
Serum chemotaxis is universal across all stages  
I have demonstrated that both human MV3 and WM239A MM cells perform highly 
accurate chemotaxis towards 10% FBS.  This poses the question of whether 
metastases arise when non-chemotactic cells acquire chemotactic ability? 
4.1.2 Serum chemotaxis is accurate across all stages 
To investigate this question, I tested the chemotactic ability of human 
melanoma cell lines from primary (RGP & VGP) as well as metastatic (MM) 
stages, using the battery of melanoma cells donated by collaborator Prof. Dot 
Bennett.  These included: WM-35 (RGP), WM98-1 & WM278 (VGP) and WM852 & 
WM1158 (MM).   
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Figure 4-2 An investigation of the chemotaxis responses of melanoma cells from all 
biological stages.  
Insall chamber standard assay experimental data presented with spider and rose plots with 
Rayleigh tests from six different melanoma cell lines from the three biological melanoma stages: 
RGP (green), VGP (purple) and MM (red). The data is generated from tracking at least 45 cells per 
cell line using 10% FBS as the chemoattractant.  
 
Using the Insall chamber, all cell lines tested demonstrated a chemotactic 
response towards serum (Fig. 2).  The spider plots all show a bias towards serum, 
although this is more subtle in the WM35 and WM278 cell lines due to the shorter 
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track lengths.  The rose plots all show a biased migration towards the 
chemoattractant with 95% confidence intervals comfortably falling over the 
direction of the gradient.  The exception is the WM278 line, which demonstrates 
the weakest chemotaxis response to serum.  Although a 95% confidence interval 
was not calculable for this cell line, the rose plot suggests biased migration, but 
with a smaller proportion of cells moving towards the gradient.  
By grouping the data by melanoma stage (Fig. 3A & Movie S3 (RGP), Movie S4 
(VGP) & Movie S5 (MM)), I show that chemotactic accuracy increases with 
progressive disease stage, with a weakly significant increase in CI between RGP 
and MM cells was confirmed (p=0.044).  However, even early stage cells 
possesses considerable chemotactic accuracy towards serum (CI plot) and with a 
significant one sample t test. 
4.1.3 Speed is stage dependent 
The dominant change in motility parameters between these biological stages is 
speed.  Whilst RGP and VGP cells are indistinguishable, MM cells are moving with 
approximately double the speed (Fig. 3B). 
It has been suggested that metastases arise when non-chemotactic cells acquire 
chemotactic ability.  However, my data instead show that melanoma cell 
chemotaxis to serum is almost universal and even RGP cells possess significant 
chemotactic ability.  Rather, the main difference between metastatic and non-
metastatic cells is the doubling of speed between the primary and metastatic 
stages. 
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Figure 4-3 Chemotaxis index and speed filtered by melanoma stage. 
Sub-analysing the data generated for Fig. 2. A Pooled chemotaxis index plots generated by 
melanoma stage. B Pooled box and whisker plots of speed against melanoma stage. Data 
generated in A and B has been compared statistically using the student’s unpaired t-test.  
 
Identifying the chemoattractant(s) in serum 
Current evidence suggests that chemotactic signalling occurs through two major 
classes of receptors Receptor Tyrosine Kinases (RTKs) or G-protein coupled 
receptors (GPCRs) by GFs or chemokines respectively (Smirnova and Segall, 
2007).  Given the chemotactic accuracy of melanoma cells across all stages of 
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disease progression, I next asked whether a single agent within serum was 
capable of reproducing this effect?  
4.1.4 Growth factors drive chemokinesis 
There is a wealth of literature supporting the role of growth factor signalling via 
RTKs in chemotaxis both in vitro and in vivo (Goswami et al., 2005; Haugh et al., 
1999; Patsialou et al., 2009; Stracke et al., 1989; Wells, 2000).  Many different 
growth factors and their receptors have been shown to be upregulated in cancer 
cells and human tumours (Easty et al., 2011; Otsuka et al., 1998; Goswami et 
al., 2005; Pierce et al., 1991; Philippar et al., 2008).  I reviewed the key growth 
factors known to stimulate cell motility and tumour invasion, with most 
evidence supporting EGFR signalling in breast cancer (Desmarais et al., 2009; 
Smirnova et al., 2012; Wang et al., 2004; Wyckoff et al., 2004).   
I selected a number of GFs as putative cancer cell chemoattractants based on 
the literature review to perform a detailed assessment of their ability to induce 
chemotaxis in melanoma cells.  GFs bind to their receptors within a narrow 
range, and binding is complicated by further complexity in the receptor 
conformation, with biphasic affinities for the same receptor ligand combination 
(Bjorkelund et al., 2011). I therefore used both low and high concentrations 
known to stimulate motility in melanoma or cancer cells.  The GFs and their 
concentrations used in the assay included: EGF (6.25 & 25 ng/mL), PDGF (25 & 
100 ng/mL), HGF (6.25 & 25 ng/mL) and SCF (10 & 100 ng/mL).  The chemokine 
SDF-1 (100 & 300 ng/ mL) was also tested.  (Belmadani et al., 2009; Bjorkelund 
et al., 2011; Deuel et al., 1981; Jensen et al., 2011; Jourquin et al., 2006; Kwok 
et al., 2012; Monypenny et al., 2009; Taylor et al., 2001; Zicha and Dunn, 1995) 
The results of testing the putative GF chemoattractants are presented in Figures 
4 and 5.  The spider plots demonstrate no evidence of bias in migration in the 
direction of the gradient for any of the potential attractants under investigation.  
The rose plots highlight more subtle biases, and for PDGF (high/ low) and EGF 
(low), they demonstrate slight reverse chemotaxis with the 95% confidence 
intervals orientated away from the gradient.  However, this does not reach 
statistical significance in the Rayleigh test for PDGF and there is a low level of 
significance for EGF (low; p=2.47x10-2). 
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Figure 4-4 The effect of gradients of GFs on melanoma cell motility.  
Spider and Rose plots with Rayleigh tests performed on WM239A cells migrating in the presence 
of low (left panel) and high gradients (right panel) of growth factors (GFs) in the Insall chamber 
standard assay. More than 40 cells were tracked for each condition. GFs included EGF (6.25 & 25 
ng/mL), PDGF (25 & 100 ng/mL), HGF (6.25 & 25 ng/mL) and SCF (10 & 100 ng/mL). The 
chemokine SDF-1 (100 & 300 ng/ mL) was also tested. 
 
This interesting observation is consistent with another study investigating the 
chemoattractant effects of PDGF and IGF on two sarcoma cell lines through 
direct observation (Zicha and Dunn, 1995).  They discovered that the direction 
of biased migration could deviate as much as 170o from the gradient orientation.  
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They conclude that GFs induced the autocrine release of a chemoattractant and 
question whether GFs are ever genuinely chemotactic.  In the same paper, this 
was supported by the finding that the proposed released chemoattractant could 
act in a paracrine manner on cells that were poorly responsive to GFs. 
 
Figure 4-5 Quantification of the effect of gradients of GFs on melanoma cell motility.  
A Chemotaxis indices plotted with SFM and 10% FBS controls for the Insall chamber standard 
assays performed in Fig. 15. One sample t tests are highlighted. B Box and whisker plots of speed 
are plotted with SFM and 10% FBS controls. EGF and PDGF demonstrated the greatest 
chemokinetic effects. Statistical comparisons are performed using the unpaired student t test. 
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The other main observation is the spider track lengths that clearly vary between 
the low and high concentrations of GFs suggesting that the two concentrations of 
factors are exhibiting differing chemokinetic responses. 
Viewing the graph of chemotaxis index in Fig. 5A, none of the GFs, regardless of 
concentration, induce any significant chemotaxis.  However, although 
directionality was unaffected by GFs, they consistently increased speed in a 
dose-dependent manner. The spider plot track length variation between the low 
and high concentrations of GFs is clearly mirrored with varying speeds induced 
by the different factors and concentrations used (Fig. 5B).  All the factors tested 
ranged between the SFM and 10% FBS control experiments.  The greatest 
difference is seen between the SFM control and the low concentration of PDGF 
(p<0.0001) with EGF (high) also exerting a marked increase in chemokinesis 
(p=0.0007).   
The spider or rose plots from previous direct visualisation studies of chemotaxis 
to GFs often show more subtle biases and not the degree of chemotaxis 
exhibited by melanoma cells in my assay chemotaxing towards serum (Sturge et 
al., 2003; Wang et al., 2004).  One of the key reasons that RTK signalling fails to 
produce such accurate chemotaxis is due to its method of signal transduction.  
Following the binding of the ligand to its receptor, the ligand-receptor complex 
is internalised and signalling continues even during transit within the cytosol 
(Haugh et al., 1999).  The result of this is reduced spatial sensing and an 
increased receptor off time with a likely net effect of a blunted chemotactic 
response. 
These data strongly suggest that GFs are primarily regulators of speed, with EGF 
and PDGF demonstrating the greatest chemokinetic effects, and are not 
responsible for the chemotaxis response generated by serum. 
4.1.5 LPA is sufficient to drive chemotaxis with efficiency 
approaching that of 10% FCS 
Single agents such as fMLP drive highly accurate chemotaxis of neutrophils and 
cAMP in Dictyostelium, binding and transducing their signals through GPCRs (Kay 
et al., 2008).  In evolutionary terms, their ability to respond to chemotactic cues 
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is essential for the survival of the mammal or amoeba respectively.  This “do or 
die” response has therefore evolved with the ability to react rapidly and 
accurately (Van Haastert and Devreotes, 2004).  Given the accuracy of serum 
chemotaxis and the failure of GFs to induce chemotaxis, I asked whether the 
signalling is occurring through GPCRs? 
In 1992, LPA was identified as a key factor found within serum, which was able 
to rapidly induce a conformational change in the actin cytoskeleton and signals 
through GPCRs (Bathena et al., 2011; Bot et al., 2013; Ridley and Hall, 1992; 
Swaney et al., 2010; Xue et al., 2010).  LPA was therefore chosen as a putative 
chemoattractant based on the data supporting its signalling pathway, and its 
reported effects on motility and cancer cell invasion.  These attributes therefore 
make LPA an ideal candidate for investigation.  I used a chemoattractant 
concentration of 1µM LPA, which is within the 1-5 µM range found within serum 
(Eichholtz et al., 1993; Tigyi and Miledi, 1992).  
The results of three independent experiments are summarised (Fig. 6A).  Across 
multiple independent experiments, the WM239A cells consistently chemotaxed 
towards LPA (Movie S6). This statistically significant chemotaxis is reflected in 
both the spider and rose plots. 
The track pattern of WM239A cells migrating in a 1µM LPA gradient is very 
similar to the pattern when migrating towards the 10% FBS positive control (Fig. 
6B).  The comparison of the response compared to serum can be seen most 
clearly on the CI plot (Fig. 6C).  I therefore conclude that 1 µM LPA is sufficient 
to produce chemotaxis with accuracy approaching that of 10% FBS. 
Analysing the speed data during the 6-12 hour window shows mild inter-
experimental variation although the pooled data were not statistically different 
from the pooled 10% FBS control (Fig. 7A).  Although, analysing the speed over 
time (Fig. 7B) did show a trend towards the cells slowing towards the last half of 
the time window in the LPA gradient. 
Chapter 4 
 129 
 
Figure 4-6 Characterisation of the chemotaxis response induced by LPA.  
Insall chamber standard assay data generated from tracking over 160 cells in 3 independent 
experiments investigating the chemotaxis responses of WM239A MM cells using 1µM LPA as the 
chemoattractant. A Spider and rose plots with Rayleigh tests by experimental repeat from left to 
right. B Spider plots of cells chemotaxing in the presence of a 1µM LPA gradient and a 10% FBS 
gradient control. C Chemotaxis index plots for the experiments in A. The pooled responses of cells 
chemotaxing towards 1µM LPA and 10% FBS are statistically compared using an unpaired t test. 
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Figure 4-7 Analysis of speed during LPA chemotaxis. 
The data from figure 4 has been further analysed to generate speed data. A 6-12 hour window 
speed for individual experiments and pooled and presented as box and whisker plots. The pooled 
LPA response is compared to the pooled 10% FBS response using an unpaired t test. B The 
pooled data from A is presented over the 6-12 hour window time frame.  
 
LPA is the dominant attractant in 2D & 3D assays 
The previous experiments suggest that this naturally occurring lipid may be 
responsible for the majority of serum chemotaxis identified in 2D chemotaxis 
assays.  Serum contains many potential chemoattractants and I therefore ask the 
question of whether LPA is necessary as well as sufficient for serum chemotaxis? 
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4.1.6 LPA is necessary to drive chemotaxis towards serum in 
WM239A metastatic melanoma cells 
To determine if LPA is the major chemoattractant in serum, the first approach I 
took was to attempt to strip the serum of LPA using charcoal.  Attempts were 
made to strip the serum using a protocol described with activated charcoal 
(Gaetano et al., 2009).  Unfortunately, this gave no alteration to the serum 
chemotaxis phenotype and this may have been due to the failure of charcoal to 
strip the serum of LPA (although I was not able to quantify this at the time), or 
due to the ability of serum to re-generate LPA through autotaxin (Aoki et al., 
2008; Moolenaar and Perrakis, 2011).  Given the potential complexity of 
subsequently depleting autotaxin I pursued an inhibitor strategy. 
I previously discussed the LPAR receptors that are known to be important in 
cancer cell motility and LPAR1 emerged as a clear favourite to target initially.  
There are several commercially available LPA receptor (LPAR) antagonists that 
have been well characterised (Choi et al., 2010).  I chose to use the inhibitor 
Ki16425 because its inhibition profile was most specific for antagonising LPAR 1.  
It inhibits LPAR 3 to a lesser extent, and it has 20 times less affinity for LPAR 2 
(Ohta et al., 2003).  There is also a growing body of literature for its use in vivo 
(Boucharaba et al., 2006; Pradere et al., 2007; Subramanian et al., 2010). 
Ki16425 is a readily available competitive antagonist discovered after a screen of 
150,000 low-molecular weight compounds that selectively inhibited the LPARs.  
The inhibition profile described above was calculated for a 10µM concentration 
of inhibitor.  Importantly, it was shown to exhibit excellent LPAR specificity 
without any appreciable agonistic or antagonistic effect on EGF and PDGF 
receptors (Ohta et al., 2003).   
To confirm that Ki16425 is operating through antagonism of LPA receptors, its 
effect was studied in the presence of a 1µM LPA gradient and compared to 
vehicle (Fig. 8).  The three chemotaxis parameters presented here (spider plots, 
rose plots and Rayleigh test) all confirm complete inhibition of LPA chemotaxis.  
This experimental evidence supports the conclusion that Ki16425 is completely 
antagonising LPAR signalling. 
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Figure 4-8 Confirmation of the effect of Ki16425 on LPA chemotaxis. 
Insall chamber standard assay data generated from experiments comparing the effect of Ki16425 
and vehicle on 1µM LPA chemotaxis of WM239A MM cells. The spider and rose plots are 
presented with their respective Rayleigh tests. 
 
Following the manufacturer’s protocol with pre-treatment and treatment 
throughout the duration of the experiment, a series of 3 experimental repeats 
was performed (Fig. 9).  All 3 vehicle controlled experiments demonstrated 
strong chemotaxis but in the inhibitor treated experiments, all measures of 
chemotaxis were consistently and profoundly inhibited.   
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Figure 4-9 The effect of Ki16425 on WM239A serum chemotaxis. 
Insall chamber standard assay data generated from 3 independent experiments investigating the 
chemotaxis responses of WM239A MM cells to 10% FBS +/- Ki16425. The cells were pre-treated 
and treated throughout the duration of the experiments. The spider and rose plots with Rayleigh 
tests are presented for Ki16425 and vehicle controls. 
 
Further quantitative assessment of the impact of the inhibitor indicated that the 
movement of the 10% FBS plus inhibitor treated group is almost identical to the 
SFM experiment, although the track lengths are longer in the inhibitor group 
(Fig. 10A).  The CI plot again highlights the excellent concordance between 
experimental repeats and the pooled result clearly demonstrates that Ki16425 
not only reduces chemotaxis, but it completely inhibits this response with a CI≈0 
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(Fig. 10B).  This is compared to the pooled vehicle treated cells that perform 
accurate chemotaxis with a CI >0.4.  One sample t tests confirm that the CI for 
the pooled vehicle treated cells is significant (p<0.0001), and there is a 
significant difference between the CI for the pooled vehicle and pooled Ki16425 
group. Examples of cells moving in the presence of Vehicle (Movie S7) and 
Ki16425 (Movie S8) are provided. 
 
Figure 4-10 The quantitative effect of Ki16425 on WM239A serum chemotaxis.  
A Representative spider plots from the experiments in Fig. 7 alongside a SFM control. B Chemotaxis index plot for all 3 
experiments individually and pooled, alongside the SFM control. The results of one sample t tests are marked adjacent to 
the corresponding result, each comparing the chemotaxis index mean to the theoretical mean of 0.  
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To confirm that the inhibitor was not abolishing chemotaxis through other 
effects on cell motility, I examined the impact on speed in more detail. The 
results showed a slight initial reduction in speed in the Ki16425 treated group 
compared with the vehicle treated group (Fig. 11A).  However, the reduction in 
speed is only temporary until 12 hours, when the cells then continue to migrate 
with an average speed similar to the vehicle treated group.  Importantly, this 
difference is not significant during the window period of assessment (Fig. 11B). 
 
Figure 4-11 The effect of Ki16425 on the speed of cells. 
The data from the experiments in Figs. 7 & 8 has been further analysed to compare the speed of 
cells in the presence of Ki16425 or vehicle. A Mean speed  is plotted against time for vehicle and 
Ki16425 treated conditions, alongside a SFM control throughout the duration of the 21 hour assay. 
B Speed during the 6-12 hour window is presented as box and whisker plots and the pooled 
vehicle and Ki16425 treated conditions are compared using an unpaired t test.  
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These data support the inhibition of chemotaxis to serum as the primary effect 
of Ki16425 with a relatively minor effect on chemokinesis.  In the context of 
Ki16425 inhibiting chemotaxis in the presence of serum it can be concluded that 
LPA is necessary to drive chemotaxis towards serum in WM239A metastatic 
melanoma cells. 
4.1.7 LPA is necessary to drive chemotaxis to serum consistently 
across multiple melanoma cell lines 
To test whether LPA is the major attractant in serum in all stages of melanoma, 
I investigated the effect of Ki16425 with the panel of melanoma cells presented 
in Fig. 2 & 3. All three chemotaxis parameters were significantly reduced or 
abolished as a result of Ki16425 treatment in RGP and VGP cells (Fig. 12) as well 
as MM cells (Fig. 13).  
Comparing the effects of the inhibitor using the quantitative CI plot largely 
concurs with the above findings (Fig. 14A).  The degree of chemotaxis is in 
keeping with the qualitative findings described earlier in Fig. 2 & 3, with WM278 
being the least chemotactic cell line overall and WM852 the least chemotactic 
MM cell line.  The inhibitor has a profound effect on the chemotactic responses 
of WM35, WM98-1, WM239A and WM1158. Interestingly, the inhibitor had least 
effect on the cell lines that were performing the least efficient chemotaxis ie.  
WM278 (VGP) and WM852 (MM).  These data suggest that if cells are chemotaxing 
inefficiently towards serum, then they are less likely to respond to the LPA 
inhibitor and raises the question of differential LPAR expression.   
Filtering these data by melanoma stage confirms that the inhibitor is effective 
across all stages (Fig. 14B).  Although there is a mild residual chemotactic 
response in the inhibitor treated MM group (p=0.004), this is markedly reduced 
compared to the corresponding MM vehicle treated group. The residual 
chemotaxis is not a surprise considering the method of action of Ki16425, acting 
as a competitive antagonist. 
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Figure 4-12 The effect of Ki16425 on primary melanoma chemotaxis. 
The chemotactic responses of 3 different primary melanoma cell lines (1xRGP(green) and 
2xVGP(purple)) were tested +/- Ki16425 in the presence of 10% FBS employing the standard Insall 
chamber assay. The spider and rose plots are presented with their respective Rayleigh tests. 
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Figure 4-13 The effect of Ki16425 on metastatic melanoma chemotaxis. 
The chemotactic responses of 3 different metastatic melanoma cell lines (red) were tested +/- 
Ki16425 in the presence of 10% FBS employing the standard Insall chamber assay. The spider 
and rose plots are presented with their respective Rayleigh tests. 
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Figure 4-14 The quantitative effect of Ki16425 on chemotaxis of primary and metastatic 
melanoma cells. 
The chemotaxis indices of all cells from Figs. 11 & 12 are presented by cell line (A) and melanoma 
stage (B). The results of one-sample t tests are marked adjacent to the corresponding results in 
(B). 
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4.1.8 LPA is necessary for invasion into 3D organotypic assays 
The data thus far have confirmed that LPA is necessary and sufficient for 
chemotaxis of melanoma cells in 2D.  Next I wished to examine whether LPA is 
also necessary for invasion into the more complex environment of a 3D 
organotypic matrix.  I previously discussed the rationale for investigating cell 
biology mechanisms in both 2D and 3D due to the biological variances in 
behaviour that can be observed (Baker and Chen, 2012; Meyer et al., 2012; 
Petrie and Yamada, 2013; Tang et al., 2013). 
Not all cells that are motile in 2D will invade in 3D.  This is due to cell lines 
showing unique growth and invasive patterns, depending on the derived cell line 
(Meier et al., 2000).  The panel of melanoma cells were seeded on organotypic 
assays and I identified WM98-1 (VGP) and WM1158 (MM) as the most invasive cell 
lines, which I used to study the effect of Ki16425. 
Representative images from organotypic assays seeded with 2x105 cells and then 
harvested after 12 days at the air-liquid interface are shown in Fig. 15A.  The 
assays were either treated with vehicle or Ki16425 10µM.  There is a marked 
contrast in the degree of invasion of the melanoma cells treated with the 
inhibitor.  Both cell lines are capable of invading into the vehicle treated gels, 
but almost completely fail to invade into the Ki16425 treated gels.  Quantifying 
the degree of invasion (Fig. 15B), there is a highly significant reduction in 
invasion in both cell lines.   
These data strongly support the invasion of cancer cells into 3D organotypic 
matrices arising after the induction of a chemotactic gradient.  I hypothesise 
that the gradient formation is self-generated by the overlying cancer cells 
through an as yet unidentified mechanism.  The central result is that LPA is 
necessary for invasion into 3D organotypic matrices. 
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Figure 4-15 LPA is necessary for invasion into 3D organotypic assays. 
A Panels of representative images of organotypic assays seeded with 2x105 cells of WM98-1 and 
WM1158 are shown +/- Ki16425. B Invasion index was calculated as the percentage of total cells 
on the organotypic matrix that invaded beyond ~30 µm as a ratio of cells on top of the matrix. 
>1000 cells were counted per condition plotted and the results demonstrate a significant reduction 
in invasion with Ki16425 in both cell lines. 
 
The role of Growth factors in LPA chemotaxis  
I have demonstrated that GFs drive chemokinesis and I next asked whether they 
play a role in LPA chemotaxis? 
4.1.9 Growth factors act as accessory factors to enhance LPA 
chemotaxis 
To test whether GFs can modulate LPA chemotaxis I designed an experiment 
combining GFs with 1 µM LPA (Fig. 16).  The combination of GFs with LPA 
produced not only longer cell tracks, suggesting greater speed, but more tightly 
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bunched tracks in the direction of the gradient when compared to 1µM LPA 
alone, indicating enhanced chemotaxis (Movie S9).  There are fewer tracks in the 
opposite direction to the gradient in the combined GF LPA group.  Based on the 
evidence supporting the role of GFs as chemokinetic agents, I then performed a 
competition experiment, with cells able to move freely in opposing gradients of 
LPA (gradient increasing to the right) and GFs (gradient increasing to the left).  
The spider plot for this experiment shows a track pattern very similar to LPA 
alone, although with slightly enhanced chemotaxis accuracy. 
The chemotactic responses are quantified for comparison in the CI plot (Fig. 16 
B). There is a trend towards the addition of growth factors enhancing the 
chemotaxis response to LPA but this was not statistically significant.  Most 
interesting is the result for the opposing gradients of LPA and GFs.  Again there 
is a trend towards enhanced chemotaxis towards LPA.   
The speed data for these GF plus LPA experiments are presented in comparison 
to the SFM and FBS controls (Fig. 17).  The chemokinetic effect of LPA alone 
compared to SFM is statistically highly significant (p<0.001).  The effect of the 
GFs can again be seen over and above the chemokinetic effect of LPA alone.  
LPA + PDGF is statistically significant compared to LPA alone (p=0.049) and the 
graph of mean speed against time also highlights that for the majority of the 21 
hour assay, these cells are migrating with greater speed. 
In summary, these data indicate that GFs act as accessory factors and enhance 
the accuracy and speed of chemotaxis towards LPA.  The competition 
experiment clearly demonstrates the potency of LPA as a chemoattractant in 
comparison to GFs. 
Chapter 4 
 143 
 
Figure 4-16 The effect of combining GFs with LPA on melanoma cell chemotaxis. 
A Spider plots of the WM239A cells chemotaxing in gradients of LPA, LPA+EGF+PDGF (top) and 
LPA v a negative gradient of EGF +PDGF alongside a 10% FBS control. B Plot of chemotaxis 
index for the experiment in A, plus the additional experiments combing LPA with EGF and PDGF 
as single agents. This allows the comparison of chemotactic accuracy. Statistical comparisons are 
performed using the unpaired student t test. 
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Figure 4-17 The effect of combining GFs with LPA on melanoma cell speed. 
The speed data extracted from the experiments in Fig. 17 are presented for each condition along 
with SFM and 10% FBS controls. Statistical comparisons are performed using the unpaired student 
t test. (A) box and whisker plots from the time window with statistical comparisons performed using 
the unpaired student t test. (B) mean cell speed over time. 
 
Discussion 
The model of efficient chemotaxis driven invasion as a paradigm has been 
gaining greater appreciation in recent years (Condeelis et al., 1992; Hughes-
Alford and Lauffenburger, 2012).  I sought to comprehensively explore the 
relationship between the chemotactic behaviour of melanoma cells at different 
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stages of progression and demonstrated that even primary melanoma cells 
possess significant chemotactic ability.  In the context of melanoma this may 
explain why primary melanomas are capable of metastasising so early in disease 
progression.  
The major difference between primary and metastatic melanoma cells was the 
doubling of speed.  Cell motility is known to be a pre-requiste for cancer cell 
invasion and metastasis (Bravo-Cordero et al., 2012; Liotta, 1986; Olson and 
Sahai, 2009; Provenzano et al., 2009).  It is not clear if this results in earlier 
metastasis and is therefore of clinical relevance. 
A major aim of this thesis was to identify the key drivers of melanoma cell 
chemotaxis. I found that the inflammatory signal LPA was not only the principal 
attractant, it was also active across all tumour stages. I also found LPA to be 
both sufficient and necessary for chemotaxis in both 2D and 3D assays. 
The failure of all melanoma cells to produce a chemotactic response to serum in 
the presence of Ki16425 highlights the importance of LPARs 1 (and to a lesser 
extent 3) in transducing the signal necessary for chemotaxis.  This is the first 
time an LPAR inhibitor has been used in direct visualisation studies and been 
shown to unequivocally abolish chemotaxis.  Previous studies using indirect 
techniques were only able to conclude that Ki16425 reduced motility and 
diminished chemotaxis.  It would be interesting to identify what LPAR receptors 
are expressed by all the cells and in particular WM278 and WM852 that revealed 
the weakest chemotactic response to serum.  One would hypothesise that they 
have a different expression profile of LPARs, with less LPAR 1 & 3 in particular. 
My data indicate that growth factors, which are frequently described as tumour 
chemoattractants, are in fact primarily chemokinetic agents in my conditions.  
All the GFs tested failed to induce a significant chemotactic response.  
Investigating the role of GFs in melanoma chemotaxis has qualified an earlier 
report that questioned whether they are truly chemotactic (Zicha and Dunn, 
1995).  I also found similar results, with trends towards unimodal directionality 
away from the gradient direction.  Interestingly, EGF has been demonstrated to 
increase LPA production in ovarian cancer cells and this raises the question of 
whether this could be responsible for the autocrine and paracrine signalling 
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described (Snider et al., 2010) PDGF has also been shown to induce LPA 
production in fibroblasts following only 20 minutes of stimulation (Fukami and 
Takenawa, 1992).   
One explanation for the lack of any response induced by GFs may be that the 
cell line investigated does not overexpress for example, the EGFR, which has be 
shown to enhance chemotaxis in cancer cells (Blaine et al., 2009; Hyun et al., 
2011; Phillips et al., 2005; Smirnova et al., 2012). Conversely, the cells I tested 
did exhibit a chemokinetic response to EGF and given the strong chemotactic 
response induced by LPA across the majority of melanoma cell lines tested, I 
consider that EGFR overexpression is unlikely to be of such significance or equal 
importance.   
However, I did identify a role for GFs acting as accessory factors, potentiating 
the chemoattractant activity of LPA.  The addition of growth factors not only 
increases the speed during LPA chemotaxis, but it enhances the chemotactic 
accuracy to that of 10% FBS, even when a reverse gradient of GF is applied.  
4.1.10 Conclusion 
My data support LPA chemotaxis as a major driver of melanoma invasion across 
multiple cell lines from all biological stages of development.  I also show how 
GFs, which are frequently described as tumour chemoattractants, are in fact 
primarily chemokinetic agents, and are capable of potentiating LPA’s 
chemoattractant activity.  It has been well documented that LPA is released 
from activated platelets and my finding therefore implicate the clotting system 
in the invasion of melanoma (Eichholtz et al., 1993; Tomas et al., 2003).  The 
mechanism and physiological relevance of these findings will be explored in 
subsequent chapters. 
 
  
 
 
 
Chapter 5:  
The Self-Generation of LPA Gradients Drives 
Melanoma Cell Dispersal 
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Introduction 
Having identified LPA chemotaxis as a key driver of melanoma motility and 
invasion, I wished to verify that this is responsible for the outward migration of 
cells from the primary tumour.  I considered the three main modes of directed 
motility driving the cells to invade: positive chemotaxis (towards a gradient of 
chemoattractant), negative chemotaxis (away from a chemorepellent) and 
contact inhibition of migration.  I excluded contact inhibition as a driver of 
invasion in 3D because this would still have been evident in the submerged cells.  
This also needs to be confirmed in 2D as well as exploring the possibilities of 
either positive or negative chemotaxis.    
During standard Insall chamber assays I occasionally performed experiments with 
uniform serum in addition to uniform SFM controls.  Interestingly, in the 
presence of serum, cells consistently migrated towards the nearest edge of the 
bridge (Fig. 1; Movie S10).  This figure shows cells dispersing from the centre of 
the bridge, towards the nearest edge. This is most clearly seen from the spider 
plots for each half of the bridge and this finding highlights the importance of 
directly observing the cells and even then, not relying on the standard spider 
plot alone, which conceals this observation.   
This dispersal effect has been termed the “edge-effect” and is acknowledged in 
the chemotaxis literature (Zigmond et al., 2001).  It has been described in 
experiments when differing concentrations of a chemoattractant are used in 
either well rather than uniform concentration.  This was hypothesised to be due 
either to the consumption of a chemoattractant within the medium, thereby 
generating a gradient of the chemoattractant towards one edge of the bridge, or 
the production of a chemorepellent driving cells to the nearest edge.  In uniform 
SFM experiments I have already presented data to show that cells move 
randomly over the bridge and this supports the gradient consumption hypothesis.  
These effects arise in the Insall chamber due to the relatively small volume of 
fluid present over the bridge compared to the wells.  The cells and media over 
the bridge are in other words, spatially restricted.  This is an important feature 
in keeping with the complex restricted environment cells co-habit in vivo (Chioni 
and Grose, 2008). 
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Figure 5-1 Observing the behaviour of cells in uniform serum. 
With the Insall chamber standard assay, WM239A cells were added to the chamber in the 
presence of uniform serum (10% FBS in both inner and outer wells). These cells were imaged for 
24 hours. The bridge was divided into 2 equal halves longitudinally and the cells were tracked 
based on their starting location into the 2 sub-groups: left of right. The upper spider plot combines 
all the cell tracks and the smaller spider plots present the tracks based on the starting position of 
the cells. 
 
Whilst establishing the Insall chamber standard assay, I also observed that at 
very low cell densities, chemotaxis to serum was poor and the edge effect was 
less marked in uniform serum experiments.  This suggests that melanoma cells 
are capable of exerting a communal effect on the response, supporting the 
hypothesis that they are capable of modifying the gradient or producing a new 
one.  I therefore asked the question of whether this dispersal effect is also 
driven by positive LPA chemotaxis? And if so, how is it generated? 
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Melanoma cells disperse in serum by positive 
chemotaxis 
5.1.1 Melanoma cells disperse in uniform 10% FBS media 
To test the mode of the dispersal effect, we devised the “centre well assay”, 
which is useful for observing the behaviour and initial response of cells to an 
undisturbed chemoattractant (Muinonen-Martin et al., In Press). A comparison 
with the standard assay can be seen in figure (Fig. 2).  Importantly, there are no 
cells on the bridge that can modify the gradient. It therefore allows the 
observation of single and multicellular migration patterns over the entire 
distance of the bridge, thus allowing the probing of mechanism of migration with 
greater clarity. Another important difference to the standard assay is that cells 
can only move initially in a 180° arc directed towards the bridge and this can 
therefore be considered to be a simplified model of the dispersal of cells from a 
tumour.  This assay was established by Prof David Knecht (Dept Molecular & Cell 
Biology, University of Connecticut) and the experiments that have been carried 
out by him are marked accordingly in the figure legends.  All the work has been 
generated with our joint intellectual input. 
We attempted to generate the equivalent of the edge-effect response in the 
centre well assay.  We did this by establishing the centre well assay with 
WM239A MM cells in centre well immersed in uniform 10% FBS and observed their 
response over the course of 18 hours.  The experiment was successful and cells 
actively migrated onto the bridge (Fig. 3).  A refined example of this experiment 
has been performed by Olivia Susanto who compared migration of WM239A cells 
in uniform serum (Movie S11) and 0-10% FBS (Movie S12) in the centre well assay.  
This process of autonomous cell dispersal will now be investigated in further 
detail.   
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Figure 5-2 Two Insall chamber assays for investigating chemotaxis.  
A The standard assay starts with cells spread evenly and predominantly singly across a coverslip 
and therefore throughout the chemotactic gradient on the bridges. B The centre-well assay is set-
up with all the cells originating in the centre-well from which they can emerge into an undisturbed 
gradient (over the viewing bridges. 
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Figure 5-3 Cell migration in the centre-well assay 
Images of WM239A melanoma cells spreading from the Insall chamber centre well assay in wave 
formation across the bridge over 18 hours duration. Panels represent time-lapse images taken 
every 6 hours during this window.  
 
5.1.2 Melanoma cells do not disperse by contact inhibition of 
locomotion in 2D or 3D 
To investigate which mode of directional migration is the underlying driver of 
the dispersal effect, we first investigated contact inhibition of locomotion using 
the centre well assay with uniform medium (Fig. 4).  In the presence of a 10% 
FBS gradient cells can be seen to be dispersing whether or not they are in 
contact with one-another and cells can also be seen migrating in a chain out 
from the centre well (Movie S13).  These observations confirm that contact 
Chapter 5 
 153 
inhibition of locomotion is not the mechanism driving melanoma cell dispersal in 
these 2D assays. 
 
Figure 5-4 Observing the mode of migration in 2D 
A Images of the standard assay with a 10% FBS gradient with 2 different experiments with WM35 
cells shown in the large panel on the left and WM1158A cells on the right. There are exploded 
views with cells contacting in one image and migrating singly in the other B Images of WM1158 
melanoma cells spreading during an Insall chamber centre-well assay. This latter experiment was 
performed by Prof David Knecht. 
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Investigating the mode of dispersal in 3D organotypic matrices is more 
challenging because of the more complex environment.  There is also no proven 
mechanism by which cells disperse in the assay. The accepted dogma revolves 
around the induction of a chemotactic gradient that drives invasion generated by 
raising the gel to the air-liquid interface (Timpson et al., 2011).  This assumption 
is generally accepted within the field, although there is neither evidence for 
how this gradient is generated, nor any confirmation that a gradient exists 
(Berking and Herlyn, 2001; Meier et al., 2000).   
If one considers the situation where a gel is lifted to the air-liquid interface 
without any cells seeded over the upper surface, one would postulate that the 
gel would remain saturated due to the large pool of serum under the gel with no 
sink.  No gradient would therefore be formed assuming the serum pool was 
regularly replenished with frequent fresh CGM changes (Zicha et al., 1991).  
Therefore the key factor involved in generating the gradient must be the 
addition of cells seeded onto the surface of the gel.  Friedl et al postulated that 
contact inhibition of locomotion may maintain a high degree of polarity in cells 
invading collectively and this process would contribute to the directional 
persistence of motility even in the absence of a chemotactic gradient (Friedl et 
al., 1995).  If the gels are kept submerged with a layer of cells on the upper 
surface, a gradient cannot form due to the saturating level of serum surrounding 
the matrix and cells.  I therefore performed a simple experiment comparing the 
invasion of cells kept submerged versus the invasion of cells on gels lifted to the 
air-liquid interface to test the role of contact inhibition of locomotion in 3D.   
Keeping the gels submerged resulted in complete failure of invasive cells to 
breach the integrity of the gel (Fig. 5). This result clearly rejects the hypothesis 
that invasion is driven by contact inhibition, which would predict invasion in 
both circumstances.  However, it supports the theory that chemotaxis is the 
main mechanism by which cells invade into the gels, but direct evidence for 
positive or negative chemotaxis has yet to be identified.  I speculate that once 
the gel is raised to the air-liquid interface, an LPA gradient is produced in a self-
generated fashion by the overlying cancer cells and this steers their invasion. 
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Figure 5-5 Observing the mode of migration in 3D 
Representative images of organotypic assays seeded with 2x105 WM98-1 cells and either kept 
submerged (left) or raised to the air-liquid interface (right) for 14 days. 
 
5.1.3 Melanoma cell dispersal is density dependent 
To test the assertion that dispersal is density dependent, we seeded cells at 
different densities in the centre well assay.  Representative images are shown at 
the same 17 hour time point for each density (Fig. 6A).  It is clear from the 
images that as the cell density increases, the number of cells migrating onto the 
bridge increases (Fig. 6B,C).  Not only does the number of cells migrating onto 
the bridge increase, but the distance migrated and the proportion of total cells 
migrating onto the bridge also increases.  This implies that the cells are co-
operating with one another to disperse more efficiently and this supports cell 
dispersal as a density dependent autonomous process.    
Chapter 5 
 156 
 
Figure 5-6 The effect of increasing cell density on autonomous cell dispersal. 
A Images of the uniform media centre well assay with 3 different cell densities of the MM cell line 
WM1158/ well: 2x103, 6x103 and 2x104. The images represent the same 17 hour time point in each 
assay. These data are quantified by (B) distance travelled by the furthest 3 cells and (C) migration 
index (the proportion of cells on the bridge relative to the total number of cells in the field of view). 
This experiment was performed by Prof David Knecht. 
 
5.1.4 Melanoma cell dispersal is overwhelmingly driven by 
positive chemotaxis through depletion of a serum factor(s) 
To investigate dispersal via positive or negative chemotaxis, we performed the 
centre well assay with WM1158 cells in the absence of serum (Fig. 7A).  Over the 
time course of 17 hours, the cells completely failed to migrate onto the bridge.  
The result of this experiment argues against the hypothesis that cell dispersal is 
driven by negative chemotaxis (the production of a chemorepellent) and 
combined with the results from previous uniform medium experiments, indicates 
that there is a factor within serum that is necessary for dispersal. 
This suggests that the directed migration in uniform serum arises as a result of 
breaking down a serum factor(s) acting as the chemoattractant(s).  This process 
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of degrading the factor(s) generates a gradient to which the cells can chemotax.  
We than asked the question of whether the application of a pre-formed outward 
gradient of serum would drive dispersal?  
 
Figure 5-7 Examining the mechanism of dispersal +/- 10% FBS gradient. 
A Image of Insall chamber centre-well assay demonstrating WM1158 cells spreading to the nearest 
edge on the bridge seen clearly on the spider plots (overall and subdivided into cells starting on left 
or right sides of the viewing bridge). B WM239A cells in the centre well assay in the presence of an 
artificially generated 10% FBS gradient. These experiments were performed by Prof David Knecht. 
 
Chapter 5 
 158 
Repeating the centre-well assay, but this time adding an external outward 
gradient of 10% FBS (Fig. 7B), the WM1158 cells dispersed with at least 
equivalent efficiency onto the bridge during the same 17 hour time frame 
compared to the experiment in uniform serum (See Movies S11 & 12). This 
further supports the depletion of a serum factor, with the chemotaxis in uniform 
serum appearing very similar to the positive chemotaxis arising when an 
externally applied gradient is applied. 
Melanoma cells degrade LPA to generate gradients 
driving dispersal 
5.1.5 Degradation of a serum factor(s) drives chemotaxis 
I reasoned that conditioning fresh media with melanoma cells would result in 
degradation of the serum factor(s).  Establishing a standard assay with fresh 
media in one well and conditioned media in the other would in effect generate 
an external gradient towards the fresh media. Melanoma cells should therefore 
migrate in the direction of the fresh media. 
The result of the migration analysis comparing fresh media mock conditioned for 
0 hours (T0) to fresh media conditioned for 48 hours (T48) overall produced a 
spider plot with accurate chemotaxis towards the T0 media (Fig. 8).  Compare 
control experiment (Movie S14) to conditioned experiment (Movie S15). This is 
indicative of the efficient chemotaxis seen towards LPA and serum.  Sub-dividing 
the data into the half of the bridge that the cells originated from confirmed that 
cells starting on both sides migrated with similar efficiency towards the control 
side.  The data for all the conditioned media time points are available (see 
appendix 5). 
This result supports the hypothesis that melanoma cells perform chemotaxis in 
uniform serum by depleting a serum factor.  Based on the results in chapter 4 
showing that LPA is the major driver of melanoma chemotaxis I hypothesised 
that it is the depletion of LPA that drives this response. 
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Figure 5-8 The effect of conditioning media on the dispersal effect of serum. 
Image of the standard assay cells with 10% FBS T0 (No conditioning) and 10% FBS T48 (Prior 
conditioning in the presence of WM239A cells for 48 hours) in opposing wells. The large spider 
represents all the tracks and the sub-divided data based on side of the bridge is below. 
 
5.1.6 LPA is depleted in melanoma cell conditioned medium 
To determine whether the LPA levels were modified by conditioning, we 
quantified the concentration of LPA in all the samples that I tested.  The same 
conditioned media used in the Insall chamber assays along with SFM conditioned 
media was analysed by LC-MS by my collaborator (Prof. Mike Wakelam) to 
quantify the total and sub-species of LPA. The total LPA fell in both FBS 
conditioned media experiments over time with the rate of depletion being faster 
for FBS conditioned media 2 than FBS conditioned media 1 (Fig. 9A).  This can be 
explained by the greater number of cells (approximately 10 times more at 24 
hours) used to condition FBS conditioned media 2.  The SFM conditioned media 
LPA concentration remained consistently negligible and did not vary over the 
duration of conditioning.  
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Figure 5-9 LC-MS quantification of the [LPA] within media conditioned by WM239A cells. 
The fresh media conditioned by WM239A melanoma cells in Fig. 6 was analysed by LC-MS to 
quantify the total LPA. This experiment was repeated twice with fresh media: FBS CM1 and 2. SFM 
media was also conditioned with WM239A cells with the same technique. Samples were 
immediately frozen on dry ice to prevent the sample from degradation. A Line graph representing 
the total LPA (mean +/- SEM) against conditioning time. The total LPA is presented normalised to 
the volume of CM analysed (750µL). The cell counts at 24 hours are marked. Line graphs of (mean 
+/- SEM) for LPA subspecies and total LPA normalised to T0 for the (B) FBS and (C) SFM 
experiments.  
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These data confirm that LPA is quantifiable and present at significant levels and 
is depleted over time by the WM239A MM cells.  The rate of degradation 
correlates with the number of cells conditioning the media.  The conclusion from 
the SFM conditioned media result is that there is no net production of LPA over 
time, although the cells may require LPC in serum.  These data therefore show 
that melanoma cells are capable of generating a gradient of LPA over time and 
in a density dependent manner. 
5.1.7 Biologically active LPA species are preferentially depleted 
The biological activity of LPA is known to vary with its structure.  In particular, 
there is a positive correlation with the biological activity of LPA and acyl chain 
length (Jalink et al., 1995; Moolenaar, 1995; Van Corven et al., 1992).  We 
therefore quantified the subspecies present in the samples. 
Analysing the subspecies following normalisation to the T0 result (Fig. 9B), there 
is a clear trend towards the longer chain and polyunsaturated sub-species of LPA 
being degraded most efficiently in both experiments.  There was a very small 
quantity of LPA quantifiable in the SFM experiment, but not all the sub species 
were identifiable and there was no overall trend (Fig. 9C). 
The finding that the different LPA species are preferentially depleted with the 
most biologically active species creating the steepest gradients is therefore 
significant.  To the best of my knowledge, these are the first data to reveal that 
the most biologically active species of LPA are preferentially degraded. 
This raises important questions regarding the specificity of the different LPA 
degrading enzymes (LPPs) for their substrate LPA. Is the slightly enhanced 
chemotactic response generated by MM cells related to differential expression of 
LPPs? One could hypothesise that they are capable of degrading the most 
biologically active LPA species more efficiently.     
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5.1.8 LPA is sufficient to generate a dispersal effect  
Having demonstrated the ability of melanoma cells to deplete LPA over time, I asked 
whether a uniform concentration of LPA is sufficient to generate a dispersal or “edge-
effect”? I tested the ability of a uniform 1µM LPA to generate the dispersal effect in the 
standard Insall chamber assay (Fig. 10).  
Figure 5-10 Examining the ability of 1 µM LPA to generate an “edge-effect”. 
With the Insall chamber standard assay, WM239A cells were added to the chamber in the 
presence of uniform 1 µM LPA (1 µM LPA in both inner and outer wells). These cells were imaged 
for 24 hours. The bridge was divided into 2 equal halves longitudinally and the cells were tracked 
based on their starting location into the 2 sub-groups: left of right. The upper spider plot, rose plot 
and Rayleigh test are calculated based on all the cell tracks and the smaller spider plots present 
the tracks based on the starting position of the cells. The chemotaxis index plot is calculated for all 
3 scenarios. 
 
Whilst the overall spider plot reveals no trend and the Rayleigh test is highly 
non-significant.  The rose plot suggests there are 2 populations of cells moving 
directionally towards the edges of the bridges.  Sub-analysing the data based on 
initial bridge position, the data unambiguously reveal a dispersal effect.  I can 
therefore conclude from these data that LPA is sufficient to generate a dispersal 
effect. 
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5.1.9 LPA is necessary to generate a dispersal effect 
I then wished to question whether LPA is necessary for the dispersal effect in 
serum? This experiment involved comparing the dispersal effects of WM239A 
cells in the presence or absence of the LPA inhibitor Ki16425.   
 
Figure 5-11 Examining the effect of Ki16425 on the “edge-effect”. 
With the Insall chamber standard assay, WM239A cells were added to the chamber in the 
presence of uniform serum (10% FBS in both inner and outer wells) with vehicle (A) of the LPA 
inhibitor Ki16425 (B). These cells were imaged for 24 hours. The bridge was divided into 2 equal 
halves longitudinally and the cells were tracked based on their starting location into the 2 sub-
groups: left of right. The upper spider plot in each combines all the cell tracks and the smaller 
spider plots present the tracks based on the starting position of the cells. C The chemotaxis index 
is calculated for all 6 scenarios and tested for deviation from a CI=0 with one sample t tests. 
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The vehicle controlled experiment (Fig. 11A; Movie S16) demonstrates a strong 
dispersal effect with a bipolar bias as seen previously.  The addition of Ki16425 
generates a completely random overall plot (Fig. 11B; Movie S17).  Sub-analysing 
the data based on starting position on the bridge reveals spider plots that appear 
entirely random on both sides of the bridge.  These results are presented with 
greatest clarity on the CI plot (Fig. 11C).  The robust and highly significant 
dispersal effect in the vehicle treated group is completely abolished in the 
inhibitor treated group, with the CIs all failing to deviate from 0. 
These data firstly confirm that LPA is necessary for the edge effect.  Secondly, 
they implicate LPARs 1 and 3 in the transduction of the signal required to 
respond to the self-generated gradients. 
Fibroblasts and keratinocytes also degrade LPA 
I was interested to see whether other skin cells have the ability to degrade LPA 
or whether this was a melanoma specific phenomenon.  I therefore conditioned 
media with Tiff fibroblasts and HaCaT keratinocytes.  The functional 
chemotactic effects of these media on WM239A cells were compared using the 
standard assay with exactly the same technique as for the melanoma (WM239A) 
conditioned media experiments. 
Both the fibroblast (Fig. 12A upper left) and keratinocyte (Fig. 12B lower left) 
mock conditioned media produced edge-effects when uniformly distributed.  The 
dispersal effect was strongest with the keratinocyte conditioned media.  Adding 
T48 conditioned media to the wells on the right hand side resulted in strong 
chemotaxis to the mock conditioned media.  This confirms that other host cells 
are capable of self-generating gradients. 
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Figure 5-12 Investigating the effect of keratinocyte and fibroblast conditioned media on the 
dispersal of melanoma cells. 
A Fibroblast and B keratinocyte CM was used to investigate their respective effects on the 
dispersal of WM239A melanoma cells. The conditioning was performed as per the melanoma cell 
CM. The panels on the left represent the positive control experiments with T0 CM both sides and 
the T0 – T48 CM experiments are on the right. The larger plots to the right of the images represent 
the pooled tracks and the smaller plots present the tracks based on the starting position of the 
cells. 
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Patterning associated with self-generated gradients  
5.1.10 A wave precedes the patterning of the bridge with 
evenly spaced cells 
Reviewing the movies of cells dispersing in uniform 10% FBS, a wave passes to 
the nearest edge in the standard assay (Movie S16), or more strikingly, across 
the bridge in the centre-well assay (Movie S11).  This wave is moving 
independently of the mass of cells in the centre well.  Of particular interest is 
the way in which cells dropping off the back of the way are left relatively 
motionless, dendritic in morphology and evenly spread across the bridge.  This 
finding is reproducible when Dictyostelium cells migrate in uniform folate in the 
under agar assay (equivalent to the centre-well assay; Movie S18). 
Discussion 
In this chapter, I have shown that the dispersal of melanoma cells in uniform 
serum is driven by positive chemotaxis, which is serum dependent.  The process 
of positive chemotaxis is driven by the ability of cells to deplete LPA from the 
immediate microenvironment to generate outward gradients that drive the 
dispersal of cells.  Cells are therefore capable of dispersing in uniform serum, 
but the effect is amplified by applying an external gradient.  This is almost 
certainly due to LPAR saturation in uniform media and following a period of LPA 
degradation, the LPA concentration falls to around the Kd of its receptor (Hulme 
and Trevethick, 2010; Tabchy et al., 2011).  Near this concentration, the LPAR 
receptors are able to sense the gradient and transduce the signal with 
subsequent chemotaxis.  With an externally applied gradient, the LPA 
concentration is already nearer to the Kd for the receptor producing a much 
greater and more rapid chemotactic response.  
I noted that there was a time delay before dispersal in the conditioned media 
experiments, potentially corresponding to this initial period of receptor 
saturation.  I hypothesised that there would therefore be a shorter delay before 
dispersal with increased duration of conditioning.  An attempt was made to 
quantify this by comparing the delay with media conditioned for increasing 
durations, but the result was inconsistent and this line of investigation was not 
Chapter 5 
 167 
pursued (see appendix 5).  Alternatively, this lack of correlation may be 
explained by receptor adaptation after a period of saturation.  LPA degradation 
by LPPs is very rapid and LPA has a short half life of only 3 minutes in plasma. 
Therefore it is likely that a gradient is established relatively quickly (regardless 
of the duration of conditioning) in the Insall chamber and the delay is in fact due 
to the time it takes for the receptors to adapt and sense the gradient following 
the fall below the receptor saturation concentration.  To investigate this more 
accurately, the Insall chamber could be further modified by installing a 
micropump to provide a continual source of fresh media to further investigate 
the role of self-generated gradients. I hypothesise that cells would fail to 
disperse in the centre well assay if 10% FBS was being constantly replenished, 
because the ability of cells to generate a gradient would overwhelmed by the 
supply of LPA.   
The scattering/ dispersal of cells in response to LPA was first described in 
keratinocytes (Jourquin et al., 2006).  Interestingly, this response was enhanced 
by a period of serum starvation.  The finding was confirmed with gastrointestinal 
cancer cells and was shown to be dependent on LPAR1 receptor expression with 
cells only expressing LPAR2 unable to perform this.  The underlying mechanism 
behind the dispersal effect of LPA was not elucidated (Shin et al., 2009).  
However, these experiments were performed in a standard cell culture dish with 
overlying media and all the cells were in contact in small colonies.  It is likely 
therefore that this is an entirely different mechanism, reliant on alterations in 
adherens junctions rather than the dispersal of individual cells through self-
generated gradients.  In keeping with the scattering effect being dependent on 
LPAR 1 signalling, I found that LPAR 1+/- LPAR 3 were also necessary for the 
dispersal effect elicited in the Insall chamber with the use of Ki16425. 
I have shown that LPA is both sufficient and necessary for the dispersal or “edge-
effect”, acting through the mechanism of self-generated gradients.  With the 
cell conditioning experiments, I have demonstrated that the greater the number 
of cells, the higher the rate of LPA depletion.  This density dependent finding 
translates well to the ability of a larger proportion of melanoma cells to disperse 
further in higher cell densities.  Applying the same mechanism to human 
melanoma invasion one would expect larger melanomas, containing a higher cell 
number, to be more invasive and produce a disproportionate number of 
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circulating tumour cells.  Although, the current model supports depth of invasion 
as the best predictive marker for metastasis, there is evidence to support 
tumour volume as a better predictive marker (Friedman et al., 1991; Marghoob 
et al., 2000; Payette et al., 2009).  This evaluation is currently considered 
impractical compared to a simple one dimensional measurement, although it 
would provide an even closer approximation to the model I am proposing. 
LPA has been shown to promote wound healing in skin (Balazs et al., 2001), 
healing of the intestinal epithelium (Sturm et al., 1999), healing of corneal 
ulceration (Xu et al., 2007) and it has been recovered from blister fluid 
(Mazereeuw-Hautier et al., 2005).  It also promotes keratinocyte chemotaxis and 
cell motility using transwell chambers (Jans et al., 2013; Sauer et al., 2004).  
The mechanism by which LPA induces keratinocytes to migrate across a wound is 
not yet known and the finding that keratinocytes can generate gradients may 
explain the mechanism by which they produce wound re-epithelisation.  
Supportive of this hypothesis is the finding that LPARs 1-3 are expressed in 
keratinocytes, which enables transduction of the LPA signal (Anliker and Chun, 
2004). 
Fibroblasts have been shown to migrate towards wounds in response to LPA 
(Balazs et al., 2001).  In vitro wound remodelling and contraction is directed by 
LPA in experiments measuring the contraction of 3D organotypic gels (Lee et al., 
2003).  This mechanism again may well be directed through LPAR1.  Fibroblasts 
are known to express LPAR1 (Ohta et al., 2003; Hama et al., 2004) and Ki16425 
has been shown to significantly reduce motility in scratch assays (Tanaka et al., 
2009) and Boyden chamber assays (Hama et al., 2004), but LPA chemotaxis has 
not been quantified using a direct visualisation method.  It would therefore be 
interesting to see the effect of the conditioned medium on the chemotactic 
responses of fibroblasts and keratinocytes.  The evidence from my conditioned 
media experiments and the literature suggests that self-generated gradients may 
explain the predicted chemotactic response to serum or LPA by both cell types.   
The fact that numerous cells can degrade LPA complicates the emerging model, 
although regardless of the cell type breaking down the LPA, the process will 
remain density dependent.  Therefore one would hypothesise that a primary 
melanoma will disproportionately breakdown LPA compared to keratinocytes and 
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fibroblasts in particular.  The keratinocytes may play a role in distorting the LPA 
gradient above a melanoma, given their relative abundance. 
Following the observation that WM239A cells preferentially break down the more 
biologically active LPA species, it will be important to repeat this result in other 
MM cell lines and to compare the results with the sub-species profile generated 
in conditioned media from RGP and VGP cells.  This raises the question of 
whether strongly serum responsive melanoma cells are capable of degrading the 
most biologically active LPA species more efficiently than weakly responsive 
cells? We will need to identify the LPP and LPAR expression profile by the 
different cells (or stage).   
Finally, the patterning of cells observed in our final experiments in this chapter 
is created by an advancing wave of cells driven by a self-generated gradient. 
The cells at the back of the wave then drop off the back in an evenly spaced 
distribution.  The fact this finding is consistent in both Dictyostelium and 
mammalian cells suggests it may be an important conserved mechanism for the 
equal spreading or patterning of cells. I hypothesise that the number of cells in 
the wave could be maintained by a mitotic rate equal to the rate of cells lost 
from the back of the wave.  When cells show a defect in melanoblast migration 
during development, one of the phenotypes they produce is a white belly, 
whereby the cells fail to migrate around the trunk (Li et al., 2011). It is 
interesting to hypothesise whether this arises due to a lack of chemoattractant, 
a failure to generate gradients or a slowing of growth. The latter would result in 
the wave petering out or slowing before critical survival signals result in the 
melanoblasts invading the epidermis wherever they had reached and 
interestingly, defects in cell-cycle progression and cytokinesis have been 
confirmed in these Rac1 deficient mice. 
5.1.11 Conclusion: 
Through the use of a direct visualisation assay, we show that the dispersal of 
melanoma cells is overwhelmingly driven by positive chemotaxis.  Melanoma cells 
deplete LPA in their immediate vicinity to generate gradients of LPA that drive 
positive chemotaxis.  I hypothesise that this process may also be the mechanism 
employed by other cell types resulting in wound closure by keratinocytes or 
Chapter 5 
 170 
ensuring the even distribution of melanoblasts during development.  The efficiency 
of the mechanism is enhanced by the preferential degradation of biologically 
active LPPs.  I hypothesise that self-generated LPA gradients will drive the 
invasion of melanoma cells in vivo and the efficiency of this process may depend 
on the LPP expression profile. 
 
  
 
 
 
Chapter 6: 
The Identification of LPA Gradients Across the 
Margins of Melanomas In Vivo 
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Introduction  
The data presented in chapter 4 indicates that the inflammatory signal LPA is 
the key chemoattractant in serum. To demonstrate the physiological relevance 
of this finding I hypothesised that a gradient of LPA will exist across the margin 
or invasive front of a melanoma in vivo.  The data presented thus far would 
suggest that this gradient is a marker for active LPA chemotactic invasion and 
may therefore represent a much needed prognostic marker for the risk of 
metastasis (Mackie, 2000).   
To test this hypothesis, I decided to sample the LPA concentration across the 
margin of a melanoma.  I first considered the shape and nature of the gradient.  
It would be important to prove that there exists an outward gradient of LPA 
from the melanoma, ie. lower within the tumour and higher outside the tumour.  
This would provide the key signal to melanoma cells at the periphery of the 
tumour to invade and indicate that the melanoma cells are actively self-
generating a gradient. This outward gradient should be present in all directions, 
and would act as a tumour-centric dispersive force that drives outward invasive 
migration in all directions.  This could explain the pagetoid (upward) spread 
commonly associated with invasive melanoma (Brenn, 2012; Petronic-Rosic et 
al., 2004; Trotter, 2011) and the lateral spread necessitating wide local 
excisions to excise these micrometastases following initial excision of the 
primary melanoma (Marsden et al., 2010).  The source of LPA in this model 
arises from within the tumour as a result of inflammation and platelet 
activation.  The final chapter will discuss this further as this hypothesis has not 
formerly been tested. 
The presence of LPA has only been investigated in human skin on one previous 
occasion (Mazereeuw-Hautier et al., 2005).  This study quantified the presence 
of LPA in serous blister fluid from patients with a range of bullous dermatoses 
using a simple and highly sensitive radioenzymatic assay (Saulnier-Blache et al., 
2000).  LPA was detected in the blisters of all 24 patients at physiological 
concentrations (0.60 +/- 0.0087 µM).  LPA is now detectable by liquid 
chromatography-mass spectrometry (LC-MS) and I opted to use this highly 
accurate technique in collaboration with Prof Mike Wakelam to quantify the 
concentration of LPA in the tumour and surrounding skin (Wakelam et al., 2008; 
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Wakelam and Clark, 2011).  I therefore acquired fresh melanoma tissue from 
murine models of melanoma to pilot and validate the technique.  These models 
are considered highly representative of human disease and cancer (Van Dyke and 
Jacks, 2002).  
To the best of my knowledge, the existence of a chemotactic gradient across a 
tumour has never been demonstrated in vivo and the discovery of this gradient 
would further support the chemotactic driven invasion paradigm.  In particular it 
would improve understanding about the generation of chemotactic gradients in 
vivo, provide important information about the tumour microenvironment’s 
sphere of influence and perhaps pave the way to develop a novel prognostic 
marker. 
The generation of murine melanomas  
6.1.1 The Tyr::CreERT2 BRAFV600E/+ PTENlox/+ mouse melanoma 
model  
The Tyr::CreERT2 BRAFV600E/+ PTENlox/+ melanoma model has been described in 
the introductory chapter.  Based on the McMahon model, it was generated and 
maintained by Dr. Colin Lindsay, Dr. William Faller, through the breeding 
programme of Prof Sansom and Prof Ozanne at the Beatson Institute (Dankort et 
al., 2009).   
6.1.2 Suitability & characterisation of the Tyr::CreERT2 BRAFV600E/+ 
PTENlox/+ mouse melanoma model for sampling LPA 
gradients 
This model has been thoroughly characterised in Dr Lindsay’s PhD thesis 
(Lindsay, 2012).  The specific details about the alleles used in the model and the 
method of induction are covered in chapter 2.  The results in this section on 
suitability and characterisation were obtained by Dr Lindsay and are presented 
with his express permission.  
A comparison of overall survival between the Tyr::CreERT2 BRAFV600E/+ PTENlox/+ 
model model and the Tyr::CreERT2 BRAFV600E/+ PTENlox/lox model, revealed that 
the latter’s survival was considerably shortened.  This was due to the extremely 
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rapid overgrowth and ulceration of the tumours and so the model using the PTEN 
heterozygote allele was considered a more faithful representation of the human 
disease.  Importantly, this melanoma model is driven by the BRAFV600E mutation.  
This is the most common mutation found in approximately 50% of human 
melanomas and is therefore highly desirable to study from a translational 
perspective (Broekaert et al., 2010; Ellerhorst et al., 2011). An NRAS model was 
less desirable for the reasons outlined in the introduction. 
Histologically, the tumours generated demonstrated a nodular melanoma (NM) 
morphology with, which is typical of mouse melanoma models.  Epithelioid and 
spindle cells are found intradermally and most of the tumours were amelanotic 
with pigmented cells predominantly found in the dermis. Following induction 
with tamoxifen, the median time to melanoma induction was approximately 10 
weeks and by 22 weeks, all mice have developed a primary melanoma.  
Following melanoma induction, the median time until death was approximately 3 
weeks. 
Macroscopically, 19/23 melanomas demonstrated ulceration at a median 
diameter of 7mm and 2 mice in the cohort were not assessed. Morphologically, 
the melanomas are clearly delineated and after shaving the skin, it is easy to 
identify where the tumour margin resides.  As the skin on the back is activated 
with tamoxifen, the majority of tumours are located on this very accessible and 
easy to sample area. 
6.1.3 Incorporation of the 3Rs: replacement, reduction and 
refinement 
The project had already explored and utilised “replacement” alternatives in the 
work described in chapter 4, particularly with the use of 3D organotypic assays.  
Advancing the understanding a stage further and discovering whether LPA 
gradients are physiologically relevant by proving their existence in vivo was 
considered potentially of great scientific and medical importance. 
The Tyr::CreERT2 BRAFV600E/+ PTENlox/+ murine model has been developed and 
“refined” for generating melanomas.  Importantly, the fact they were being 
bred for another simultaneous project meant that no extra animals were 
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required for this work.  Having incorporated the 3Rs in the experimental 
proposal, I considered the proposed work ethically sound. 
Sampling & quantifying LPA in vivo 
6.1.4 Quantification of LPA  
A collaboration was established with Prof. Mike Wakelam (Babraham Institute, 
Cambridge) who has pioneered the use of high-sensitivity liquid chromatography-
mass spectrometry (LC-MS) technology to rapidly and comprehensively measure 
the levels of lipids in a wide range of cells, tissues and tumours (Wakelam, 
2013).  This robust technique has been used to quantify the LPA concentration 
within different tissues.  The key factors to consider were firstly that the 
sensitivity of the technique necessitated that at least 1 mg of tissue was 
required per sample. Secondly, LPA is known to have a short half-life of only 3 
minutes in plasma and therefore all biopsies were attempted within this time 
frame (Samadi et al., 2011).  Therefore, to ensure that no LPA is lost through 
enzymatic degradation, the samples were snap frozen in liquid nitrogen and 
transported to the Babraham Institute on dry ice for LPA extraction and 
quantification.   
6.1.5 Sampling methodology  
Ideally, I wished to measure the LPA gradient downwards in the y-plane across 
the invasive front because this is known to correspond to the key prognostic 
marker for primary melanomas, the Breslow thickness (Balch et al., 2009; Haass 
and Smalley, 2009; Mackie, 2000; Marghoob et al., 2000).  However, slicing the 
core sample in the y-plane would provide insufficient material to measure the 
LPA due to the limited thickness of the skin (Lee and Hwang, 2002).  Based on 
the hypothesis of the “global outward LPA gradient model”, I instead sampled 
across the edge of the melanoma in the x-plane. 
For reproducibility, I opted to sample the tumour and surrounding skin using a 
punch biopsy technique.  This technique is commonly employed by 
dermatologists for biopsying cutaneous neoplasms or inflammatory dermatoses 
and involves taking a cylindrical core of tissue of a set diameter by rotating the 
circular blade down through the epidermis and dermis, and into the 
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subcutaneous fat (Zuber, 2002).  The punch biopsies employed by dermatologists 
commonly vary between 3-6mm in diameter and the tools are available in 1mm 
increments.   
By sampling at points within, at the margin and outside the tumour I planned to 
demonstrate a gradient of LPA across the margin of the melanoma (Fig. 1). For 
mice that developed more than one melanoma, the melanomas were sampled in 
a direction that was equidistant from other melanomas to reduce the risk of 
contamination from the microenvironment of these other tumours.   
 
Figure 6-1 Schematic of in vivo melanoma sampling methodology. 
This schematic represents the locations of the punch biopsies (red ring) for sampling tissue for LPA 
quantification in relation to the melanoma (brown filled circle). The distance from the tumour margin 
is marked by a dashed line. 
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The identification of LPA gradients across murine 
melanomas 
6.1.6 LPA gradients exists across the margins of non-ulcerated 
murine melanomas 
Only mice with non-crusted and non-ulcerated tumours were included in this 
analysis (Fig. 2A). 6 melanomas were analysed from 3 separate mice.  All the 
melanomas demonstrated a clear outward gradient of total LPA (Fig. 2B).  The 
concentration of LPA was lowest in the tumour, slightly higher at the margin and 
much higher outside the tumour and this was extremely reproducible and 
statistically significant. 
Analysis was performed after normalising the data to position A for subspecies of 
LPA relative to the total LPA (Fig. 2C).  The signalling LPAs all generated steeper 
gradients that the non-signalling, saturated LPA subspecies.   
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Figure 6-2 Quantification of [LPA] across the margins of non-ulcerated murine melanomas 
A Photographs of murine melanomas following dissection of a large area of dorsal skin down to the 
subcutaneous layer, before and after sampling the tumours with a 6mm punch biopsy tool, within 5 mins of the 
mouse being sacrificed. The melanomas are generated with the Tyr::CreERT2 BRAFV600E/+ PTENlox/+ 
melanoma model. This example highlights the phenotypic difference between normal melanomas and 
crusting/ ulcerated melanomas (green and blue rings respectively). Crusting/ ulcerated melanomas were 
excluded from this analysis. The position of the biopsy is note from A-D B Line graph representing the in vivo 
concentration of LPA (mean +/- SEM) across the margins of 6 melanomas in 3 mice. The total LPA (ng/mg 
tissue) was quantified by mass spectrometry after weighing the snap frozen specimens and extracting the 
LPA. Statistical comparisons have been performed by anova and tukey comparison of the means C log scale 
plot of (mean +/- SEM) for LPA subspecies and total LPA normalised to the value at position A and plotted 
across positions B and C. 
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6.1.7 Inverse LPA gradients exists across the margins of 
ulcerated murine melanomas 
The previous figure showed photographs of a mouse with mixed non-ulcerated 
and ulcerated tumours.  The mouse shown here developed 2 distinct ulcerated 
melanomas over its back (Fig.  3A).  Again, these were sampled in an orientation 
to control for and reduce the risk of contamination from the microenvironment 
from the other melanoma.   
In total, 3 ulcerated/ crusted melanomas were sampled across 2 mice.  In 
complete contrast to the non-ulcerated melanomas, the gradient of LPA was 
inverted, from high within the tumour to low outside, which was statistically 
significant (Fig. 3B).  Interestingly, the level of LPA at C was lower still than 
nearer to the tumour, suggesting that the source of LPA is derived from or within 
the immediate microenvironment of the tumours. 
Interestingly, the data for sub-species of LPA, the trend towards steeper 
gradients of signalling LPAs was not evident in ulcerated melanomas (Fig. 3C).  
Although, the most shallow gradient belonged to 18:0, 16:0 produced a steep 
gradient.  LPA quantification for individual murine melanomas is available 
(appendix 6). 
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Figure 6-3 Quantification of [LPA] across the margins of ulcerated murine melanomas 
A The photographs show an example of 2 ulcerated/ crusted melanomas arising on the dorsal 
aspect of one mouse. These are seen more clearly with the exploded view. The photograph on the 
right depicts the dissected skin after the punch biopsy samples were acquired. In addition to the 
standard samples, a sample was taken at a site distant to both melanomas. B Line graph 
representing the in vivo concentration of LPA (mean +/- SEM) across the margins of 3 ulcerated/ 
crusted melanomas in 2 mice. The total LPA (ng/mg tissue) was quantified by mass spectrometry 
after weighing the snap frozen specimens and extracting the LPA. C Line graph of (mean +/- SEM) 
for LPA subspecies and total LPA normalised to the value at position A and plotted across 
positions B and C. 
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6.1.8 Steady LPA levels exist across normal murine skin 
To investigate the concentration of LPA across normal skin, mice with the same 
genetic background (Tyr::CreERT2 BRAFV600E/+ PTENlox/+) were also treated with 
tamoxifen to activate the alleles.  The same sampling technique was used and 3 
replicates were taken per mouse (Fig. 4A).  In total, normal skin from 2 mice, 
with 2 replicate series in each was used for LPA quantification. 
The result showed no evidence of a gradient and instead revealed a stable and 
reproducible concentration of LPA across the skin (Fig. 4B).  Further analysing 
the data based on normalised sub-species of LPA, revealed no trend base on 
signalling LPAs (Fig. 4C).  Performing statistical analyses, there was no 
significant difference between sites A, B or C. 
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Figure 6-4 Quantification of [LPA] in normal murine skin in vivo. 
A The photographs show an example of normal skin on the dorsal aspect of one mouse. This skin 
is sampled from the same Tyr::CreERT2 BRAFV600E/+ PTENlox/+ melanoma model, which has been 
activated with tamoxifen, but not yet developed any melanomas at the time of tissue sampling. The 
photograph on the right depicts the dissected skin after the punch biopsy samples were acquired. 
Samples A-C (each separated by 5mm) are used for comparison with 3 experimental replicates 
acquired per mouse. B Line graph representing the in vivo concentration of LPA (mean +/- SEM) 
across the positions A-C on a sample of normal skin from 2 mice, with 2 replicate series in each. 
The total LPA (ng/mg tissue) was quantified by mass spectrometry after weighing the snap frozen 
specimens and extracting the LPA. C Line graph of (mean +/- SEM) for LPA subspecies and total 
LPA normalised to the value at position A and plotted across positions B and C. 
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The identification of LPA gradients across a human 
melanoma 
There are concerns about translating the results from murine models to the 
human disease due to anatomical differences (Becker et al., 2010; Walker and 
Hayward, 2002).  From a pigment cell perspective, mouse melanocytes are 
distributed in the hair follicles, rather than the hair follicles and the inter-
follicular skin along the dermo-epidermal junction as found in humans 
(Billingham and Silvers, 1971; Buac and Pavan, 2007).  Having successfully shown 
gradients of LPA across the margins of murine melanomas I established ethical 
approval to collect fresh primary human melanomas for analysis to investigate 
the presence of an LPA gradient with exactly the same methodology as for 
murine melanomas.   
A suitable subject was identified meeting the minimum criteria for the width of 
the primary lesion (see Chapter 2: materials and methods).  The 81-year-old 
female patient presented with an ulcerated nodule arising in a long standing 
naevus and the overall lesion measured 4.5 cm.  The central nodule was biopsied 
confirming the diagnosis of an ulcerated superficial spreading melanoma (SSM) 
with a Breslow thickness of 22 mm.  Following informed consent, the lesion was 
photographed in situ prior to a 3cm wide-local excision (Fig. 5A).  Following 
excision, the lesion was immediately examined by the attending consultant 
pathologist and following his approval, samples A-E were taken, along with a 
sample of the sub-cutaneous tissue within 5 minutes of the excision.   
The line graph of the total LPA from each site within this melanoma showed 
features in keeping with both ulcerated and non-ulcerated melanomas (Fig.  5B).  
The sample within the tumour (A) was higher than the margin (B) in keeping with 
an ulcerated melanoma, but then the LPA gradient increased between the 
margin (B) and 5mm outside (C).  This melanoma was sampled further out to 
provide as much detail as possible and the gradient continues to increase to 
10mm (D), before falling at 15mm (E).  
Analysing the data by sub-species of LPA following normalisation fails to show 
any clear bias for signalling over non-signalling LPAs (Fig. 5C). 
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Figure 6-5 Quantification of [LPA] across the margin of a human melanoma. 
A Photographs of the human melanoma printed with the consent of the patient. The image on the 
left demonstrates the overall morphology and the exploded view is a dermatoscopic (10x) image. 
The latter is marked with 4 of the 5, locations sampled with a 3mm punch biopsy. These included, 
positions A-E. B Line graph representing the in vivo concentration of LPA (mean) across the 
margin of 1 human melanoma. The total LPA (ng/mg tissue) was quantified by mass spectrometry 
after weighing the snap frozen specimens and extracting the LPA. C Line graph of (mean) for LPA 
subspecies and total LPA normalised to the value at position A and plotted across positions A-E. 
 
Discussion 
The introductory chapter highlighted work by the Condeelis lab who pioneered 
an in vivo needle assay to collect tumour cells that migrate into a pipette by 
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chemotaxis (Wyckoff et al., 2000).  This technique has enabled the collection of 
cells by chemotaxis in vivo.  These cells can then be isolated and studied in 
further detail.  This has generated data supporting the chemotaxis driven in vivo 
invasion of breast cancer cells towards EGF produced by macrophages (Goswami 
et al., 2005; Patsialou et al., 2009; Wyckoff et al., 2004).  One caveat with 
these in vivo chemotaxis studies is that it is not possible to know whether the 
soluble factors remain soluble or bind to some degree to the ECM. Their lab 
therefore defined chemotaxis in vivo as directional migration to either soluble or 
solid state gradients (Roussos et al., 2011). 
Studying chemotaxis responses in vivo has therefore resulted in important 
insights into the role of stromal cells in the tumour microenvironment.  The 
functional effects of chemotaxis (or chemokinesis/ haptotaxis) have therefore 
been demonstrated in vivo, but there remains no direct evidence for the EGF 
gradients proposed. To the best of my knowledge, the work carried out in this 
chapter is the first evidence to support the existence of any chemoattractant 
gradient across a tumour in vivo, thereby demonstrating the physiological 
relevance of my findings.  
It is clear from the data in this chapter that melanomas influence their 
immediate microenvironment by shaping LPA gradients in this field.  The nature 
and extent of the LPA gradient is dependent on the presence or absence of 
ulceration.  Without a tumour, the LPA concentration remains steady across 
normal skin. 
One can muse on the results produced for the ulcerated murine and human 
samples when considering the model for LPA generation.  Both show that distant 
sites have a lower concentration of LPA than proximal sites.  This supports the 
idea that the LPA detected is tumour-centric in origin.  Taken a stage further, 
following a period of inflammation or more specifically increased platelet 
activation, that may be exacerbated by ulceration, one would hypothesise that a 
surge of LPA would be released from the tumour (Peyton et al., 1998; Ruiter et 
al., 2002).  Alternatively, there is evidence that platelet activation leads to 
ulceration and may be an independent marker of elevated LPA (Tao et al., 
1995).  This LPA could subsequently diffuse in all directions into the tumour 
micro-environment.   
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The previous chapter supports the self-generation of an outward gradient.  One 
would hypothesise that following a surge in LPA generated by ulceration, there 
follows a period of gradient generation by the melanoma cells.  This would 
explain why there was a high concentration of LPA in the tumour and an outward 
gradient from the margin of the tumour in the human sample (Fig.  5B).  I would 
hypothesise based on my results in chapter 5, that the period of gradient 
generation would be instructive, acting as a signal to promote outward 
migration/ invasion, assuming the cells express LPAR 1 and possibly LPAR 3.   
The data presented in this chapter and the strength of the results are limited by 
the relatively low number of melanomas sampled.  The main limitation has been 
the number of mice with the correct genotype that have been bred by my 
collaborators during the period of study.  The technique employed is fairly 
crude, particularly trying to determine a more complex gradient shape than a 
simple linear or exponential curve. We would ideally have sampled in a bread 
slicing fashion both outward and downward from the tumour but this was not 
technically feasible due to the quantity of material required.  
A limitation has been the dependence on a murine melanoma model that more 
closely resembles human NM than the more commonly occurring SSM subtype.  
Ideally I would repeat this experiment with a different murine model with SSM 
pattern, although these are still being developed and there are concerns that 
these models are less representative of human melanoma from an oncogene 
perspective.  In vivo studies with correlative histopathological analysis have 
suggested that compared to SMM, NM is more vertically invasive with less 
horizontal growth relative to Breslow thickness and has a tendency to ulcerate 
(Liu et al., 2006; Segura et al., 2008; Shaikh et al., 2012). This perhaps explains 
why it is also the most aggressive form in humans. These characteristics have 
generated the hypothesis that NMs may arise from dermal melanocytes (Longo et 
al., 2013).  However, NMs are the fastest growing sub-category making this a 
useful model in the available time frame (Zalaudek et al., 2008).  
It has proved particularly challenging to access fresh human primary melanomas.  
This is mainly due to the tough criteria that are understandably set by the 
pathology team.  This is to ensure that the process of sampling the melanomas in 
no way risks impairing the diagnostic and prognostic information.  Unfortunately, 
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by setting the minimum melanoma diameter to 25mm, it is selecting a group of 
melanomas that are not only rare, but are almost certainly behaving in a 
different biological fashion (Kopf et al., 1982).  The one sample collected has 
supported my hypothesis and it will be important to build on this unique 
discovery. 
Ignoring the one human sample, there is a trend towards steeper gradients of 
biologically active LPA species with outward gradients and no pattern with 
inverse gradients.  I would hypothesise that the former is arising as a result of 
differential LPA species degradation, with the more biologically active species 
being degraded faster.  The latter is arising as a result of diffusion from the 
tumour and therefore, one would not hypothesise any differential alterations in 
gradient with sub-species because the process does not require active enzymatic 
degradation.   
The result from the human melanoma highlights the extent of the 
microenvironmental zone of tissue that is under the influence of LPA.  It is 
promising that this subject’s gradient tailed off within the confines of the wide-
local excision and it would be interesting to correlate not only the peak 
gradient, but the width of the gradient with the risk of metastasis.  This then 
raises the possibility of using LPA gradient detection as a prognostic test and this 
will be covered in the final chapter. 
6.1.9 Conclusion 
I have presented data supporting the presence of in vivo gradients of LPA across 
the margins of melanomas, supporting the physiological relevance of my earlier 
work.  I discovered outward gradients of LPA in non-ulcerated murine 
melanomas, inverse gradients in ulcerated melanomas and no LPA imbalance in 
normal skin.  Combined with my earlier results, I conclude that LPA chemotaxis 
drives melanoma invasion.  However, rather than LPA acting as a direct signal, it 
is the LPA gradient that drives invasion. Cells from all melanoma stages of 
disease progression are chemotactic, but the ability to create a gradient is 
density-dependent.  Therefore, the size of the tumour will determine its ability 
to promote metastasis providing there is an adequate source of LPA. 
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A summary of key findings generated by this thesis  
7.1.1 The Insall chamber is a robust assay for investigating 
chemotaxis 
We have developed two assays for investigating cancer cell chemotaxis: 1) the 
“standard assay”, which acts as a model for single cell tumour invasion, and 2) 
the “centre-well assay”, which acts as a model for collective/ single cell 
invasion from the tumour periphery.  In addition to ongoing work investigating 
the findings from this thesis, the assay is optimised for detailed higher resolution 
work, for example, investigating pseudopod dynamics and intracellular signalling 
with fluorescent probes in mammalian and Dictyostelium cells. 
7.1.2 LPA chemotaxis is a key driver of melanoma dispersal and 
invasion across all stages 
This thesis conclusively demonstrates the importance of LPA signalling in the 
chemotactic responses of melanoma cells to serum, demonstrating that LPA is 
sufficient as well as necessary for highly accurate chemotaxis and invasion.  This 
further supports the paradigm of chemotaxis driven invasion and identifies LPA 
as a key driver of melanoma invasion.  LPA signalling through LPAR 1 has 
previously been shown to be important in cell motility and invasion (Hama et al., 
2004; Shida et al., 2003; Yamada et al., 2004).  The data presented in this thesis 
provide further support for the involvement of this signalling pathway in 
melanoma invasion.  My findings in ulcerated melanomas in particular implicate 
the inflammatory response in the metastatic process. 
7.1.3 Growth factors act as accessory factors enhancing LPA 
chemotaxis 
To the best of my knowledge, this study and one other by Zicha and Dunn are 
the only two to investigate the role of Growth Factors in long-term direct 
visualisation assays of cancer cell motility (Zicha and Dunn, 1995).  My findings 
concur with their outcome that Growth Factors are primarily chemokinetic 
agents, but, I also conclude that combined with LPA, the efficiency of 
chemotaxis is enhanced.  I therefore propose that this combination may 
potentiate invasion and requires further study.   
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7.1.4 Melanoma cells perform positive chemotaxis through the 
self-generation of outward gradients  
I conclude that melanoma cells self-direct their invasion through a programme of 
LPA gradient generation in vitro and in vivo.  The self-generation of chemotactic 
gradients generates a cell dispersal effect and thus provides a mechanism for 
the “edge-effect”, or dispersal of cells to the nearest edge, which was first 
described by Zigmond in her eponymous direct visualisation chamber (Zigmond 
et al., 2001).  This gradient generation behaviour was observed through the 
direct visualisation of chemotaxis.  Using this approach, I demonstrated that the 
ability of cells to locally degrade LPA and generate a gradient acts as the signal 
driving melanoma cell migration and invasion.  The ability of cells to self-
generate gradients and migrate by positive chemotaxis has important 
implications for melanoma metastasis and the broader cell motility field.  This 
model dictates that provided with a supply of chemoattractant and a high 
enough cell density to efficiently degrade the attractant, the cells will 
efficiently disperse.  Therefore the source of LPA within the microenvironment 
and the growth of the tumour are likely to be the rate limiting factors in the 
dispersal of melanoma cells. 
Key questions & future perspectives 
Throughout this thesis I have discussed the direct implications of the results at 
the end of each chapter.  This section aims to cohesively expand on these by 
bringing together many of the concepts highlighted in the summary of key 
findings.  In doing so, I will discuss the implications of this work on the fields of 
chemotaxis and melanoma biology.  The implications of this work in relation to 
clinical practice are of particular importance and are therefore discussed in 
detail.  Together these raise important questions and I therefore highlight 
several key experiments that are necessary to answer them and expand on the 
knowledge and test the hypotheses generated from this thesis.  It is envisaged 
that these will be performed by a combination of researchers with ongoing work 
by colleagues in the laboratory, and future work by a clinical fellow(s) as well as 
personal ongoing research. 
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7.1.5 The role of platelets in LPA generation and metastasis 
7.1.5.1 Are platelets the primary source of LPA and does its presence 
correlate with the risk of metastasis?  
The source of LPA in vivo is not known.  In many cancer sub-types, including 
melanoma, the increased expression of Autotaxin has been associated with 
tumour progression (Saunders et al., 2008).  As discussed in the introductory 
chapter, LPA is produced via the autocrine action of Autotaxin on 
Lysophosphatidylcholine (LPC).  The LPA produced from Autotaxin would 
therefore be tumour centric, which after diffusion would create inward-facing 
gradients (ie. a gradient highest in the tumour and lowest outside the tumour).  
Rather than promoting tumour dispersal, my data suggest this would drive 
inward chemotaxis, tending to prevent the escape of tumour cells.  Contrary to 
this, I found that there was a net loss of LPA in conditioned media experiments, 
despite the relative abundance of the substrate LPC in serum once the cell 
density reaches a critical point.  My work is consistent with the initial tumour-
centric production of LPA following ulceration, but suggests that this LPA is 
subsequently modified after its diffusion through the microenvironment to 
generate outward-facing gradients (ie. a gradient lowest in the tumour and 
highest outside the tumour).  The effect of this outward-facing gradient is to 
drive cell dispersal by positive chemotaxis.   
Current evidence supports two main pathways for LPA production as reviewed in 
detail in the introduction.  The concentration of LPA in the immediate 
environment is dependent on the homeostatic cellular mechanisms controlling 
extra-cellular LPA concentrations, with Autotaxin producing a net gain and the 
Lipid phosphate phosphatases (LPPs) producing a net loss of LPA (Brindley and 
Pilquil, 2009), My data clearly show an outward gradient of LPA and therefore 
suggest that there is a relative reduction in Autotaxin activity compared to that 
of the LPPs. If Autotaxin activity is low, I hypothesise that LPA is instead being 
generated via the alternative pathway from platelets.  Phosphatidic acid (PA) is 
hydrolysed by sPLA2 to produce LPA and both the substrate and the enzyme are 
secreted from platelets in membrane microvesicles following platelet activation 
(Eichholtz et al., 1993; Fourcade et al., 1995).  This process is reinforced by 
positive feedback, with LPA inducing further platelet aggregation and activation, 
thereby generating an LPA rich microenvironement.  Current in vivo evidence 
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suggests that there is slowing of platelets in the tumour microcirculation.  
Although thrombus formation is not evident, modelling supports slow enough 
flow to allow for localised release of platelet vesicles (Manegold et al., 2003). 
The association between platelets and cancer was initially cited by Trousseau 
who observed the increased risk of venous thrombosis in cancer (Rak et al., 
2006).  Platelet activation is amplified in cancer and thrombocytosis is one 
amongst several aberrantly activated markers representing the hypercoagulable 
state (Gay LL, 2011).  There is limited evidence that the activation of the 
coagulation and fibrinolytic system potentiates invasiveness and metastasis 
(Gabazza et al., 1993).  In the setting of melanoma, patients with normal 
fibrinogen levels had a significant 1-year survival benefit over patients with 
elevated levels (87.7% v 58.4% (p=0.031) respectively; Tas et al., 2012).  This 
group did not normalise their data based on Breslow thickness.  I hypothesise 
that patients demonstrating elevated markers of platelet activation are at 
increased risk of metastasis due to increased LPA release at the tumour site.  P-
selectin (CD62p) is present in the α-granules of platelets and is translocated to 
the cell surface upon platelet activation.  It is therefore a useful marker for 
platelet-activation and has been shown to correlate with metastasis in mouse 
models (Coupland et al., 2012).  To the best of my knowledge, no one has yet 
identified the melanoma patients that are at increased risk of metastasis based 
on identifying markers of platelets or platelet activation in melanoma tissue or 
blood samples.   
To test the hypothesis that platelets are the primary source of LPA in vivo and 
that this correlates with the risk of metastasis, I therefore propose the 
following. 
• Identify markers of platelets and platelet activation within human 
melanomas (CD42b (Clemetson et al., 1982), CD62p (Kamath, 2001)) and 
blood (fibrinogen and CD62p) and correlate the findings with histological 
markers (Breslow thickness, mitotic rate and ulceration) and LPA 
concentration.   
• After seeking appropriate ethical approval, this would first be piloted in 
human melanoma using formalin fixed paraffin embedded tissue from the 
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NHS pathology archive and correlated with clinical outcome data if 
possible to correlate these retrospective findings with metastasis.  The 
Scottish Melanoma Group holds records of individual patient follow-up in a 
database that would aid this study.   
7.1.5.2 Can platelet derived LPA support different stages of metastasis? 
I have reviewed the classification systems for melanoma and the current move 
towards an improved system combining genetic and morphological information 
(Viros et al., 2008).  These systems do not, however, include factors associated 
with the microenvironment that are known to influence the behaviour of cancer 
cells.  I believe that the work included in this thesis is some of the most 
persuasive data to-date supporting a role for a microenvironmental factor 
influencing the risk of melanoma metastasis through enhanced invasion.  In order 
to develop a reliable prognostic marker for melanoma, it will be important to 
identify surrogate markers for melanomas with outward gradients due to the 
difficulty and cost associated with quantifying LPA gradients by mass 
spectrometry.   
There is growing evidence to support platelets contributing to the metastatic 
process at later stages of the metastatic process following intravasation (Gay LL, 
2011).  The mechanisms aiding haematogenous metastasis are varied and include 
immune evasion through antigenic cloaking, to the formation of tumour-platelet 
heteroaggregates acting as tumour survival rafts that can mechanically lodge in 
distant organs.  Boucharaba et al demonstrated the effects of LPA on inducing 
the formation of bony metastases in mice injected with metastatic breast cancer 
cells.  This effect was shown to be mediated through LPAR 1 (Boucharaba et al., 
2006).  Two interesting results from an earlier paper showed that breast cancer 
cells did not produce LPA keeping with my results (Boucharaba et al., 2004).  
However, the cancer cells stimulated platelet activation and LPA release and 
inhibiting platelets in vivo with the specific integrin αIIbβ3 antagonist (Integrilin) 
produced a 70% fall in the concentration of circulating LPA and a 50% reduction 
in the extent of bony metastases.  These results support an endogenous source 
of local production of LPA (Guise, 2005).   
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More recently, David et al reported increased osteoclast density at the site of 
metastasis (David et al., 2010).  It is notable that osteoclasts, responsible for 
bone resorption and the generation of osteolytic lesions are highly motile and 
express LPAR 1 (Chellaiah et al., 2000; Lapierre et al., 2010).  It is tempting to 
hypothesise that osteoclasts use the gradient generated by the platelets 
(platelet-tumour heteroaggregate) to aid their migration to the site of 
metastasis, rather than LPA acting purely as a purely mitogenic agent at this 
site. 
My results therefore imply an additional mechanism by which platelets actively 
promote metastasis by driving invasion from the primary towards the 
bloodstream.  To test the hypothesis that platelet derived LPA supports 
metastasis in vivo, I propose the following: 
• First, we will establish an orthotopic murine melanoma metastasis model 
to better recapitulate the invasive stage based on previous attempts to 
produce orthotopic melanoma models (Bobek et al., 2011; Rofstad, 1994; 
Rozenberg et al., 2010).  The main complicating factor is that the primary 
often outgrows the metastases, necessitating the sacrifice of the model 
before macrometastases have appeared.  The development of a model 
allowing the resection of the primary is therefore essential.  Here, I have 
demonstrated pilot experiments to generate this model using 
subcutaneous ear injections of melanoma cells into nude mice (Fig. 1).  In 
the future, I also propose intradermal back injections of human melanoma 
cells into nude mice.  
• Having established an orthotopic melanoma metastasis model, we will 
compare the metastatic load of vehicle vs. platelet antagonist (eg.  
Integrilin) treated mice.  We will quantify platelet activation and the LPA 
concentration across the primary tumours as previously described. 
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Figure 7-1 Development of an orthotopic mouse metastasis model 
A H&E slide demonstrating the localisation of the xenografted cells (1x106 cells in 10µL RPMI) in 
the dermal/ subcutaneous space above the cartilage in the distal ear of a nude mouse. B 
Photograph of the mouse showing the subsequent development of a loco-regional metastasis at 
the base of the ear distal to the site of inoculation. C H&E and S100 stains of the locoregional 
metastasis confirming the tumour is a melanoma. 
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7.1.5.3 Is there evidence for platelet treatments reducing the risk of 
metastasis in humans? 
There are several reports of platelet targeting treatment reducing the risk of 
metastasis (Bambace and Holmes, 2011).  It is clear that targeting platelet 
activation reduces the risk of metastasis in some clinical models described in 
this review, but there is currently no evidence to support the reduction in 
metastasis occurring due to a reduction in invasion.   
Prospective studies investigating the clinical outcomes for patients with cancer 
who have been treated with platelet inhibitors found either no effect, or in 
some cases, improvement in survival (Bambace and Holmes, 2011).  For 
melanoma specifically, there are retrospective studies again showing similar 
outcomes (Asgari et al., 2008; Curiel-Lewandrowski et al., 2011; Harris RE, 2001; 
Johannesdottir et al., 2012; Joosse et al., 2009).  Last year, two meta-analyses 
were published with the finding that aspirin has a beneficial effect on reducing 
the incidence and death from cancer, in addition to the beneficial effects on 
vascular disease (Algra and Rothwell, 2012; Rothwell et al., 2012).  It is also 
interesting to note in these papers, that the reduction in metastasis is not found 
in patients receiving the anticoagulant warfarin, which does not affect platelet 
aggregation. 
Targeting platelets in melanoma as a chemo-preventative strategy is therefore a 
subject that requires further study.  Initial laboratory work is required to 
investigate the role of anti-platelet therapies at differing doses in their ability to 
reduce LPA production.  These data could then be used to inform a melanoma 
chemoprevention trial.   
7.1.5.4 Is there evidence to support Growth Factors acting as accessory 
agents in vivo?  
Given the enhancing effect of Growth Factors on chemotaxis in the presence of 
LPA, one can hypothesise that cells succeeding in intravasating are more likely 
to have achieved this through integration of GF and LPA signalling.  Well 
established sources of Growth Factors include host cells.  The breast cancer cell 
loop described earlier, is driven through paracrine signalling, with EGF produced 
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via macrophages.  Conversely, fibroblasts may potentially play a role in 
generating LPA in the presence of EGF through paracrine signalling.   
Further support for the importance of platelets in the metastatic process is the 
finding that a multitude of bioactive factors in addition to LPA are released 
following platelet activation.  These include PDGF and EGF, the Growth Factors 
that I have shown to be important chemotaxis accessory factors to LPA (David et 
al., 2010; Sierko and Wojtukiewicz, 2004). 
7.1.6 The LPA-axis as a potential prognostic and or therapeutic 
target for metastasis 
7.1.6.1 Are LPA gradients clinically significant? 
I have shown that both murine and human melanomas create outward-facing LPA 
gradients.  One could hypothesise that LPA gradients are only present in 
melanomas that are actively invasive and therefore the demonstration of a 
gradient could present a novel adverse prognostic marker.  There are therefore 
two key questions that need to be answered.  First, does the presence of a 
gradient predict the risk of invasion and ultimately metastasis?  Second, can a 
more detailed analysis of the gradient profile (ie.  steepness or distance over 
which a gradient is present) predict a highly invasive group?  To answer these 
questions, we would need to collect samples from primary melanomas.  Due to 
the ethical constraints regarding melanoma tissue collection, it might be wise to 
simplify the tissue collection regimen and sample one, or if possible, two punch 
biopsy samples lateral to the primary melanoma for LPA quantification.  This 
would provide tissue for analysis without disturbing the primary melanoma.  If 
deemed ethically sound, this approach would theoretically allow melanomas of 
all diameters to be sampled, which would enable a more clinically 
representative cohort to be assessed than has been possible during this study.  A 
further sample taken >5cm from the primary could be used as a standard.  These 
could be compared to samples taken proximal to benign and dysplastic naevi.   
We are continuing to investigate whether there is degradation of LPA in samples 
stored on ice for one hour compared to samples that are snap frozen.  Processing 
samples on ice would considerably increase the potential yield of melanomas 
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that could be sampled by enabling them to be conveniently processed by the 
consultant pathologist in the laboratory. 
To investigate the clinical significance of LPA gradients, I therefore propose the 
following: 
• To establish a prospective human study collecting fresh melanoma to 
calculate LPA gradients and blood samples for evidence of platelet 
activation and following their progress over 5 years to record the 
presence of loco-regional or distant metastases.  The results could be 
normalised to current histopathological staging criteria, and Breslow 
thickness in particular, and an assessment could be made of whether LPA 
gradients act as an independent prognostic marker.  During this study we 
would seek to obtain formalin fixed paraffin embedded tissue to identify 
other markers from the LPA-axis, which will be discussed next. 
7.1.6.2 LPARs and LPPs as potential melanoma prognostic markers  
In addition to identifying markers for the source of LPA, it would be important to 
investigate the known key regulators of external LPA concentrations in the 
microenvironment and the receptors involved in LPA signal transduction, ie.  
LPPs and LPARs and correlate their expression profile with metastasis and 
Breslow thickness. 
LPARs 
As summarised earlier in this chapter, my work has demonstrated the 
importance of LPAR 1 in the motility and chemotaxis of melanoma cells, in 
keeping with published data.  There is data to suggest that the outcome of cell 
migration is dictated by the relative expression levels of individual receptors 
(Jongsma et al., 2011).  Interestingly, Jongsma et al demonstrated that LPAR 5 
expression can mediate chemorepulsion in B16 melanoma cells, which express 
relatively less LPAR 1.  Although the mechanism behind this remains to be 
determined, the present findings warrant further studies on the expression 
patterns and clinical outcome of the LPARs in melanoma and other cancers and 
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the B16 cells may act as a useful negative control for LPAR 1 expression and 
chemotaxis towards LPA.   
LPPs 
Current thinking suggests that metastasis should be favoured by decreased LPP 
expression (and increased Autotaxin expression), which has been hypothesised to 
result in an increased extracellular LPA concentration (Moolenaar et al., 2004; 
Samadi et al., 2011).  My data however support the opposite, with increased 
expression of LPP acting as a driver of metastasis.  As discussed, there is growing 
evidence that the metastatic spread of melanoma is driven not by a linear 
increase in tumorigenic aggressiveness, but rather by switching back and forth 
between two different phenotypes of metastatic potential ie.  strong 
proliferation/weak invasiveness and weak proliferation/strong invasiveness 
(Widmer et al., 2012).  Using the gene expression-based tool generated by the 
Hoek group for predicting phenotype (the Heuristic Online Phenotype Prediction 
tool) there are statistically significant 1.8 fold and 1.9 fold increases in the 
expression of LPP1 (PPAP2A) and LPP3 (PPAP2B) respectively, in invasive 
compared to proliferative melanomas.  These very recent data are therefore 
supportive of the model I have generated. 
It is not known which of the LPPs are more important, although it may be the 
signature pattern of several LPP enzymes that is critical in determining the 
response.  My data suggests that the most biologically active LPA sub-species are 
preferentially degraded and I would therefore seek to identify the LPPs 
responsible for producing this profile.  I would also seek to confirm the finding 
that LPP activity is upregulated in advanced melanoma. 
In order to investigate the expression profiles of LPARs and LPPs expression 
profiles, I propose: 
• To perform a screen using RT-PCR across the cell lines used throughout 
this thesis across the various biological stages of melanoma development 
and also to include an assessment in melanocytes.  Based on my data, I 
hypothesise that the WM278 cell line (demonstrating the weakest 
chemotaxis), may poorly express LPAR 1 or perhaps express a profile with 
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increased LPAR 5.  Conversely, WM239A would serve as a positive control 
and we expect the expression signature to favour LPAR 1 and 3. 
• If this is successful in identifying expression profiles consistent with 
chemotactic ability I would plan to investigate this further using patient 
samples.  In the first instance I would propose to refine the technique 
using archival patient samples described already, before collecting tissue 
in a prospective manner as part of the tissue collection project described 
above. 
7.1.6.3 Targeting the LPA-axis to inhibit invasion 
Targeting cell motility to inhibit tumour cell invasion remains controversial due 
to the potential toxicity associated with this strategy, especially on normal 
cellular turnover throughout the gastrointestinal tract and skin (Wells, 2000).   
The LPA inhibitor Ki16425 would be unlikely to be tolerated for any length of 
time as a cancer treatment because LPA homeostasis is essential for health.  Its 
use could therefore result in a failure of homeostatic mechanisms, resulting in 
serious and unwanted side-effects.  It will therefore be important to develop a 
deeper understanding of the role of the LPA-axis in metastatic progression to 
identify alternative strategies to blocking this pathway in melanoma progression 
without the unwanted side-effects. 
Having screened cell lines and patient samples, I hope to discover an LPP 
signature consistent with LPA gradient generation and therefore invasion.  By 
comparing this signature with those expressed by melanocytes, it may be 
possible to identify an LPP signature that is sufficiently different to those 
necessary for physiological processes.  This will not only enhance the 
understanding of the process of gradient generation but it may identify novel 
elements of the LPA-axis that could enable the safer and less toxic targeting of 
the LPA-axis to prevention melanoma invasion. 
The in vitro models we have used throughout this work have been optimised to 
produce chemotactic responses.  A key finding using these models was the 
increased speed of the metastatic cells.  It remains uncertain whether the 
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increased speed of migration is clinically relevant, or whether the most invasive 
strains will metastasise earlier, and thus be the first to be identified and may 
therefore represent an artefact of selection.  My data suggest that even less 
invasive cells can generate LPA gradients, and move rapidly and accurately 
enough to metastasise.  In order to investigate this further it will be important 
to integrate chemotaxis into an even more complex model that includes factors 
that are known to retard cell migration.   
To more accurately investigate chemotaxis and the role of the LPA-axis in health 
and disease to identify meaningful targets, I propose the following: 
• Combine keratinocytes in the 3-dimensional organotypic model to 
investigate whether chemotaxis overrides keratinocyte-dependence, 
particularly in early stage melanoma cells.   
• Assess the ability of all melanocyte lineage cells, including melanoblasts 
and melanocytes to generate gradients and quantify the LPA 
concentration in or across the migrating melanoblast front in embryo skin 
and across naevi. 
• Using siRNA, we will attempt to knockdown relevant LPARs and LPPs to 
quantify the effect on cell motility, chemotaxis and gradient generation, 
with the aim of identifying novel LPA-axis targets. 
• More generally, it will be essential to assess whether these findings are 
relevant to other cancers.  
7.1.7 A biological explanation for the adverse prognosis 
associated with melanoma ulceration  
7.1.7.1 Do ulcerative melanomas behave more aggressively due to 
increased LPA production? 
The biological significance of melanoma ulceration is almost completely 
unknown, despite its ability to act as an independent prognostic indicator by 
enhancing metastasis (Spatz et al., 2010).  The wound paradigm in cancer 
research is based on the hypothesis that cancer is an aberrancy of the 
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physiologic processes of wound healing (Riss et al., 2006).  Within hours of 
wounding, a fibrin-rich clot is formed containing activated platelets (Schneider 
IC, 2006).  A multitude of biological mediators and growth factors are formed 
and stored in human platelets, which are released in response to an injury at the 
wounded site (Sauer et al., 2004).  There is good evidence to support LPA in 
particular being released into acute wounds from serum and platelets to aid 
wound healing (Eichholtz et al., 1993; Mazereeuw-Hautier et al., 2005; Xu et al., 
2007).   
I hypothesise that a tumour with an overlying ulcer will induce an exaggerated 
wounding response, with increased platelet activation.  In support of this, my 
results from sampling LPA concentrations across ulcerated melanomas indicate 
inward-facing gradients.  All these tumours were sampled the same day the 
ulceration was discovered in keeping with the terms of the project license.  I 
hypothesise that there is enhanced LPA release in a tumour centric-manner 
following the onset of ulceration.  Over time, I would expect the tumour cells to 
self-generate steeper outward gradients over a longer distance compared to 
non-ulcerated tumours, thereby potentiating invasion. 
Investigating this is challenging, because based on current UK Home Office 
guidance, mice must be sacrificed immediately after ulceration is discovered 
and therefore it is not possible to monitor the gradient evolving over time. I 
therefore propose the following: 
• We would seek approval to wound melanomas across a cohort of mice and 
sample the LPA gradients over time across the cohort. 
• In another identical cohort we would compare metastasis from wounded 
vs. non-wounded tumours.  We would simultaneously quantify the LPA 
gradient and quantify invasion and metastasis. To confirm that the 
process was dependent on LPA we would perform parallel experiments +/- 
Ki16425. 
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7.1.8 Implications for diagnosis & treatment 
7.1.8.1 Is tumour volume a more important prognostic indicator than 
Breslow thickness? 
My results support the requirement of a critical tumour mass with sufficient 
density to generate a gradient sufficient to drive invasion.  In Breslow’s seminal 
paper, he identified maximal tumour thickness and maximal surface area as the 
key determinants of outcome but found maximal depth to be the most important 
determinant (Breslow, 1970).  However, Breslow only investigated the 
melanomas of 98 patients and as discussed, there are more recent papers 
suggesting that tumour volume is more important than Breslow thickness.  Given 
my findings, it is important to revisit his premise and design a study to 
accurately assess the effect of tumour volume on recurrent or metastatic 
disease and survival.   
7.1.8.2 Could incisional biopsies promote metastasis? 
Assuming the main source of LPA is derived from platelets, I hypothesise that 
incisional biopsies into primary melanomas may enhance the risk of metastasis 
by inducing further platelet activation.  This is supported with the finding of 
increased circulating tumour cells (CTCs) shed into the blood 3-4 weeks post-
operatively after complete excision (De Giorgi et al., 2010).  It is not known 
whether these cells are clinically significant as this study found no correlation 
between number of CTCs and staging criteria.  However, shortcomings of this 
study include a cohort that was possibly not large enough to show statistical 
significance and the follow up was only 17 months despite the fact that the 
majority of metastases arise over a three-year window following diagnosis 
(Dicker et al., 1999). 
Further longitudinal studies on larger series of patients are required and in 
addition to CTC collection, this could be correlated with a quantitative measure 
of LPA with a biopsy lateral to the primary melanoma, in addition to markers of 
platelet activation.  I would propose a similar technique to De Giorgi by 
detecting CTCs by performing RT-PCR for tyrosinase mRNA from samples 
collected in the prospective study I have described. 
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7.1.8.3 Could LPA gradients define the size of the WLE required? 
For melanomas that have invaded less than 1mm Breslow thickness, current UK 
guidelines advise taking a 1cm margin and for melanomas that have invaded 
more than 1mm then at least a 1-3cm margin is required (Marsden et al., 2010).  
Assuming that an LPA gradient drives lateral invasion/ dispersal, this suggests 
that the effect of an LPA gradient may involve tissue up to 3cm from the primary 
lesion in deep melanomas.  Therefore a greater understanding about the extent 
of the LPA gradient could potentially establish the optimal excision margin and 
allow tailoring of the wide local excision would reduce risk of recurrence.  I 
propose to define the extent of the LPA gradient surrounding tumours as part of 
the experiments already described. 
7.1.9 Self-generated gradients: a universal model for cell 
dispersal in morphogenesis and disease? 
7.1.9.1 Evidence for self-generated gradients from other model systems. 
Our data supports the migration of melanoma cells in a wave-like formation 
towards LPA.  This is very reminiscent of the migration of dermal fibroblasts, 
which migrate as a population over days into a fibrin-rich clot following 
wounding (Schneider IC, 2006).  Schneider and Haugh found that fibroblasts 
require a narrow range of absolute chemoattractant concentration to migrate.  
This necessitates a novel mechanism to enable them to migrate over distances 
many orders of magnitude greater than their cellular dimensions and they do this 
by eroding the gradient of PDGF.  This erosion by a high density of fibroblast 
cells constantly maintains the PDGF gradient in the optimal range around the Kd  
of the receptor, ensuring that the front of the cells will advance “at a constant 
linear rate within the wound, settling into the gradient sensing sweet spot” 
(Schneider IC, 2006).   
Researchers in the motility field are struggling to understand how attractive 
signals can be integrated by a migratory group (Theveneau et al., 2010).  I 
believe that the wave formation that we have observed implies an important 
model.  At the leading edge of the wave, it is likely that the melanoma cells 
propagate through a similar mechanism to fibroblasts through a coupling 
between gradient generation and chemoattractant sensing.  It is therefore 
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tempting to hypothesise that dermal fibroblasts are also entering a wound in 
wave formation.   
I hypothesise that the wave phenomena arises by the following mechanism.  
Cells upstream of the wave move randomly due to there being no chemotactic 
gradient and all their receptors being saturated until they are seemingly swept 
along by the wave.  This is likely to occur because the cells are dense enough in 
the wave to self-generate a chemotactic gradient and the cells are able to sense 
a difference in receptor occupancy and therefore perform positive chemotaxis.  
However, the cells at the rear of the wave fall behind and become stationary 
because the chemoattractant has been degraded to the point of there being 
essentially uniform loss of the attractant.  If this mechanism of wave-like 
chemotaxis is a key biological mechanism for the migration of populations of 
cells then it is important to seek examples across different species and 
organisms.  It is therefore even more convincing that we observed the exact 
same behaviour in Dictyostelium cells migrating in the presence of a uniform 
gradient of chemoattractant (data generated by Prof. D Knecht). 
Rather than the linear motility response observed by dermal fibroblasts, it may 
be that melanoma cells are able to respond across a wider concentration range 
with LPPs acting to degrade LPA in proportion to its physiological concentration 
(Brindley and Pilquil, 2009).  Moolenaar predicted that LPP activity would serve 
to prevent receptor downregulation and concluded that future studies should 
substantiate the relative importance of ligand degradation versus receptor 
desensitisation in controlling LPA signal duration and strength (Moolenaar et al., 
2004).  I concur and reflecting on the model of tumour cell dispersal I have 
generated and the wave formation I have observed, I conclude that the 
chemoattractant message resides in the gradient, which drives cell dispersal, 
rather than the absolute concentration of LPA predicted by the Autotaxin and 
other traditional chemoattractant models. 
7.1.9.2 Can melanoblast spreading and patterning be explained by the same 
mechanism? 
As discussed in the previous section, cells intermittently fall off the back of the 
wave and this was consistently observed in videos of melanoma and 
Chapter 7 
 206 
Dictyostelium cells migrating in wave formation from an area of high density in 
uniform chemoattractant conditions.  After the wave has spread across the 
bridge, these residual cells remain immotile and evenly dispersed.  This 
mechanism of spreading and the resulting patterning has to the best of my 
knowledge not been described previously and therefore presents a fascinating 
starting point from where to examine whether this model can explain the even 
patterning of melanocytes found after the melanoblasts have completed their 
dorso-lateral migration.  
We know that SCF has an important role in determining when melanoblasts 
migrate into the epidermis, along with spatio-temporal expression patterns of 
cadherins, but little is known about signals that control directionality.  Based on 
the response I have seen from melanoma cells to LPA, I hypothesise that either 
this or another factor(s) acting through the same G-protein subunits may 
therefore be responsible.  Data to support a role for LPA has been generated by 
Ohuchi et al who described the spatial and temporal expression patterns of 
different LPAR genes during embryogenesis (Ohuchi et al., 2008).  They found 
that LPAR 1 is expressed where migratory neural crest cells would be expected 
to reside around E8.5 at exactly the time when they commence dorso-lateral 
migration. LPAR 1 expression therefore has the correct spatial and temporal 
credentials. One might therefore expect a pigmentary phenotype in the LPAR 1 
deficient mouse, but this has not been described.  The lack of pigmentary 
phenotype in the LPAR 1 deficient mouse may well occur as a result of functional 
redundancy due to perhaps compensation by LPAR 3 signalling (Contos et al., 
2000; Mills and Moolenaar, 2003).  It is also possible that the system is extremely 
robust with many more cells commencing dorso-lateral migration than are 
actually required to evenly cover the embryo. 
The most convincing data supporting a role for LPA in the in vivo migration of 
cells is derived from LPP knockout models in Drosophila, which show impaired 
germ cell migration.  LPPs belong to a large phosphatase family that includes 
Wunen proteins in Drosophila (Samadi et al., 2011).  Drosophila expresses two 
Wunen proteins, wun and wun2, that are homologous to LPP 3.  In germ cells 
they act redundantly as repellent factors that disperse migrating germ cells in 
Drosophila embryos to the gonads (Renault et al., 2010).  The repellent effect is 
hypothesised to result from the spatially restricted degradation of an unknown 
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lipid factor that guides the germ cells and acts as a survival factor (Brindley and 
Pilquil, 2009). 
In mice, disruption of the gene encoding LPP 3 caused a very severe phenotype 
[Escalante-Alcalde et al., 2003].  These LPP 3 deficient mouse embryos failed to 
form a chorio-allantoic placenta and yolk sac vasculature.  However, as with the 
LPAR knock-out mice, no pigmentary defect was seen, but as with the 
Drosophila models this may be due to functional redundancy.  
I therefore hypothesise that LPA plays an important role in guiding melanoblast 
dispersal and patterning.  To investigate this further I propose the following: 
• To investigate the role of LPA signalling in melanoblast dispersal in vivo 
using an explant assay +/- Ki16425. If this fails, then we would explore 
treating the mother with Ki16425 at different times during dorso-lateral 
melanoblast migration from E8.5 and 10.5. 
7.1.9.3 What is the mechanism behind the preferential degradation of 
biologically active LPA subspecies? 
Leading researchers in the field of lipid metabolism have highlighted that further 
work is needed to establish how the individual LPPs differentially control the 
metabolism of exogenous and endogenous lipid phosphates and thereby elicit 
their different functions in regulating cell signalling (Brindley and Pilquil, 2009).  
A correlation between increasing disease activity and increasing LPA 
polyunsaturation was identified from LPA species detected in bronchoalveolar 
lavage fluids after induction of allergic airway inflammation (Georas et al., 
2007).  The authors concluded that LPPs generated this profile but further 
research was required to investigate the significance.  This raises the question of 
whether strongly serum responsive melanoma cells are capable of degrading the 
most biologically active LPA species more efficiently than weakly responsive 
cells.  It will therefore be important to confirm the LPP and LPAR expression 
profiles of the different cells and identify whether there is a signature 
associated with enhanced degradation of the most biologically active LPA 
species that may point towards specific LPPs associated with melanoma invasion.   
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Model for melanoma invasion 
To summarise the key findings in this thesis, I have generated an enhanced 
model of melanoma invasion based on the schematic of the biological stages of 
melanoma development in chapter 1.  This model assumes that LPA is derived 
from platelets and is released at a saturating concentration around the 
melanoma. (Fig. 2) 
This model will require ongoing refinement to incorporate the effect of other 
host cells in shaping the LPA rich field. 
Summary 
The aim of this project was to investigate the role of chemotaxis in melanoma 
cell invasion.  I have shown that chemotaxis has a central, if not essential, role 
in the invasion of melanoma cells and LPA has been identified as a key driver of 
this response.  The challenges and complexities of cancer research have meant 
that the final aim of identifying a novel prognostic and therapeutic marker 
remains at the hypothesis stage.  However, given the novelty and apparent 
importance of the data I have generated, it will be essential to interrogate the 
role of the LPA-axis in this process.  Similarly, I hypothesise that this model can 
be applied to melanoblast dispersal during embryogenesis and therefore the role 
of the LPA-axis in this context requires rigorous investigation.  The implication 
that the inflammatory response and, in particular, platelet activation plays an 
essential role in melanoma progression is an area that requires particular 
attention. 
This thesis has generated results that challenge current concepts about how 
populations of cells migrate, highlighting their ability to perform chemotaxis to 
self-generated gradients.  Detailed work will therefore be required to validate 
the hypotheses generated through this work in respect to not only pigment cells, 
but also to other cell types more generally.  Finally, it would appear essential to 
investigate whether these findings are translatable across other cancer types. 
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Figure 7-2 Model for LPA driven melanoma invasion 
This schematic represents the different stages of melanoma progression. It should be stressed that 
the source of LPA and the effect of ulceration remain speculative at this stage. A An early 
melanoma initiates an inflammatory response with platelet activation and subsequent LPA release. 
B The melanoma continues to proliferate with increasing platelet activation and greater LPA 
release, saturating all the melanoma cell LPA receptors. C The melanoma reaches a critical 
density whereby it is able to degrade the local LPA. These self-generated gradients thereby drive 
outward dispersal and as the cells remain keratinocyte dependent the tumour spreads radially 
migrate (RGP melanoma). D The melanoma undergoes further mutations rendering it keratinocyte 
independent and the cells are now able to continue degrading the local LPA and spread or invade 
vertically (VGP melanoma). E If the melanoma ulcerates LPA rich serum is released into the wound 
following enhanced platelet activation and this surge of LPA diffuses from the tumour to extend 
further than prior to ulceration. It is subsequently degraded by the cells and they invade more 
aggressively. 
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Figure 9-1 Appendix: Cell line characterisation 
Cell lines acquired from collaborator Prof Dot Bennett through the Wellcome Trust Genomics Cell 
Bank. Sequencing performed by K Nathanson Lab. Information presented here adapated from 
Meenhard Herlyn's and Dot Bennet's cell bank holding websites. 
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Figure 9-2 Appendix: R&D project approval 
R&D approval letter for fresh melanoma tissue collection 
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9.1.1 DECLARATION OF HELSINKI 
9.1.2 WORLD MEDICAL ASSOCIATION DECLARATION OF 
HELSINKI 
9.1.3 Ethical Principles for Medical Research Involving Human 
Subjects 
Adopted by the 18th WMA General Assembly 
Helsinki, Finland, June 1964 
and amended by the 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 
1996 
and the 
52nd WMA General Assembly, Edinburgh, Scotland, October 2000  
 
9.1.4 A. INTRODUCTION  
1. The World Medical Association has developed the Declaration of Helsinki as a 
statement of ethical principles to provide guidance to physicians and other 
participants in medical research involving human subjects. Medical research 
involving human subjects includes research on identifiable human material or 
identifiable data. 
2. It is the duty of the physician to promote and safeguard the health of the 
people. The physician's knowledge and conscience are dedicated to the 
fulfilment of this duty. 
3. The Declaration of Geneva of the World Medical Association binds the 
physician with the words, "The health of my patient will be my first 
consideration," and the International Code of Medical Ethics declares that, "A 
physician shall act only in the patient's interest when providing medical care 
which might have the effect of weakening the physical and mental condition of 
the patient."  
4. Medical progress is based on research which ultimately must rest in part on 
experimentation involving human subjects. 
5. In medical research on human subjects, considerations related to the well-
being of the human subject should take precedence over the interests of science 
and society. 
6. The primary purpose of medical research involving human subjects is to 
improve prophylactic, diagnostic and therapeutic procedures and the 
understanding of the etiology and pathogenesis of disease. Even the best proven 
prophylactic, diagnostic, and therapeutic methods must continuously be 
challenged through research for their effectiveness, efficiency, accessibility and 
quality.  
7. In current medical practice and in medical research, most prophylactic, 
diagnostic and therapeutic procedures involve risks and burdens.  
8. Medical research is subject to ethical standards that promote respect for all 
human beings and protect their health and rights. Some research populations are 
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vulnerable and need special protection. The particular needs of the 
economically and medically disadvantaged must be recognised. Special attention 
is also required for those who cannot give or refuse consent for themselves, for 
those who may be subject to giving consent under duress, for those who will not 
benefit personally from the research and for those for whom the research is 
combined with care.  
9. Research Investigators should be aware of the ethical, legal and regulatory 
requirements for research on human subjects in their own countries as well as 
applicable international requirements. No national ethical, legal or regulatory 
requirement should be allowed to reduce or eliminate any of the protections for 
human subjects set forth in this Declaration. 
 
9.1.5 B. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH  
10. It is the duty of the physician in medical research to protect the life, health, 
privacy, and dignity of the human subject.  
11. Medical research involving human subjects must conform to generally 
accepted scientific principles, be based on a thorough knowledge of the 
scientific literature, other relevant sources of information, and on adequate 
laboratory and, where appropriate, animal experimentation. 
12. Appropriate caution must be exercised in the conduct of research which may 
affect the environment, and the welfare of animals used for research must be 
respected. 
13. The design and performance of each experimental procedure involving 
human subjects should be clearly formulated in an experimental protocol. This 
protocol should be submitted for consideration, comment, guidance, and where 
appropriate, approval to a specially appointed ethical review committee, which 
must be independent of the investigator, the sponsor or any other kind of undue 
influence. This independent committee should be in conformity with the laws 
and regulations of the country in which the research experiment is performed. 
The committee has the right to monitor ongoing trials. The researcher has the 
obligation to provide monitoring information to the committee, especially any 
serious adverse events. The researcher should also submit to the committee, for 
review, information regarding funding, sponsors, institutional affiliations, other 
potential conflicts of interest and incentives for subjects.  
14. The research protocol should always contain a statement of the ethical 
considerations involved and should indicate that there is compliance with the 
principles enunciated in this Declaration.  
15. Medical research involving human subjects should be conducted only by 
scientifically qualified persons and under the supervision of a clinically 
competent medical person. The responsibility for the human subject must 
always rest with a medically qualified person and never rest on the subject of 
the research, even though the subject has given consent.  
16. Every medical research project involving human subjects should be preceded 
by careful assessment of predictable risks and burdens in comparison with 
foreseeable benefits to the subject or to others. This does not preclude the 
participation of healthy volunteers in medical research. The design of all studies 
should be publicly available. 
17. Physicians should abstain from engaging in research projects involving human 
subjects unless they are confident that the risks involved have been adequately 
assessed and can be satisfactorily managed. Physicians should cease any 
Appendix 
 260 
investigation if the risks are found to outweigh the potential benefits or if there 
is conclusive proof of positive and beneficial results.  
18. Medical research involving human subjects should only be conducted if the 
importance of the objective outweighs the inherent risks and burdens to the 
subject. This is especially important when the human subjects are healthy 
volunteers.  
19. Medical research is only justified if there is a reasonable likelihood that the 
populations in which the research is carried out stand to benefit from the results 
of the research.  
20. The subjects must be volunteers and informed participants in the research 
project. 
21. The right of research subjects to safeguard their integrity must always be 
respected. Every precaution should be taken to respect the privacy of the 
subject, the confidentiality of the patient's information and to minimise the 
impact of the study on the subject's physical and mental integrity and on the 
personality of the subject. 
22. In any research on human beings, each potential subject must be adequately 
informed of the aims, methods, sources of funding, any possible conflicts of 
interest, institutional affiliations of the researcher, the anticipated benefits and 
potential risks of the study and the discomfort it may entail. The subject should 
be informed of the right to abstain from participation in the study or to 
withdraw consent to participate at any time without reprisal. After ensuring that 
the subject has understood the information, the physician should then obtain the 
subject's freely-given informed consent, preferably in writing. If the consent 
cannot be obtained in writing, the non-written consent must be formally 
documented and witnessed.  
23. When obtaining informed consent for the research project the physician 
should be particularly cautious if the subject is in a dependent relationship with 
the physician or may consent under duress. In that case the informed consent 
should be obtained by a well-informed physician who is not engaged in the 
investigation and who is completely independent of this relationship.  
24. For a research subject who is legally incompetent, physically or mentally 
incapable of giving consent or is a legally incompetent minor, the investigator 
must obtain informed consent from the legally authorised representative in 
accordance with applicable law. These groups should not be included in research 
unless the research is necessary to promote the health of the population 
represented and this research cannot instead be performed on legally competent 
persons.  
25. When a subject deemed legally incompetent, such as a minor child, is able 
to give assent to decisions about participation in research, the investigator must 
obtain that assent in addition to the consent of the legally authorised 
representative.  
26. Research on individuals from whom it is not possible to obtain consent, 
including proxy or advance consent, should be done only if the physical/mental 
condition that prevents obtaining informed consent is a necessary characteristic 
of the research population. The specific reasons for involving research subjects 
with a condition that renders them unable to give informed consent should be 
stated in the experimental protocol for consideration and approval of the review 
committee. The protocol should state that consent to remain in the research 
should be obtained as soon as possible from the individual or a legally authorised 
surrogate. 
27. Both authors and publishers have ethical obligations. In publication of the 
results of research, the investigators are obliged to preserve the accuracy of the 
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results. Negate as well as positive results should be published or otherwise 
publicly available. Sources of funding, institutional affiliations and any possible 
conflicts of interest should be declared in the publication. Reports of 
experimentation not in accordance with the principles laid down in this 
Declaration should not be accepted for publication.  
 
9.1.6 C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH 
COMBINED WITH MEDICAL CARE  
28. The physician may combine medical research with medical care, only to the 
extent that the research is justified by its potential prophylactic, diagnostic or 
therapeutic value. When medical research is combined with medical care, 
additional standards apply to protect the patients who are research subjects. 
 
29. The benefits, risks, burdens and effectiveness of a new method should be 
tested against those of the best current prophylactic, diagnostic, and 
therapeutic methods. This does not exclude the use of placebo, or no treatment, 
in studies where no proven prophylactic, diagnostic or therapeutic method 
exists. 
30. At the conclusion of the study, every patient entered into the study should 
be assured of access to the best proven prophylactic, diagnostic and therapeutic 
methods identified by the study. 
31. The physician should fully inform the patient which aspects of the care are 
related to the research. The refusal of a patient to participate in a study must 
never interfere with the patient-physician relationship. 
32. In the treatment of a patient, where proven prophylactic, diagnostic and 
therapeutic methods do not exist or have been ineffective, the physician, with 
informed consent from the patient, must be free to use unproven or new 
prophylactic, diagnostic and therapeutic measures, if in the physician's judgment 
it offers hope of saving life, re-establishing health or alleviating suffering. Where 
possible, these measures should be made the object of research, designed to 
evaluate their safety and efficacy. In all cases, new information should be 
recorded and, where appropriate, published. The other relevant guidelines of 
this Declaration should be followed. 
 
Figure 9-3 Appendix: Declaration of Helsinki 
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Figure 9-4 Appendix: Melanoma tissue collection advert with inclusion criteria 
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Figure 9-5 Appendix: WM239A dispersal in conditioned media – all time-points 
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Figure 9-6 Appendix: Individual murine melanoma LPA quantification 
 
